SUMMARY OF CHANGES – Protocol  
Protocol #: HCC# 20-266 
Protocol Date:  02/23/2024  
# Section  Change  
1.  Rationale: The research agreement between the University of Pittsburgh and 
Zucero was terminated as of 2/3/2024 for HCC#20- 266. This trial has stopped 
enrolling patients, and t he principal investigator has decided to terminate follow up.  
The following language was added to various parts of the protocol.  
 
Added: Note – Patient accrual was terminated early owing to the discontinuation of 
pixatimod supply. Follow -up assessments will no longer be completed upon IRB 
approval of protocol version 02/23/2024 . 
 
 
 
  
Protocol  Number:  ZU545201 / HCC 20-266 
IND Number: 155695  
ClinicalTrials.gov  number:  [STUDY_ID_REMOVED]  
Date:  02/23/2024  
 
 
CLINICAL  PROTOCOL  ZU545201  
 
Phase IIA Basket Study of Pixatimod (PG545) in Combination with Nivolumab in PD -1 
Relapsed/Refractory  Metastatic  Melanoma and NSCLC  and Pixatimod  (PG545)  in Combination 
with Nivolumab and low -dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma 
(mCRC)  
 
 
PRINCIPAL  INVESTIGATOR  
Diwakar  Davar,  MD 
University  of Pittsburgh  Medical  Center  and Hillman  Cancer  Center 
5117 Center Avenue, Suite 1.32d, Pittsburgh, PA 15213 
Telephone (office): 1 -412-623-7368  
Pager:  1-412-263-7762 
Fax: 1-412-623-7704 
 
STATISTICIAN  
Hong Wang,  PhD 
UPMC Hillman Cancer Center Biostatistics Shared Resource 
Sterling  Plaza  Suite  325, 201 N. Craig  St., Pittsburgh,  PA 15213 
Telephone:  412-383-1588 
E-mail:  how8@pitt.edu 
 
 
DOCUMENT  HISTORY:  
Original 04/26/2021 
First revision  07/19/2021  
Second revision  11/15/2021 
Third revision 03/11/2022 Fourth revision 04/07/2022 
Fifth revision 04/21/2022 
Sixth revision 07/25/2022 
Seventh version 02/10/2023 
Eighth revision 04/18/2023 
Ninth revision 08/08/2023 
Tenth revision 02/23/2024 
 
 
  
Table  of Contents  
 
DOCUMENT  HISTORY  ............................................................................................................... 1 
1. SYNOPSIS  .......................................................................................................................... 6 
2. SCHEDULE  OF ACTIVITIES ............................................................................................. 11 
3. INTRODUCTION  ........................................................................................................... 15 
3.1 Study  Rationale  ......................................................................................................... 15 
3.2 Pharmaceutical  and Therapeutic  Background:  Nivolumab  .......................................... 16 
3.3 Pharmaceutical  and Therapeutic  Background:  Pixatimod  (PG545)  ............................. 17 
3.4 Pharmaceutical  and Therapeutic  Background:  Cyclophosphamide  ............................. 19 
3.5 Preclinical and Clinical Trial Data:  Nivolumab  ............................................................. 20 
3.6 Preclinical and Clinical Trial Data:  Pixatimod  (PG545)  ................................................ 20 
3.7 Preclinical and Clinical Trial Data:  Cyclophosphamide ................................................ 22 
3.8 Rationale  ................................................................................................................... 22 
3.8.1 Rationale for Combining Pixatimod  (PG545)  with Anti-PD(L)1  Antibody  ............. 22 
3.8.2 Rationale for Adding  Low-dose Cy in MSS mCRC  .............................................. 23 
3.8.3 Rationale for Dose  Selection:  Nivolumab  ............................................................ 23 
3.8.4 Rationale for Dose  Selection:  Pixatimod  (PG545)  ............................................... 24 
3.8.5 Rationale for Dose  Selection:  Cyclophosphamide  ............................................... 24 
4. OBJECTIVES AND ENDPOINTS  ...................................................................................... 25 
4.1 Primary  Objective,  Hypothesis,  and Endpoint  ............................................................. 25 
4.1.1 Primary  Objective  ............................................................................................... 25 
4.1.2 Primary  Hypothesis  ............................................................................................  25 
4.1.3 Primary  Endpoint  ................................................................................................ 25 
4.2 Secondary  Objectives,  Endpoints  and Hypotheses  .................................................... 25 
4.2.1 Secondary  Objectives ......................................................................................... 25 
4.2.2 Secondary  Hypotheses  ...................................................................................... 25 
4.2.2.3  Secondary  Hypothesis  3 ..................................................................................... 26 
4.2.3 Secondary  Endpoints  ......................................................................................... 26 
4.2.3.3  Secondary  Endpoint  3 ............................................................................................  26 
4.3 Exploratory  Objectives,  Hypotheses,  and Endpoints ................................................... 26 
4.3.1 Exploratory  Objectives  ........................................................................................ 26 
4.3.2 Exploratory  Hypotheses  ..................................................................................... 26 
4.3.3 Exploratory  Endpoints  ........................................................................................ 27 
5. STUDY  DESIGN  ................................................................................................................ 28 
5.1 Study  Design  ............................................................................................................. 28 
5.2 Trial Procedures  .........................................................................................................  28 
5.3 Number  of Participants  ............................................................................................... 29 
6. STUDY  POPULATION ....................................................................................................... 30 
6.1 Inclusion Criteria  ........................................................................................................ 30 
6.1.1 General  Inclusion Criteria  ................................................................................... 30 
6.1.2 Cohort  1 (MSS  mCRC)  ....................................................................................... 30 
6.1.3 Cohort  2 (PD-1 R/R melanoma)  ......................................................................... 30 
6.1.4 Cohort  3 (PD-1 R/R NSCLC)  .............................................................................. 31 
6.1.5 Other Criteria  ..................................................................................................... 32 
6.2 Exclusion  Criteria  ....................................................................................................... 33 
7. TRIAL  TREATMENTS  ....................................................................................................... 36 
7.1 Treatment  Details  ....................................................................................................... 36 
7.2 Nivolumab  Dose  Selection,  Modification,  Timing,  and Duration .................................. 36 
7.2.1 Nivolumab  dose selection  ................................................................................... 36 
7.2.2 Nivolumab  dose modification .............................................................................. 36 
7.2.3 Nivolumab  timing  of administration  ..................................................................... 38 
7.2.4 Nivolumab  duration of administration  .................................................................. 38 
7.3 Pixatimod  (PG545)  Dose  Selection,  Modification,  Timing  and Duration ...................... 38 
7.3.1 Pixatimod  (PG545)  dose selection  ...................................................................... 38 
7.3.2 Pixatimod  (PG545)  dose modification  .................................................................  38 
7.3.3 Pixatimod  (PG545)  prophylaxis  .......................................................................... 38 
7.3.4 Pixatimod  (PG545)  timing  of administration ........................................................ 39 
7.3.5 Pixatimod  (PG545)  duration of administration ..................................................... 39 
7.4 Cy Dose  Selection,  Modification,  Timing  and Duration  ............................................... 39 
7.4.1 Cyclophosphamide dose  selection  ..................................................................... 39 
7.4.2 Cyclophosphamide dose  modification  .................................................................  39 
7.4.3 Cy timing  of administration ................................................................................. 39 
7.4.4 Cy duration of administration .............................................................................. 40 
7.5 Treatment  Allocation  .................................................................................................. 40 
7.6 Concomitant  Medications  ........................................................................................... 40 
7.6.1 Acceptable Concomitant  Medications  .................................................................  40 
7.6.2 Prohibited Concomitant  Medications  ...................................................................  40 
7.7 Rescue Medications  and Supportive Care .................................................................. 41 
7.7.1 Supportive Care  Guidelines  ................................................................................ 41 
7.8 Subject  Withdrawal/Discontinuation Criteria  ............................................................... 44 
7.9 Subject  Replacement  Strategy  ................................................................................... 44 
7.10 Clinical Criteria  for Early  Trial Termination .................................................................. 45 
8. STUDY  ASSESSMENTS AND PROCEDURES  .................................................................  46 
8.1 Trial Procedures  ......................................................................................................... 46 
8.2 Treatment  Period ....................................................................................................... 46 
8.3 Administrative  Procedures  ......................................................................................... 46 
8.4 Clinical Procedures  and Assessments ........................................................................ 47 
8.4.1 Adverse Events  (AE) monitoring  ......................................................................... 47 
8.4.2 Full physical  exam  ..............................................................................................  47 
8.4.3 Vital signs ........................................................................................................... 47 
8.4.4 Eastern  Cooperative Oncology  Group  (ECOG)  performance scale  ..................... 47 
8.5 Visit Requirements  ..................................................................................................... 47 
8.5.1 Requirements  ..................................................................................................... 47 
8.5.2 Screening  ........................................................................................................... 47 
8.5.3 Thirty -day safety  follow- up .................................................................................. 48 
8.5.4 End of Treatment  (EOT)  ..................................................................................... 48 
8.5.5 Post-treatment  Surveillance  Phase ..................................................................... 48 
8.5.6 Survival  follow up ............................................................................................... 48 
8.6 Laboratory  Assessments  ............................................................................................  48 
8.6.1 Screening laboratory  assessments  ..................................................................... 49 
8.6.2 On-treatment  laboratory  assessments  ................................................................ 49 
8.7 Efficacy Assessments  ................................................................................................ 50 
8.7.1 Tumor  imaging and disease assessment  ............................................................ 50 
8.7.2 Initial tumor  imaging ........................................................................................... 51 
8.7.3 Tumor  imaging  during  the study  ......................................................................... 51 
8.7.4 End of treatment  and follow -up tumor  imaging .................................................... 51 
8.7.5 RECIST  v1.1 disease  assessment  .....................................................................  51 
8.7.6 iRECIST  disease assessment  ............................................................................ 52 
8.8 Adverse Events  (AEs)  ................................................................................................ 55 
8.8.1 Definitions  .......................................................................................................... 55 
8.8.2 Evaluation of AEs and SAEs  .............................................................................. 56 
8.8.3 Timeframe  for AE/SAE Collection  ....................................................................... 58 
8.8.4 Recording AEs/SAEs  ......................................................................................... 59 
8.8.5 Reporting SAEs  and Serious  Unexpected  AEs (SUAE)  ...................................... 59 
8.8.6 IND safety  report  ................................................................................................ 61 
8.8.7 Follow -Up ........................................................................................................... 64 
8.8.8 Disclaimer  .......................................................................................................... 64 
8.8.9 Reporting AEs to the responsible Institutional  Review Board (IRB)  ..................... 64 
8.8.10 Follow -up of AEs and SAEs  .................................................................................... 65 
8.9 Tumor  Tissue Collection  and Correlative  Studies  ....................................................... 65 
8.9 Pharmacokinetics  Sampling ....................................................................................... 66 
8.10.1  Pixatimod  (PG545)  Pharmacokinetics  ................................................................ 66 
8.10.2  Cyclophosphamide Pharmacokinetics  ................................................................ 67 
9. STATISTICAL  CONSIDERATIONS  ................................................................................... 69 
9.1 Study  Design  ............................................................................................................. 69 
9.2 Safety  Monitoring ....................................................................................................... 69 
9.3 Efficacy  Decision  Rule ............................................................................................... 71 
9.4 Efficacy Analysis  ........................................................................................................ 71 
9.5 Safety  Analysis  .......................................................................................................... 72 
9.6 Biomarker  Analysis  .................................................................................................... 72 
9.7 Data  Safety  and Monitoring Plan ................................................................................ 73 
10. LABELING,  PACKAGING,  STORAGE,  AND RETURN OF CLINICAL  SUPPLIES  .........75 
10.1 Investigational  Product:  Pixatimod  (PG545)  ............................................................... 75 
10.1.1 Packaging and Labeling Information:  Pixatimod  (PG545)  ....................................... 75 
10.1.2 Handling,  Storage and Accountability:  Pixatimod  (PG545) ...................................... 76 
10.1.3 Dispensing:  Pixatimod  (PG545) .............................................................................. 76 
10.2 Commercial  Product:  Nivolumab  ................................................................................  76 
10.3 Commercial  Product:  Cyclophosphamide  ...................................................................  77 
11. REFERENCES  .............................................................................................................. 78 
12. APPENDICES  ............................................................................................................... 87 
12.1 Appendix  1: ECOG  Performance  Status115 ......................................................................................................... 87 
12.2 Appendix  2: Common  Terminology  Criteria  for Adverse  Events  V5.0 (CTCAE)  ..........88 
12.3 Appendix  3: Contraceptive Guidance and Pregnancy  Testing .................................... 89 
12.4 Appendix 4:  Description of the iRECIST Process for Assessment of Disease 
Progression  ........................................................................................................................... 90 
12.5 Appendix  5: Dietary  History  Questionnaire  (DHQ -3) Administration ............................ 95 
 
 
 
 
 
 
 
  
 
 
 
5 
1. SYNOPSIS  
 
Summary:  Nivolumab  and other  agents  directed  against  PD-1/PD -L1 pathway  are associated  with improved 
response and survival rates in multiple malignancies including advanced melanoma and PD -L1 
expressing NSCLC with objective response rates (ORR) of 35% -45%, the majority of which are 
durable.1-6 However, the majority of treated patients do not respond and not all responses are 
durable.  
 
Pixatimod (PG545, and hereafter referred to as pixatimod) is a small molecule heparan sulfate 
(HS) mimetic  that has natural  killer (NK) cell-dependent  anti-tumor  effects. PG545 is not a TLR9 
agonist that directly activates TLR9, rather, pixatimod results in CpG accumulation in the 
lysosomal compartment of DCs, leading to enhanced production of IL- 12, which is essential for 
pixatimod- mediated NK cell activation7,8. In a phase Ia dose- escalation study, single agent 
pixatimod monotherapy  at doses  up to 150  mg weekly (25 -150 mg weekly) demonstrated dose - 
proportional pharmacokinetics and innate immune cell activation.8 In a phase Ib study, 
combination of pixatimod with nivolumab demonstrated promising results in uninflamed tumors 
including microsatellite- stable colorectal carcinoma.9 
 
Low-dose cyclophosphamide has several immunomodulatory properties including: depletion of 
regulatory T cells; increased IFN production, induction of immunogenic cell death; increased 
CD8+ effector T cells; increased NK cell number and function.10 Pre-clinically, low- dose 
cyclophosphamide diminished immunosuppressive TGF-β and IL-10 and had synergy  with intra- 
tumoral  type B CpG SD-101 in injected  and uninjected  tumors.11 Preclinical synergy  with PG545 
has also been reported in a murine model of established lymphoma.12 Clinically, low- dose 
metronomic cyclophosphamide has primarily been used in breast cancer, castrate- resistant 
prostate cancer, ovarian cancer and CRC at varying doses (50 -100 mg daily) and schedules 
(daily, 1 -week -on, 1- week -off). 
 
We hypothesize that the nivolumab/pixatimod combination in PD -1 relapsed/refractory (R/R) 
cutaneous melanoma and NSCLC patients will be associated with anti -tumor effects. We also 
hypothesize that the nivolumab/pixatimod/cyclophosphamide combination  in microsatellite  stable 
(MSS) metastatic colorectal carcinoma (mCRC) patients will be associated with anti -tumor 
effects. We further hypothesize that nivolumab/pixatimod/cyclophosphamide combination in MSS 
mCRC patients  and nivolumab/pixatimod  combination in PD-1 R/R melanoma  or NSCLC  will be 
associated with increased CD8+ T cells intra- tumorally  and PD-1+Ki67+ CD8+ T cells peripherally 
in responders  on treatment  compared to baseline;  and that response  will be associated  with 
evidence  of antigen -specific  immunity  responses  intra-tumorally  and peripherally.  
Study 
Population:  Men or women,  ≥18 years  of age, with selected  solid tumors  and an Eastern  Cooperative  
Oncology  Group (ECOG)  performance  status  of ≤1 and have  at least  2 lesions  with measurable 
disease  as defined  by Response  Evaluation  Criteria  in Solid  Tumors  (RECIST)  Version  1.1. 
 
 
 
 
  
 
 
 
 
  
 
6 
Objectives  and 
Endpoints:   
 Objective  Endpoint   
Primary  
• To assess efficacy of 
nivolumab/pixatimod  combination in 
PD-1 R/R melanoma and NSCLC.  
 
 
• To assess efficacy of 
nivolumab/pixatimod/cyclophosphamide combination in MSS mCRC patients   
• Objective response  rate by 
RECIST v1.1 to  
nivolumab/pixatimod  combination 
in PD- 1 R/R melanoma and 
NSCLC.  
 
• Objective response  by RECIST 
v1.1 to nivolumab/pixatimod/ cyclophosphamide combination 
in MSS  mCRC  patients  
Secondary  
• To assess safety of 
nivolumab/pixatimod combination in 
PD-1 R/R melanoma  and NSCLC;  and 
nivolumab/pixatimod/cyclophosphamide 
combination in MSS mCRC patients  
 
• To assess  efficacy using alternative 
response endpoints.  
 
 
 
 
 
• To assess CD8+  T cell infiltrate  in pre- 
and on- treatment tumor samples by 
multiplex IHC/IF.  
 
 
 
 
• To assess median and landmark 
progression- free survival (PFS)  and 
landmark overall survival (OS) in participants treated with nivolumab/pixatimod or 
nivolumab/pixatimod/  
cyclophosphamide   
• Incidence of all -grade related 
adverse events (AE), serious adverse events  (SAE)  and dose- 
limiting toxicities (DLT) if any in each cohort.  
 
• Objective response by iRECIST 
to nivolumab/pixatimod/ 
cyclophosphamide combination 
in MSS mCRC patients and 
nivolumab/pixatimod  combination 
in PD- 1 R/R melanoma and 
NSCLC.  
 
• Summary measures of change 
(or % change) from baseline in 
the CD8+ T cell or NK cell 
infiltrate  in the tumor  and TME  in 
tumor biopsies at pre- and on- 
(approximately 4 weeks) treatment timepoints.  
 
• Median PFS, landmark PFS (6 months, 1 -year and 2- year), 
median OS and landmark  OS (1- 
year, and 2 -year) in participants 
treated with nivolumab/pixatimod 
or nivolumab/pixatimod/  
cyclophosphamide  
Exploratory  
• To explore potential association between biomarkers and clinical 
efficacy  of nivolumab/pixatimod or 
nivolumab/pixatimod/ 
cyclophosphamide combination  
• Correlation/measures of association of biomarkers  and 
clinical effect of nivolumab/pixatimod or nivolumab/pixatimod/  
cyclophosphamide  combination  
 
7 
Overall  Study 
Design:  This is a study of nivolumab in combination with pixatimod (PG545, hereafter referred to as 
pixatimod) in 3 separate cohorts:  
 
• Cohort  1: MSS mCRC in combination with low-dose  cyclophosphamide  
• Cohort  2: PD-1 relapsed/refractory  melanoma 
• Cohort  3: PD-1 relapsed/refractory  NSCLC.  
 
Each cohort comprises a two- stage Simon phase IIA trial. The goal of this study is to assess 
response of PD -1 R/R melanoma/NSCLC to nivolumab and pixatimod; and MSS mCRC to 
nivolumab, pixatimod and low -dose cyclophosphamide.  
Study 
Evaluation:  Participants  meeting  enrollment  criteria  will be enrolled  depending  on histology  into one of 3 
cohorts (cohort 1: MSS mCRC; cohort 2: PD -1 R/R melanoma; cohort 3: PD -1 R/R NSCLC).  
Number  of 
Participants:  In the 1st stage  of cohort  1 (MSS mCRC),  we will enroll  13 patients.  If ≥1 response(s)  are seen,  
14 additional patients will be enrolled in the 2nd stage. The 
nivolumab/pixatimod/cyclophosphamide combination will be considered worthy of further 
evaluation if ≥4 responses (ORR 15%) are seen across both stages in this cohort.  
 
For cohorts  2 (PD-1 R/R melanoma)  and 3 (PD-1 R/R NSCLC),  we will use the same design,  but 
separately, as  follows.  In the 1st stage  of each cohort, will enroll  9 patients.  If ≥1 response(s)  are 
seen, 8 additional patients will be enrolled in the 2nd stage. The combination will be considered 
worthy  of further  evaluation if ≥3 responses  (18%)  are seen across  both stages  in either  (or both)  
cohorts.  
Treatment 
Arms  and 
Duration:  There are 3 cohorts in this study: cohort 1: MSS mCRC; cohort 2: PD -1 R/R melanoma; cohort 
3: PD -1 R/R NSCLC.  
 
Nivolumab has demonstrated clinical activity in participants with melanoma and NSCLC. 
However, single- agent nivolumab has negligible efficacy in PD -1 R/R melanoma/NSCLC and 
MSS mCRC.  
 
Treatment will be assigned based on histology. Combination therapy will be administered until 
toxicity/discontinuation or completion of 2 years of combination treatment.  
Study 
Assessments 
and Analyses Primary  Endpoint  
• Objective response by RECIST v1.1 to nivolumab/pixatimod/cyclophosphamide 
combination in MSS mCRC (cohort 1) patients and nivolumab/pixatimod combination in 
PD-1 R/R melanoma and NSCLC (cohorts 2 and 3).  
 
Secondary  Endpoints  
• Objective response by iRECIST to nivolumab/pixatimod/cyclophosphamide combination 
in MSS mCRC (cohort 1) patients and nivolumab/pixatimod combination in PD -1 R/R 
melanoma and NSCLC (cohorts 2 and 3).  
• Summary measures of change (or % change) from baseline in the CD8+ T cell and NK 
cell infiltrate in the tumor and TME in tumor biopsies at pre - and on-  (approximately 4 
weeks) treatment timepoints.  
• Median PFS,  landmark  PFS (6 months,  1-year and 2-year),  median  OS and landmark 
OS (1 -year, and 2 -year) in participants treated with nivolumab/pixatimod or 
nivolumab/pixatimod/cyclophosphamide.  
 
Exploratory  Endpoints  
• Correlation/measures of association of biomarkers and clinical effect of 
nivolumab/pixatimod  or nivolumab/pixatimod/cyclophosphamide  combination.  
 
8 
  
Safety  Outcome  Measures  
• Adverse events  (AE) will be assessed continuously  during the study  and for 100 days 
after the last dose of study treatment.  
• AEs will be graded using National  Cancer  Institute  (NCI)  Common Terminology  Criteria 
for Adverse Events (CTCAE) Version 5.0.  
 
Efficacy Measurements  
• Disease assessment with computed tomography (CT) and/or magnetic resonance 
imaging (MRI), as appropriate, will be performed at baseline and every 8 weeks (± 7 
days) until disease progression, at the completion of follow -up, or until participants 
withdraw  from the study.  Tumor  responses  will be derived for evaluable participants  as 
defined by RECIST Version 1.1 based on recorded tumor measurements. 
• Serologic  tumor  markers  will be collected,  as appropriate.  
• At the Sponsor -Investigator’s  discretion,  scans  and measurements  may be collected 
and reviewed by independent radiologists at a later date, or at any time during the study.  
 
Biomarker  Measures:  
• A broad  translational plan to evaluate  predictive biomarkers  for combination therapy 
(see Section 8.9.1 ). Analysis of interest may include, but are not limited to:  
• Systemic Immunity:  
o Serial peripheral blood samples will be obtained for immuno-monitoring by 
multiplex  flow- cytometry  and proteomic  analysis  of immunologically  relevant 
soluble factors.  
• Tumor  Microenvironment:  
o Multiplex  IF and IHC to evaluate tumor  microenvironment  and to assess 
relationships between baseline and on- treatment immune contexture.  
o Transcriptome  analysis  (to understand gene  expression signatures  and 
pathways that mediate response, resistance and toxicity).  
o Whole exome  sequencing (to understand the relationship between driver 
mutations and response, resistance and toxicity, and to understand the relationship between mutational load and neo -antigens to response).  
o Peripheral blood circulating tumor deoxyribonucleic acid (ctDNA) or cell -free 
DNA  (cfDNA;  to compare  this technology  to findings  derived directly  from the 
tumor).  
• Host Status  
o Whole blood whole- genome sequencing (WGS) or whole exome sequencing 
(WGS; to assess for the relationship between germline single nucleotide polymorphisms  with response,  resistance and toxicity, and for making  mutational 
calls on the tumor DNA sequencing).  
o Stool  for microbiome  (to assess the impact  of fecal  metagenomics  on IO 
response, resistance and toxicity).  
 
Statistical 
Considerations  Sample  size calculation:  
Stage 1 ( cohort 1  – 13 patients;  cohorts 2/3 – 9 patients).  
Stage 2 ( cohort  1 – 14 patients;  cohorts  2/3 – 8 patients). 
Total enrollment for 1st stage across all 3 cohorts = 31.  
Total  enrollment  for both stages  across  all 3 cohorts  = 61. 
 
Sample  size justification:  
 
9 
 In the 1st stage  of cohort  1 (MSS  mCRC ), we will enroll  13 patients.  If ≥1 response(s)  are seen,  
14 additional patients will be enrolled in the 2nd stage. The 
nivolumab/pixatimod/cyclophosphamide combination will be considered worthy of further 
evaluation if ≥4 responses (ORR 15%) are seen across both stages in this cohort. This study 
design,  using Simon’s  2-stage Minimax  design,  provides  80% power  with 5% type I error  to detect 
a response rate of 20% against a null hypothesis of 5%.  
 
For cohorts 2 ( PD-1 R/R melanoma ) and 3 (PD-1 R/R NSCLC), we will use the same design, 
but separately, as follows. In the 1st stage, will enroll 9 patients. If ≥1 response(s) are seen, 8 
additional patients  will be enrolled in the 2nd stage.  The combination will be considered worthy  of 
further evaluation if ≥3 responses (ORR 18%) are seen across both stages. This study design, 
using Simon’s optimal 2 -stage design, provides 80% power with 5% type I error to detect a 
response rate of 25% against a null hypothesis of 5%.  
 
Statistical  plan:  
In the interest of maximizing safety while minimizing exposure to a potentially ineffective 
combination, we have designed parallel two- stage phase II studies in three cohorts. We 
hypothesize that nivolumab/pixatimod combination (and low -dose Cy in MSS mCRC ) will 
increase the frequency of responding patients in each cohort.  
 
Although the nivolumab/pixatimod combination  is being evaluated  in advanced studies  and DLT 
of pixatimod has been established in a prior phase I study,8 the nivolumab/PG545/Cy combination 
has not been evaluated. However, given the Cy dose being studied, no DLTs are expected.  To 
mitigate  toxicity, we will monitor  toxicities continuously  (cohort  1) and implement  a 4-week DLT 
monitoring period during the enrollment of the first 3 patients across cohorts 2- 3. During this 
period, only 1 patient will be enrolled every 4 weeks. If no DLT occurs for the first 3  
patients  during  the DLT monitoring  period,  this enrollment  cap will be lifted.  
 
 
     
 
     
 
     
 
    
 
 
 
10 
 
2. SCHEDULE  OF ACTIVITIES  
 
Procedure/ 
Assessment  Screening  
(Day  -28 to - 
1)A Treatment  CyclesB End of 
Treatment 
C 30 Day 
Follow - 
UpD Post - 
Treatment 
SurveillanceE 
 Cycle  1 
Day 1 Cycle  1 
Day 2 Cycle  1 
Day 4 Cycle  1 
Day 8 Cycle  1 
Day 15 Cycle  1 
Day 22 Cycle  2 
Day 1 Cycle  2 
Day 8 Cycle  2 
Day 15 Cycle  2 
Day 22 Cycle  3+ 
Visit Windows   None  None  None  ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 days ± 2 
days ± 2 days ± 7 days ± 7 days ± 14 days 
NivolumabF  X      X (q4 
weeks)     X (q4 
weeks)     
Pixatimod 
(PG545)G  X   X X X X X X X X 
(weekly)     
CyH (Cohort  1 
CRC only )  XH      XH    XH    
Informed  consent  X               
Eligibility  criteria 
assessment  X               
Physical  exam 
including vital  
signsI X X      X    X (D1) XC XD XE 
Vital signsI     X X X  X X X X (D 
8/15/22)     
Electrocardiogram 
(ECG)J X X              
Laboratory 
assessments  XK-S XK-B    XK-T (D15 
only)   XK-B  XK-T (D15 
only)   XK-B (D1 
only)  and  XD XE 
including       XK-T (D15   
screening  labsK      only)    
Serum/urine 
pregnancy  testL X               
Pixatimod 
pharmacokinetic 
(PK) samplingM  XM-1 XM-1 XM-1 XM-1           
Cy PK samplingN  XN-1 XN-1             
Tumor  biopsyO XO-S       XO-O     XO-P   
Exploratory  X    X X  X  X (C2D15,   X (q8 X   
biomarker     (C2D15,  C2D22)  weeks)   
analysesP    C2D22)     
Stool  samplingQ  X         X X (q8 X   
     weeks)   
       
Dietary  history 
questionnaireR  X              
 
 
11 
 
Disease 
assessmentS X           X (q8 
weeks 
starting 
with 
C3D1)    XE 
 
Study  Calendar  Notes:  
AScreening period  is 28 days  (≤4 weeks)  prior to first dose  of pixatimod/nivolumab.  
• Screening studies  including magnetic  resonance imaging  (MRI)/computed  tomography  (CT) imaging  must  be performed ≤4 weeks  prior to first dose  of 
pixatimod/nivolumab.  
• During Screening,  MRI brain with contrast  (or CT equivalent)  should be performed  to exclude  CNS  metastatic  disease  for melanoma  and NSCLC patients.  
• CNS  imaging is not required  for MSS mCRC patients  at Screening  unless  patient  is symptomatic.  
• CNS  imaging need not be repeated  on study unless  patient  is symptomatic.  
• CNS  imaging  should  be repeated at investigator’s  discretion in patients  with a history  of treated  CNS  metastases.  
BTreatment  cycle  
• Each  cycle  is 28 days  long.  
CEnd-of-treatment  (EOT) assessments to  be performed within 7 days  following removal  of subject  from pixatimod treatment.  Removal of a subject  from pixatimod 
treatment is defined as the time in which the Investigator decides to discontinue pixatimod treatment for a subject.  
• Management  of patients  who develop unacceptable toxicity  is defined in Section  8.5.4 . 
o Patients who develop unacceptable toxicity deemed related to pixatimod (or if applicable, cyclophosphamide) but not nivolumab may continue 
Nivolumab (and if applicable cyclophosphamide) after pixatimod discontinuation for duration as defined in Sections 7.3.2 and 7.4.2 . 
o Patients  who develop  unacceptable  toxicity  deemed  related to nivolumab but not pixatimod  must  discontinue both pixatimod and nivolumab.  
D30-day  follow -up. 
• This begins  +30 days  following completion  of last dose of study  treatment  or EOT,  whichever  is earlier.  
• Procedures  to be followed during this phase are outlined in Section  8.5.3  and will include  a visit, labs (CBC,  CMP,  TSH,  free T3, free T4) and any other 
studies deemed necessary at the discretion of the treating physicians and according to established Standard of Care.  
EPost-treatment  surveillance.  
• This phase begins  upon  completion of 30 day follow  up. 
• Procedures  to be followed during this phase are outlined in Section  8.8.5  will include imaging  (CT or PET/CT),  labs (CBC,  CMP,  TSH,  free T3, free T4) 
and any other studies deemed necessary at the discretion of the treating physicians and according to established Standard of Care.  
• Note – Patient accrual was terminated early owing to the discontinuation of pixatimod supply.   Follow -up assessments will no longer be completed upon IRB approval of 
protocol version 02/23/2024.  
FNivolumab  dosing  
• Nivolumab  will be dosed  at 480 mg q4 weeks IV. 
GPixatimod  
• Pixatimod  will be  dosed 25 mg weekly IV. 
• Pixatimod  will be administered  through  either  a large- bore IV line placed  in the antecubital  fossa  or central  venous  catheter.  
• Patients  in whom  pixatimod is administered through a small -bore/distal  IV may developed  a delayed-type  hypersensitivity  reaction.  
o This should not be treated  as an infusion reaction  and should recur  upon the administration  through a proximal  large-bore IV line. 
HCyclophosphamide dosing  (Cohort  1 only) 
• 50 mg PO twice  daily (D1-D7; D15-D21)  with a 7-day drug free interval  (D8-D14  and D22-D28).  
• Cyclophosphamide dose compliance  will be assessed using  a pill diary.  
IPhysical  exams  will be conducted at Screening,  each  pixatimod treatment  visit, EOT,  30-day follow -up and during  Post-treatment  surveillance.  
• Screening physical  exam  may be performed up to 72 hours  prior to the Cycle 1  Day 1  visit.  
• Physical  exams  should be repeated on each D1 visit and should include  assessment  of ECOG  performance status.  Requirements  are defined  in Section 
8.4.2.  
 
12 
• On D8/D15/D22  for all cycles,  a formal  physical  exam  is not required and only vital signs  will be recorded.  
• Height  will be recorded  at Screening visit only.  
JElectrocardiograms  (ECGs) should be obtained at Screening and prior to administration  of pixatimod  C1D1.  
• ECG  need not be repeated unless  clinically  indicated at subsequent  visits.  
KLaboratory  assessments  
• Laboratory  assessments to  be obtained  at Screening (XK-S): CBC,  renal  and liver function,  coagulation  parameters,  infectious  parameters (HIV,  Hep B/C 
screening), thyroid function (TSH, free T3 and free T4), and urinalysis.  
o NOTE:  In patients  who are currently  or have recently  (within  6 months)  been  on heparin,  low-molecular  weight  heparin,  fondaparinux  or other 
similar agents, anti -heparin antibodies should be obtained during Screening. Per Section 6.2.3 , the presence of anti -heparin antibodies is 
exclusionary.  
• Laboratory  assessments  to be obtained on Baseline (Cycle  1 Day 1; XK-B): CBC,  renal  and liver function,  coagulation parameters,  fasting  lipids,  thyroid 
function (TSH , free T3 and free T4) and urinalysis.  
• Laboratory  assessments  to be obtained on On-Treatment  (XK-T): CBC,  renal  and liver function,  fasting  lipids  (D1 of each cycle  only starting  with C2D1 ) 
coagulation parameters, and urinalysis.  
• There is a 48-hour  window  to obtain  Screening (XK-S), Baseline  (XK-B) and/or  On-Treatment  (XK-T) laboratory  assessments.  
LPregnancy  testing  
• Only required  at screening  in women of childbearing  potential  (WOCP).  
MPixatimod  PK sampling  
• Pixatimod  PK timepoints  (relative  to pixatimod infusion):  
o 1 – to be performed at pre-dose , 30min  (± 5 min),  2h (± 15 min),  4h (± 15 min),  6h (± 30 min),  24h (D2; ± 60 min), 72h (D4; ± 24 hours) and 
168h  (prior  to C1D8;  ± 24 hours)  post infusion;  
o Windows:  
o Pixatimod  PK sampling will be  collected  from 10 subjects  in Cohort  1, and a total  of 10 subjects from Cohorts 2  and 3. 
• Samples  to be collected as delineated in Section  8.10.1  and will be processed as delineated  in the Laboratory  Manual.  
NCyclophosphamide PK sampling 
• Cyclophosphamide PK timepoints  (relative to pixatimod  infusion):  
o 1 – to be performed at pre-dose , 10min  (± 5 min),  30min  (± 5 min),  1h (± 10 min),  2h (± 15 min),  4h (± 15 min),  6h (± 30 min),  and 24h (D2; ± 
60 min) post cyclophosphamide;  
o Cyclophosphamide PK sampling  will be collected from 10 subjects in Cohort  1 only. 
• Samples  to be collected as delineated in Section  8.10.2 and will be processed as delineated  in the Laboratory  Manual.  
OTumor  biopsy  must  be performed prior to commencing  Pixatimod/Nivolumab  treatment.  
• Punch,  core (16 gauge)  and/or  surgical  biopsies  are acceptable.  
If core biopsy  is performed,  pathology  confirmation  is required  to ensure adequate  tissue  is obtained;  and a minimum  of 6 cores  must  be obtained.  
• Tumor  biopsies  will be obtained at Screening  (XO-S), on-treatment  at C2D1  (XO-O) and at progression (if applicable;  XO-P). 
PExploratory  biomarker  analyses  will be obtained as follows:  
• Prior to administration of pixatimod/nivolumab  at Screening,  on C1D1,  C1D8,  C1D15,  C2D1,  C2D15,  C2D22  in Cycles  1-2. 
• Cycles  3 onwards:  q8 weekly.  
• Samples  to be collected  as delineated in Section  8.9 and will be processed  as delineated in the Laboratory  Manual.  
QStool  sampling will be obtained  as follows:  
• Prior to administration  of pixatimod/nivolumab  on C1D1  and C2D22 . 
• Cycles  3 onwards:  q8 weekly.  
• EOT  
• Samples  will be processed  as delineated in the Laboratory  Manual.  
RDietary  history  questionnaire will be on C1D1.  Dietary  questionnaire is detailed  in Appendix  6. 
 
13 
SCT or MRI scans  to assess  tumor  status  will be obtained at Screening  (baseline value  should be performed ≤4 weeks  prior to first pixatimod dose).  
• Screening:  Scans  should be performed ≤4 weeks  prior to first pixatimod  dose.  CT (or PET/CT  or MRI)  can be obtained  at Investigator  discretion,  however, 
contrast -enhanced CT is preferred.  
• Cycles 1-2 (+/- 7 days):  Contrast -enhanced  CT (or PET/CT) at C3D1 . 
• Cycles 3+ (+/- 7 days):  Contrast -enhanced  CT (or PET/CT) every  8 weeks.  
• Progression:  Progression  should  be confirmed with repeat  imaging study  done no sooner  than 4 weeks  after prior study.  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
  
 
  
 
  
 
 
 
 
 
 
 
  
 
 
14 
15  
 
3. INTRODUCTION 
3.1 Study Rationale  
 
PD-1 is a receptor expressed by activated T - and B - cells which binds to two known ligands: PD -L1 (B7-  
H1)13,14 and PD -L2 (B7 -DC).15,16 PD-1 negatively regulates T cell functions through the engagement of PD - 
L1, which  is expressed by a wide variety  of tissues.13-16 PD-L1 is also expressed by human tumors,  including 
melanoma, either constitutively or after treatment with IFN -α.17,18 In chronically infected mice, lymphocytic 
choriomeningitis  virus -specific  CD8+  T-cells exhibit  a diminished capability  to produce cytokines,  lyse infected 
cells and proliferate in a progressive and hierarchical  fashion.19 These “exhausted”  T-cells have been shown 
to up -regulate PD -1, and blockade of the PD -1/PD -L1 pathway led to increased cytokine production and 
proliferation, resulting in a significant reduction of the viral load.19 
 
We have previously  shown  that majority  of tumor  antigen- specific  CD8+ T  cells upregulate PD-1 expression, 
which is associated with T cell exhaustion/dysfunction in chronic viral infections in animals and humans.20,21 
We observed  that PD-1 upregulation on  spontaneous tumor antigen -specific CD8+  T cells  occurs  along with 
T cell activation and is not directly associated with an inability to produce  cytokines ex vivo upon stimulation 
with cognate  antigen.  Blockade  of the PD-1/programmed  death  ligand 1 (PD-L1) pathway  in combination with 
prolonged antigen stimulation with PD -L1+ antigen- presenting cells or melanoma cells augmented the 
frequencies  of cytokine- producing,  proliferating  and total tumor  antigen- specific  NY-ESO -1 CD8+  T cells.20,21 
Collectively, these findings support that PD -1 is a regulator of antigen- specific CD8+ T cell expansion in the 
context of chronic antigen exposure in patients with advanced cancer; and that PD -1 blockade reverses 
tumor -mediated T cell dysfunction.  
 
Immune  checkpoint  inhibitors  (ICI) directed  against  PD-1/PD -L1 are associated with improved  response and 
survival rates in multiple malignancies including melanoma, squamous/non- squamous lung cancer, bladder 
and renal cell carcinoma.4,6,22- 25 In advanced melanoma and PD -L1 expressing NSCLC, anti -PD-(L)1 
monotherapy produces overall response probabilities of 42% -45%, the majority of which are durable.1-6 
 
In Checkmate- 067, dual anti -PD-1 and anti -CTLA -4 blockade with nivolumab and high- dose ipilimumab 
(3mg/kg  every  3 weeks  for 4 doses)  further  improved  ORR (58%)  in melanoma compared to either  nivolumab 
or ipilimumab,  albeit  with significantly  greater  toxicity.26-29 Ipilimumab/nivolumab was associated with five year 
progression- free survival  (PFS)  of 36%,  compared  with 29% (nivolumab)  and 8% (ipilimumab).28 Checkmate-  
227 compared low- dose ipilimumab/nivolumab combination (nivolumab 2mg/kg every 2 weeks; ipilimumab 
1mg/kg every 6 weeks) to nivolumab monotherapy and platinum -doublet chemotherapy in PD -L1≥1% 
NSCLC. Ipilimumab/nivolumab combination produced slightly better response com pared to chemotherapy 
(36%  vs. 30%),  with commensurately  improved  PFS and overall  survival  (OS)  and led to regulatory  approval.30 
 
While anti -PD(L)1 blockade singly and in combination is remarkably efficacious in melanoma and NSCLC, ICI  
therapy  is minimally  efficacious  in microsatellite  stable (MSS)  CRC.  The remarkable efficacy  of PD-1/PD - L1 
or PD -1/CTLA -4 blockade in CRC in limited to hyper -mutated subtypes –  specifically those with microsatellite 
instability -high (MSI -H)/mismatch repair -deficient (dMMR) CRC or those with POLE mutations.31,32 In these 
patients, the response to ICI is related to increased TIL density secondary to immunogenic  neoepitopes  and 
increased tumor  mutational  burden (TMB).  However,  MSI-H tumors  constitute  
~3% of all CRC and ICI therapy  is minimally  effective  in MSS  mCRC.33 
 
Biomarkers of response to PD -(L)1 blockade include CD8+ TIL,34,35 interferon gamma (IFN -γ) gene 
expression,36,37 high tumor  mutation burden  (TMB;  37-39) or PD-L1 expression.40,41 These observations  suggest 
that uninflamed tumors represent the bulk of tumors that fail to respond to anti -PD(L)1 ICB; and argue for 
augmenting inflammation as a means to promote T cell responses in PD -1 relapsed/refractory (R/R) 
melanoma and PD -1 R/R NSCLC and MSS mCRC.  
16  
Tumor -associated DC are critical regulators of the balance between CD8+ T cell immunity versus tolerance 
to tumor antigens. There are 3 major DC subsets in humans: CD141+ myeloid/conventional DC1 (cDC1), 
CD1c+/CD11b+/BDCA -1+ myeloid/conventional  DC2 (cDC2)  and CD123+/BDCA -2+/BDCA -4+ plasmacytoid 
DC (pDC). Of these, both CD141+ cDC1 and CD123+/BDCA -2+/BDCA -4+ pDC are critical for CD8+ T cell 
priming and efficacy of PD -1 blockade.42 TLR9 agonists activate pDCs to secrete type I IFN and to express 
increased levels of co -stimulatory molecules such as CD80 (B7.1) and CD86 (B7.2). TLR9 agonism results 
in a range of secondary  effects,  including secretion of cytokines  such  as MCP -1, IP-10/CXCL10 that activate 
NK cells and expand T cell subpopulations  including CD8+  T cells and TH1 cells.43 However, TLR9 agonists 
are limited  as they have  to be administered  intra-tumorally  as systemic administration  of TLR9  agonists  results 
primarily in liver, spleen, and RES uptake with little specific activation of pDC in draining lymph nodes; and 
immature tumor -associated pDC contribute to tumor growth and an adverse prognosis in patients with 
cancer.44,45 Hence, systemically administered agents may overcome some of limitations of intra- tumoral 
innate immune agonists such as TLR9 and STING agonists, promoting antigen presentation to T cells, 
facilitating cross -priming and augmenting adaptive T cell responses in cancer.  
 
3.2 Pharmaceutical  and Therapeutic  Background:  Nivolumab 
 
The importance  of intact  immune  surveillance in controlling outgrowth of neoplastic transformation  has been 
known for decades.46 The inability of the immune system to control tumor growth does not appear to result 
from an inability  to recognize the tumor  as foreign.  Tumor  cells have  been  shown to evade  immune  destruction 
despite displaying recognizable antigens  on their surface and despite the presence of high-avidity  T cells that 
are specific for these antigens.47-50 Histologic evaluation of many human cancers show extensive infiltration 
by inflammatory and immune cells,51,52 suggesting that the immune system responds less effectiv ely to 
malignancy.  These observations  have led to the hypothesis  that dominant  mechanisms  of immune tolerance 
or immune suppression are responsible for the immune system's inability  to effectively  respond in a way that 
consistently results in rejection.  
 
There are a number of inhibitory mechanisms that have been identified to be involved in tumor -mediated 
immune suppression and include expression of the programmed death ligand- 1 (PD -L1), which can engage 
the inhibitory receptor PD -1 on activated T cells; t he presence of the tryptophan- catabolizing enzyme IDO1, 
which exploits the exquisite sensitivity of T cells to tryptophan depletion and tryptophan metabolites; and infiltration with FoxP3+ regulatory T cells (Treg), which can mediate extrinsic suppression of effector T- cell 
function. Therefore, agents that target these negative regulatory pathways and thereby allow the expansion of effector T cells present in the tumor may be beneficial in the clinic.  
 
The PD -1 receptor -ligand interaction is a major pathway stimulated by tumors to suppress immune control. 
The normal  function of PD-1, expressed on the cell surface of activated T cells under  healthy  conditions,  is to 
down- modulate unwanted or excessive immune responses, including autoimmune reactions. Programmed 
death receptor -1 (encoded by the gene Pdcd1)  is an Ig superfamily  member  related to CD28  and cytotoxic  T- 
lymphocyte -associated antigen- 4 (CTLA -4), which has been shown to negatively regulate antigen receptor 
signaling upon engagement of  its ligands  (PD-L1 and/or  PD-L2).14,15,17 The mechanism  by which PD- 1 down 
modulates T -cell responses is similar to but distinct from that of CTLA -4, as both molecules regulate an 
overlapping set of signaling proteins.53,54 
 
Programmed death (PD) receptor -1 has been shown to be expressed on activated lymphocytes including 
peripheral  CD4+  and CD8+  T cells,  B cells,  Tregs,  and natural  killer cells.55 Expression has also been shown 
during thymic development on CD4- CD8- (double negative) T cells as well as subsets of macrophages and 
dendritic  cells (DCs).  The ligands  for PD-1 (PD-L1 and PD-L2) are constitutively  expressed or can be induced 
in a variety  of cell types,  including non-hematopoietic  tissues  as well as in various  tumors.15,17,18,41,56,57 Binding 
of either PD -1 ligand to PD -1 inhibits T- cell activation triggered through the T- cell receptor. PD -L1 is expressed 
at low levels on various non- hematopoietic tissues, most notably on vascular endothelium, whereas PD -L2 
protein is only detectably ex pressed on antigen- presenting cells found in lymphoid tissue or  
17  
chronic  inflammatory  environments.  PD-L2 is thought  to control  immune  T-cell activation  in lymphoid organs, 
whereas  PD-L1 serves to dampen  unwarranted T-cell function in peripheral  tissues.  Although healthy  organs 
express  little (if any) PD-L1, a variety  of cancers  were  demonstrated to express  abundant  levels  of this T-cell 
inhibitor.  PD-1 has been  suggested to regulate  tumor -specific  T cell expansion in subjects  with melanoma.20,21 
This suggests that the PD -1/PD -L1 pathway plays a critical role in tumor immune evasion and should be 
considered as an attractive target for therapeutic intervention.  
 
Nivolumab is a fully human Ig G4 antibody that blocks PD -1. Nivolumab is approved for the treatment of 
metastatic  melanoma  following  ipilimumab  and, if BRAF  V600 mutation  positive,  a BRAF  inhibitor  (Checkmate 
037). Nivolumab is also approved for the treatment of advanced metastatic NSCLC of both squamous 
(Checkmate  017) and non-squamous  (Checkmate  057) histologies  following  progression  on or after platinum - 
based chemotherapy.  
 
3.3 Pharmaceutical  and Therapeutic  Background:  Pixatimod  (PG545)  
 
Pixatimod is a cholestanol -sulfotetrasaccharide conjugated small molecule compound that is a heparan 
sulfate (HS) mimetic with unique NK - and T cell - dependent immunomodulatory properties that is currently 
being evaluated in a variety of different tumors. Beyond anticoagulation, the therapeutic potential of heparin 
derivatives and heparan sulfate (HS) mimetics in  oncology is related to their ability to  bind and modulate the 
function of a vast array  of HS -binding proteins with pivotal roles  in cancer growth and progression.7 Defining 
the structural and functional determinants of HS mimetics has clarified the structural requirements for the 
inhibitory effects of HS mimetics on heparanase, selectins, growth factor receptor signaling, 
immunomodulatory activities while limiting potential adverse effects.7 
 
Pixatimod  has an oligosaccharide backbone that is  derived from starch, and  retains  the amylose  structure of 
α(1 → 4)-linked  glucose residues.58 Coupling  the sulfated oligosaccharide to a lipophilic  cholestanol  aglycone 
significantly increased the elimination half -life in vivo, while reducing the unwanted anticoagulant activity 
associated with similar compounds while retaining inhibition of HS -degrading enzyme heparanase- 1 
(HPSE).58-61 As such, pixatimod has a half -life of approximately 141 hours (6 days) in humans, considerably 
greater than the 7 -8 hours observed with most heparin mimetics -  enabling weekly dosing.58 
 
Pixatimod inhibits HPSE in a concentration- dependent manner; a function that is critical to its activity.60,61 
However, it is important to consider that pixatimod has significant immunomodulatory properties as well. In 
multiple orthotopic models, pixatimod inhibited infiltration of tumor -associated macrophages (TAMs).62-65 
TAMs  contribute  to cancer  progression  and therapeutic  resistance  by mediating an immunosuppressive TME 
and facilitating tumor metastases through multiple mechanisms including promotion of tumor cell 
extravasation, invasion, vascularization (see Figure 3.3 -1).66 
18  
 
 
Figure  3.3-1: Pixatimod  inhibits  tumor -associated  macrophages (TAMs).  
 
Separately, the anti -tumor effects of pixatimod are NK- dependent, which in turn was found to be IL- 12 and 
TLR9 dependent (see Figure 3.3 -2).12 
 
Figure  3.3-2: Activation  of NK cells by pixatimod in tumor -bearing  mice.  
 
Pixatimod does not possess CpG  ODN motifs  and hence does not activate TLR9 directly. Rather,  pixatimod 
increases  CpG ODN accumulation in endosomal  compartment  of DCs,  leading to enhanced production of IL- 
12, which is essential for pixatimod -mediated NK cell activation (see Figure 3.3 -3).12 

19  
 
 
Figure  3.3-3: Pixatimod  increases human  PBMC -derived  pDC activation  (CD40)  in response to 24- hour  exposure 
to CpG ODN -2006 in vitro.  
 
Preclinically, pixatimod potently inhibits solid tumor progression and metastasis in a number of syngeneic, 
orthotopic and xenograft murine  models of cancer  either singly59,63,67- 74 or in combination with chemotherapy 
such as paclitaxel  or gemcitabine.75,76 Pixatimod  has demonstrated  synergy  with cyclophosphamide,  although 
this may be immunodulatory given the effects of low- dose Cy on NK cell activation.12 
 
3.4 Pharmaceutical  and Therapeutic  Background:  Cyclophosphamide 
 
Cy [N,N-bis (2-chloroethyl) -1, 3, 2- oxazaphosphinan- 2 amine 2 -oxide] is  a nitrogen  mustard alkylating agent 
from the oxazophorine  group.  Cyclophosphamide  exists as a solid,  soluble (in water),  and a very weakly  acidic 
compound (based  on its pKa).  It is administered  orally  or intravenously.  Cyclophosphamide is activated in the 
liver, principally activated  by cytochrome P450 isoforms,  CYP2A6, 2B6,  3A4, 3A5,  2C9, 2C18, and  2C19, of 
which  the CYP2B6  isoform  has the highest  4-hydroxylase activity.  Cy undergoes  activation  to eventually  form 
active metabolites, phosphoramide mustard and acrolein.  
 
As an alkylating agent, cyclophosphamide has three different independent effects: 1) attachment of alkyl 
groups to DNA bases, resulting in DNA being fragmented by repair enzymes as it attempts to replace the 
alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA; 2) DNA cross - 
linking which inhibits strand separation for replication and/or transcription; 3) induction of nucleotide mispairing. As a cytotoxic agent, cyclophosphamide is a key agent in combinations used in the treatment of 
breast cancer,  lymphoma, leukemia, AL amyloidosis.  
 
Pioneering work by Dr. Robert North and Dr. Judah Folkmak clarified that low -dose metronomic 
cyclophosphamide had immunostimulatory and antiangiogenic properties, paving the way for combinations 
with vaccines  and other  agents.  While  it is unclear  how convergent  and/or  overlapping both these effects  are 
with low- dose metronomic cyclophosphamide, what is clear is that these effects are predicated upon the 
following observations:  
• Induction  of a T
H1/TH2 to TH17 skew in cytokine production;77,78 
• Depletion of CD4+  Foxp3+  regulatory  T cells;79,80 
• Enhancement  of long- term survival and proliferation of lymphocytes;81,82 
• Induction  of pro-inflammatory  cytokines  including IL-1β, IL-7, IL-15, IL-2, IL-21, and IFN- 
γ;83 

20  
• Augmentation the function of dendritic cells (DC);84-89 and natural killer (NK) cell number 
and function DC function.79,90 -92 
 
Low-dose cyclophosphamide has several immunomodulatory properties including: depletion of regulatory T 
cells;79,80 augmentation of DC84-89 and NK79,90- 92 cell function. The properties result in T H17 skew in cytokine 
production;77,78 increased IFN production;79,90 -92 and induction of immunogenic  cell death.  79,90 -92 Pre-clinically, 
low-dose cyclophosphamide diminished immunosuppressive TGF -β and IL- 1093 and had synergy with intra - 
tumoral type B CpG SD -101 in injected and uninjected tumors.11,93 
 
3.5 Preclinical  and Clinical Trial  Data:  Nivolumab  
 
Refer  to the Nivolumab  Investigator’s  Brochure  (IB) for Preclinical and Clinical data.  
 
3.6 Preclinical  and Clinical  Trial  Data:  Pixatimod  (PG545) 
Refer to the Pixatimod IB for Preclinical and Clinical data. 
Preliminary safety and efficacy in advanced cancer patients  
In early clinical studies, pixatimod was administered subcutaneously (SC), although following local injection 
site reactions,  this was switched  to intravenous  (IV) infusion.76 In the phase I dose- escalation study,  escalating 
doses of pixatimod (25 mg, 50 mg, 100 mg, and 150 mg weekly) were administered IV in patients with 
advanced solid tumors.8 Three dose -limiting  toxicities  (DLTs)  were  identified  in the 150 mg cohort  (2 instances 
of hypertension and 1 of epistaxis); and no DLTs were noted in the 100 mg cohort, which was identified as the maximum -tolerated dose (MTD).
8 Among 16 response- evaluable patients, no objective responses were 
reported;  however,  disease control  rate (DCR)  was 38% (6/16).8 Pharmacokinetic  exposure was proportional 
up to 100 mg with a mean  serum  half-life of 141h supporting once weekly  administration.8 Pharmacodynamic 
data revealed early increases in CD40+ pDC and NKp46+ NK cells; and increased concentration of IFNγ, 
TNF-α, CXCL10/IP- 10 and MCP -1 in plasma.8 
 
Preliminary  safety  and efficacy  in combination  with anti-PD(L)1  in advanced cancer  patients  
 
Pixatimod  has been studied in combination with nivolumab in a phase IB study  of advanced PD-1 naive  solid 
tumors. In this study, patients with a variety of malignancies (pancreatic cancer, colorectal cancer, uterine adenosarcoma, squamous cell carcinoma, endometrial carcinoma, and adrenocortical carcinoma) were 
enrolled to receive escalating doses  of pixatimod (25mg  up to 50mg)  IV weekly  in combination with nivolumab 
240mg IV q2 weekly.  
 
A total of 58 patients were enrolled: 55 patients to 25 mg pixatimod/240 mg nivolumab and 3 patients to 50 
mg pixatimod/240 mg nivolumab. Forty -eight (48) subjects withdrew due to disease progression (either 
confirmed per RECIST or unconfirmed clinical progression), seven due to adverse events (two in the 50 mg 
and five in the 25 mg pixatimod cohort),  and two withdrew  consent  Three DLTs  occurred.  Two DLTs  occurred 
in the 50 mg pixatimod cohort: multiorgan failure (assessed as related to pixatimod and nivolumab), and pulm onary oedema (assessed as related to pixatimod only). The multiorgan failure resulted in the subject’s 
death. The 50 mg pixatimod/240 mg nivolumab dose was declared a toxic dose. One DLT occurred in the 
25mg cohort: pneumonitis (assessed as related to pixatimod and nivolumab). A summary of treatment - 
emergent  adverse events  (TEAEs)  is presented in Table  3.6-1. Given  that only three subjects  were  recruited 
to the 50 mg pixatimod/240 mg nivolumab, only the 25 mg pixatimod/240 mg nivolumab is presented.  
21  
 
Table  3.6-1: 
TEAE Events Possibly,  Probably,  or Likely related  to Pixatimod  or P ixatimod/Nivolumab – Occurring  in 
Three or More Subjects (Safety Set)1 
Event  Type  25 mg/240  mg2 
N = 55 
General  disorders  and administration  site conditions  
Fatigue 
Pyrexia 
Chills  
Gastrointestinal  disorders  
Nausea 
Diarrhoea  
Metabolism and nutrition  disorders  
Decreased  appetite  
Investigations  
Alanine aminotransferase increased Aspartate aminotransferase increased  
Skin and subcutaneous  tissue  disorders  
Pruritus  
Respiratory,  thoracic and mediastinal  disorders  
Pneumonitis   
12 (21.8)  [17] 
7 (12.7)  [8] 
3 (5.5)  [3] 
 
 
14 (25.5)  [19] 
10 (18.2)  [16] 
 
 
8 (14.5)  [9] 
 
 
5 (9.1)  [6] 
4 (7.3)  [6] 
 
 
6 (10.9)  [6] 
 
 
3 (5.5)  [3] 
 
1 50 mg Pixatimod/240 mg Nivolumab data not presented  as only three  subjects  were  recruited.  
2 For any given  adverse event,  the results  are presented  as the number  of patients  with the event:  n, the proportion of patients  with 
the event: (%), and the number of events: [e].  
 
Preliminary data from 26 evaluable patients were previously reported: 3 MSS mCRC patients had objective 
responses, 7 had SD with 12% ORR and 38% disease control rate (DCR).9 Based on this study, the 
recommended phase II dose of pixatimod in combination with anti -PD(L)1 blockade is 25 mg IV weekly.  
 
A summary  of severe treatment  related adverse drug reactions  for both cohorts  is presented in Table  3.6-2. 
 
Table  3.6-2: 
Severe Treatment -Emergent  Adverse Events, Possibly, Probably, or  Likely related 
to Study Drug by MedDRA SOC and Prefered Term (Safety Set)  
 
 
Event  Type  25 mg/240  mg1 
n (%)  
N = 55 50 mg/240  mg1 
n (%)  
N = 3 
Causal  Agent  Pixatimod  Pix/Nivo  Pixatimod  Pix/Nivo  
General  disorders  and administration  site 
conditions  
Multiple  organ dysfunction  syndrome 
Fatigue   
0 (0%) [0]  
0 (0%) [0]  
0 (0%) [0]  
1 (33%)  [1] 
 
0 (0%) [0]  
1 (2%) [1]  
0 (0%) [0]  
0 (0%) [0] 
22  
 
Gastrointestinal  disorders  
Diarrhoea 
Colitis  
Metabolism and nutrition  disorders  
Hyponatremia  
Investigations  
Aspartate aminotransferase increased  
Vascular  disorders  
Hypertension 
Nervous  system  disorders  
Encephalopathy 
Respiratory,  thoracic and mediastinal  disorders  
Pneumonitis 
Pulmonary  oedema 
Hepatobilliary  disorders  
Autoimmune  hepatitis  
Cardiac  disorders  
Cardiomyopathy   
0 (0%)  [0]  
2 (4%)  [2]  
0 (0%) [0]  
0 (0%) [0] 
0 (0%) [0] 1 (2%) [1] 0 (0%) [0] 0 (0%) [0] 
 
0 (0%) [0]  
1 (2%) [3]  
0 (0%) [0]  
0 (0%) [0] 
 
0 (0%) [0]  
1 (2%)  [1]  
0 (0%) [0]  
0 (0%) [0] 
 
2 (4%)  [6]  
0 (0%)  [0]  
0 (0%)  [0]  
0 (0%)  [0] 
 
0 (0%)  [0]  
1 (2%)  [1]  
0 (0%)  [0]  
0 (0%)  [0] 
 
0 (0%)  [0]  
1 (2%)  [1]  
0 (0%)  [0]  
0 (0%)  [0] 
0 (0%)  [0] 0 (0%)  [0] 1 (33%)  [1] 0 (0%)  [0] 
 
0 (0%)  [0]  
1 (2%)  [1]  
0 (0%)  [0]  
1 (33%)  [1] 
 
0 (0%)  [0]  
0 (0%)  [0]  
0 (0%)  [0]  
1 (33%)  [1] 
1 For any given adverse  event,  the results  are presented  as the number  of patients  with the event:  n, the proportion of patients 
with the event: (%), and the number of events: [e].  
 
Fifty -three (53) serious adverse events were reported in 30 subjects; 13 events were assessed as being possibly/probably,  likely, 
or certainly related to the combination. Treatment- related serious adverse events comprised: multiorgan failure, pulmonary 
oedema, cardiomyopathy, and autoimmune hepatitis in the 50 mg pixatimod cohort; autoimmune hepatitis, pneumonitis (three 
even ts in two subjects), encephalopathy, diarrhea, fever (two events  in one subject), and transaminitis  in the 25 mg Pixatimod 
cohort.  
 
 
3.7 Preclinical  and Clinical  Trial  Data:  Cyclophosphamide 
 
Low-dose cyclophosphamide has several immunomodulatory properties including: depletion of regulatory T 
cells;79,80 augmentation of DC84-89 and NK79,90- 92 cell function. The properties result in T H17 skew in cytokine 
production;77,78 increased IFN production;79,90 -92 and induction of immunogenic  cell death.  79,90 -92 Pre-clinically, 
low-dose cyclophosphamide diminished immunosuppressive TGF -β and IL- 1093 and had synergy with intra - 
tumoral type B CpG SD -101 in injected and uninjected tumors.11,93 
 
Clinically, low- dose (metronomic) cyclophosphamide has primarily been used in breast cancer, castrate-  
resistant  prostate  cancer,  ovarian cancer  and CRC  at varying  doses  (50-100 mg daily)  and schedules  (daily, 
1-week -on, 1-week -off).94 Two single -arm studies  studied cyclophosphamide and PD-1 blockade  in sarcomas 
and reported limited activity with unusual toxicity  signals.95,96 In these studies, Cy was dosed at 50 mg twice 
daily, 1 -week -on, 1 -week -off. 
 
3.8 Rationale 
 
3.8.1 Rationale  for Combining  Pixatimod (PG545)  with Anti-PD(L)1  Antibody 
 
The activity  of pixatimod  is complementary  to that of anti-PD(L)1  antibodies  in the treatment  of malignancies. 
Pixatimod  has the dual functions  of activating  NK cells via DC,12 and inactivating tumor -infiltrating  
23  
macrophages by inhibiting heparanase.63,65 In a syngeneic breast cancer model, pixatimod in combination 
with anti -PD-1 improved anti -tumor control compared to anti -PD-1 antibody alone.97 Examination of the 
tumors from this study revealed that the combination significantly increased CD8 and CD4 effector memory 
T cells and NK cell infiltration into the tumors supporting the complementarity of these agents.97 Separately, 
a phase Ib study  of the combination of pixatimod with nivolumab showed promising results  in MSS mCRC,  a 
cancer type that had previously demonstrated negligible response to PD -1 therapies.9 
 
3.8.2 Rationale  for Limiting  Enrollment  by an Immune -inflammatory Biomarker  Cutoff  
 
Immune- inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with multiple cancers 
treated with immuno -oncologic agents. Several blood- based, easily obtained, IIBs have demonstrated 
prognostic relevance in the advanced setting in cancer patients across multiple histologies including: 
neutrophil -to-lymphocyte ratio (NLR),98-100 platelet and monocyte counts,101 and systemic immune-  
inflammation index (SII) (based on lymphocyte, neutrophil and platelet counts, but not monocytes).102,103 
 
The pan- immune -inflammation (PIV) is a weighted interaction of both the inflammatory pro -tumor (i.e. 
neutrophils,  platelets  and monocytes)  and anti-tumor  (i.e. lymphocytes)  cellular  populations  and is calculated 
as follows:  
 
PIV = [neutrophil  count  (103/mmc)  × platelet  count  (103/mmc) × monocyte  count  (103/mmc)]/lymphocyte count  
(103/mmc).  
 
PIV is a strong predictor of survival outcomes with better performance than other well -known immune 
inflammatory biomarkers in patients with 1L mCRC,104 melanoma.105 As such, based on literature data, the 
PIV cutoff utilized in this study is 1200 obtained at any time during Screening in the MSS mCRC cohort 
only (cohort 1) . 
 
3.8.3 Rationale  for Adding  Low-dose Cy in MSS mCRC  
 
The addition of cyclophosphamide to the pixatimod- anti-PD(L)1 combination in MSS mCRC may provide 
benefit via two mechanisms. Firstly, Cy selectively targets suppressive T regs which may alleviate the 
immunosuppressive environment  of the liver,  the main  site to which  CRC metastases  spread.106-108 Secondly, 
treatment with cyclophosphamide may destroy some tumor cells releasing damage- associated molecular 
patterns  (DAMP) and cancer  antigens  that serve  as activating ligands  or targets  for NK and T cells.  Evidence 
in support of this mechanism was seen in a preclinical lymphoma study of the pixatimod/cyclophosphamide 
combination where cyclophosphamide alone led to a transient decrease in A20 tumors which would have 
resulted in the release of tumor associat ed DAMP and antigens.12 In the pixatimod/cyclophosphamide 
combination, there was complete tumor remission which further analysis indicated was caused by NK cells 
mobilized by DAMP -activated DC in a TLR9 dependent manner.12 
 
3.8.4 Rationale  for Dose Selection:  Nivolumab  
 
Refer  to the eIB and the nivolumab SmPC  or USPI  for preclinical  and clinical study  data.  
 
Nivolumab 3 mg/kg has been approved as monotherapy in melanoma and NSCLC patients. Nivolumab 3 
mg/kg has been  tested in MMR -deficient  colorectal  and non-colorectal  cancers  singly  and in combination with 
low-dose ipilimumab.109-111 
 
In the current study, nivolumab will be administered at 480 mg Q4W in all 3 cohorts. The choice of 480mg 
Q4W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the 
population PK model  of nivolumab showing  that the fixed  dose  of 240 mg every 2  weeks  (and 480 mg Q4W) 
will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 2 weeks,  2) will maintain individual  patient  exposures  in the exposure  range established  in melanoma as 
24  
associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure 
range established in melanoma that are well tolerated and safe.112,113 A fixed dose regimen will simplify the 
dosing regimen to be more  convenient  for physicians  and to reduce potential  for dosing errors.  A fixed  dosing 
scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage.  
 
3.8.5 Rationale  for Dose Selection:  Pixatimod (PG545)  
 
The maximum tolerated dose for nivolumab/pixatimod in combination  with nivolumab has previously  been 
determined to be 25 mg weekly IV administered as an infusion over 1 hour.9 
 
3.8.6 Rationale  for Dose Selection:  Cyclophosphamide 
 
Rationale for low-dose cyclophosphamide in MSS  mCRC is stated  in Section 3.8.3.  
 
Low-dose cyclophosphamide is safe, and non- myelosuppressive with an immunomodulatory effect that is 
dependent upon the dose and duration of the drug- free interval.114-116 Given recent data showing rapid anti - 
tumor responses mediated by CD8+ T cells following treatment with a TLR9 agonist and low -dose Cy in a 
colorectal cancer model,11 a clinical investigation of nivolumab/pixatimod/cyclophosphamide is warranted in 
MSS mCRC.  
 
In this context, the ideal immunological dose and schedule of low -dose cyclophosphamide which shows 
sustained natural  killer (NK) T cell function and induction of TA- specific  memory  CD8+  T cells is 50 mg twice 
daily, 1 -week -on, 1- week -off.114-116 This dose has been explored in two studies (PEMBROSARC, and 
[STUDY_ID_REMOVED]) in combination with PD -1 inhibitor pembrolizumab in patients with advanced osteosarcoma 
and soft tissue sarcomas.95,96 
25  
4. OBJECTIVES AND ENDPOINTS  
 
4.1 Primary  Objective,  Hypothesis,  and Endpoint  
 
4.1.1 Primary  Objective  
 
To establish the efficacy  of nivolumab/pixatimod  combination in PD-1 R/R melanoma  and 
NSCLC; and the  efficacy  of nivolumab/pixatimod/cyclophosphamide combination in MSS 
mCRC.  
 
4.1.2 Primary  Hypothesis 
 
That nivolumab/pixatimod combination produces radiographic responses in PD -1 R/R 
melanoma and NSCLC;  and that the nivolumab/pixatimod/cyclophosphamide combination 
produces radiographic responses in MSS mCRC.  
 
4.1.3 Primary  Endpoint  
 
ORR by RECIST  v1.1 to nivolumab/pixatimod  combination in PD-1 R/R melanoma and 
NSCLC; and to nivolumab/pixatimod/cyclophosphamide combination in MSS mCRC.  
 
4.2 Secondary Objectives,  Endpoints and Hypotheses 
 
4.2.1 Secondary Objectives  
 
4.2.1.1  Secondary Objective 1 
 
To assess  safety  of nivolumab/pixatimod  combination in PD-1 R/R melanoma and 
NSCLC; and  nivolumab/pixatimod/cyclophosphamide combination in MSS  mCRC 
patients  
 
4.2.1.2  Secondary Objective 2 
 
To assess  efficacy  using  alternative response endpoints.  
 
4.2.1.3  Secondary Objective 3 
 
To assess  CD8+  T cell and NK cell infiltrate  in pre- and on- treatment  tumor  samples  by 
multiplex IHC/IF.  
 
4.2.1.4  Secondary Objective 4 
 
To assess  median and landmark  progression- free survival  (PFS)  and landmark  overall 
survival (OS) in participants treated with nivolumab/pixatimod or 
nivolumab/pixatimod/cyclophosphamide.  
 
4.2.2 Secondary Hypotheses  
 
4.2.2.1  Secondary Hypothesis  1 
 
That nivolumab/pixatimod combination augments  inflammation  by increasing CD8+  T cell 
and/or NK cell infiltrate in on- treatment compared to pre- treatment tumor samples.  
26  
4.2.2.2  Secondary Hypothesis  2 
 
That nivolumab/pixatimod combination  produces  radiographic  responses  in PD-1 R/R 
melanoma and NSCLC; and that the nivolumab/pixatimod/cyclophosphamide 
combination produces radiographic responses in MSS mCRC as assessed using 
alternative response endpoints.  
 
4.2.2.3  Secondary Hypothesis  3 
 
That nivolumab/pixatimod combination  improves  PFS and OS in PD-1 R/R melanoma 
and NSCLC and MSS mCRC.  
4.2.3 Secondary Endpoints 
 
4.2.3.1  Secondary Endpoint  1 
 
Incidence of all-grade  related adverse  events  (AE),  serious  adverse events  (SAE)  and 
dose- limiting toxicities (DLT) if any in each cohort.  
 
4.2.3.2  Secondary Endpoint  2 
 
ORR by iRECIST to nivolumab/pixatimod combination in PD -1 R/R melanoma and 
NSCLC;  and to nivolumab/pixatimod/cyclophosphamide combination in MSS  mCRC.  
 
4.2.3.3  Secondary Endpoint  3 
 
Summary measures of change (or % change) from baseline in the CD8+ T cell infiltrate 
and/or NK cell in the tumor and TME in tumor biopsies at pre - and on - (approximately 4 
weeks) treatment timepoints.  
 
4.2.3.4  Secondary Endpoint  4 
 
Median PFS,  landmark  PFS (6 months,  1-year and 2-year),  median OS and landmark  OS 
(1-year, and 2 -year) in participants treated with nivolumab/pixatimod or 
nivolumab/pixatimod/cyclophosphamide.  
 
4.3 Exploratory Objectives,  Hypotheses,  and Endpoints 
 
4.3.1 Exploratory Objectives  
 
4.3.1.1  Exploratory Objective 1 
 
To explore potential association between biomarkers and clinical efficacy of 
nivolumab/pixatimod or nivolumab/pixatimod/  cyclophosphamide combination.  
 
4.3.2 Exploratory Hypotheses 
 
4.3.2.1  Exploratory Hypothesis 1 
 
That responders  to nivolumab/pixatimod combination demonstrate evidence of immune 
activation in tumor tissue, blood, and plasma by multiparameter flow cytometry, 
transcriptomic, genomic and cytokine analyses.  
27  
4.3.3 Exploratory Endpoints  
 
4.3.3.1  Exploratory Endpoint  1 
 
Correlation/measures of association of biomarkers and clinical effect of 
nivolumab/pixatimod or nivolumab/pixatimod/  cyclophosphamide combination.  
28  
5. STUDY  DESIGN  
 
5.1 Study Design 
 
This is a phase II Simon  two-stage study  of nivolumab in combination with pixatimod in 3 separate cohorts:  
• Cohort  1: MSS mCRC in combination with low-dose  cyclophosphamide  
• Cohort  2: PD-1 relapsed/refractory  melanoma 
• Cohort 3: PD -1 relapsed/refractory NSCLC 
The study  schema  is outlined in Figure  5.1-1 below.  
We hypothesize that the nivolumab/pixatimod combination in PD -1 relapsed/refractory (R/R) cutaneous 
melanoma and NSCLC patients will be associated with anti -tumor effects. We also hypothesize that the 
nivolumab/pixatimod/cyclophosphamide combination in MSS  mCRC patients will be associated with anti - 
tumor effect. We further hypothesize that nivolumab/pixatimod/cyclophosphamide combination in MSS mCRC 
patients and nivolumab/pixatimod combination in PD -1 R/R melanoma or NSCLC will be associated with 
increased CD8+  T cells intra-tumorally  and PD-1+Ki67+  CD8+  T cells peripherally  in responders  on treatment 
compared to baseline; and that response will be associated with evidence of antigen- specific immunity 
responses intra -tumorally and peripherally.  
 
The goal of this study  is to assess response of PD-1 R/R melanoma/NSCLC  to nivolumab and pixatimod;  and 
MSS mCRC to nivolumab, pixatimod and cyclophosphamide.  
 
Figure  5.1-1: Clinical Trial  Schema  
 
5.2 Trial  Procedures 
 
The Schedule of Activities in Section 2.0 (Schedule of Activities) summarizes the trial procedures to be 
performed at each visit. Individual trial procedures are described in detail below. It may be necessary to 
perform  these procedures  at unscheduled time points  if deemed  clinically  necessary  by the investigator.  
 
Furthermore,  additional  evaluations/testing may be deemed  necessary  by the Sponsor -Investigator  and/or  

29  
Aculeus Therapeutics  for reasons related to subject safety. In some cases, such evaluation/testing may be 
potentially sensitive in nature (e.g.,  HIV, Hepatitis  C, etc.),  and thus local regulations  may require that additional  
informed consent be obtained from the subject. In these cases, such evaluations/testing will be performed in 
accordance with those regulations.  
 
5.3 Number  of Participants  
 
In the 1st stage,  13 patients  will be enrolled in cohort  1 while  9 patients  each  will be enrolled in cohorts  2 and 
3. Should pre-specified efficacy boundary  as defined  in Section 10.3 be met, further  patients  will be enrolled 
to one or more cohorts in 2nd stage. The total enrollment for 1st stage across all 3 cohorts is 31 response-  
evaluable patients.  The total enrollment  for both stages  across  all 3 cohorts  is 61 response- evaluable  patients.  
30  
6. STUDY  POPULATION  
 
6.1 Inclusion Criteria  
 
6.1.1 General  Inclusion Criteria  
 
• Male/female participants  who are at least  18 years  of age on the day of signing  informed 
consent with advanced/metastatic cutaneous melanoma, NSCLC or MSS mCRC who 
meet the following criteria will be enrolled in this study.  
• Male  participants:  
o A male participant must agree to use a contraception as detailed in Appendix 3 
of this protocol  during the treatment  period  and for at least  120 days  after the last 
dose of study treatment and refrain from donating sperm during this period.  
• Female participants:  
o A female  participant  is eligible  to participate  if she is not pregnant  (see Appendix 
3), not breastfeeding, and at least one of the following conditions applies:  
o Not a woman  of childbearing potential  (WOCBP)  as defined in Appendix  3;OR 
o A WOCBP  who agrees  to follow the contraceptive guidance in Appendix 3 during 
the treatment period and for at least 120 days after the last dose of study 
treatment.  
 
6.1.2 Cohort  1 (MSS  mCRC)  
 
• MSS is defined as 0-1 allelic  shifts  among  3-5 tumor  microsatellite  loci using a PCR-  
based assay or immunohistochemistry.  
• Must  have  received prior therapy  with a fluoropyrimidine,  oxaliplatin,  and irinotecan.  
• Prior  treatment  with an anti-PD-1/anti -PD-L1 or anti-CTLA -4 antibody  is not allowed.  
• Prior  treatment  with BRAF/MEK inhibitor  therapy  (if BRAF  mutated)  and/or  EGFR 
targeted antibody (if KRAS WT) are allowed.  
• No more  than 5 prior lines of therapy  for metastatic  disease.  
• Adjuvant  therapy  will count as  1 prior line  of therapy  if received within  the prior 6  months; 
but if not does not count towards prior line of therapy.  
 
• PIV cutoff  of 1200 as defined in Section 3.8.2  obtained on labs obtained during  
Screening.  
6.1.3 Cohort  2 (PD-1 R/R melanoma)  
 
• PD-1 refractory disease as defined as progression on treatment with anti -PD-(L)1 
inhibitor administered either as monotherapy or in combination with other checkpoint 
inhibitors  or other  therapies.  PD-1 treatment  progression is defined by meeting all of the 
following criteria:  
o Receipt  of at least  2 doses  of an approved  or investigational  anti-PD-(L)1 inhibitor.  
o Demonstrated  PD after anti-PD-(L)1 inhibitor  as defined by RECIST  v1.1.  
• Note: This determination is made by the investigator. Once PD is 
confirmed,  the initial date of PD documentation will be considered the 
date of disease progression.  
• Note: The initial evidence of PD is to be confirmed by a second 
assessment no less than 4 weeks from the date of the first 
documented  PD, in the absence of rapid clinical progression  (as 
defined by the criteria in the sub -point below).  
31  
• Subjects who progressed on/within 3 months of adjuvant therapy with 
anti-PD-(L)1 inhibitor  will be allowed;  an adjuvant  therapy  will count  as 
1 prior line of therapy if received within the prior 6 months.  
• Progressive  disease should be documented at least  12 weeks  from the 
last dose of anti -PD-(L)1 inhibitor.  
o Primary resistance: Drug exposure for at least 6 weeks with best response of 
PD, or  SD for <6 months  (including PD at any time after stopping anti-PD-(L)1 for 
any reason  unrelated  to toxicity  if best response while  receiving anti-PDx therapy 
was PD or SD <6 months).  
o Secondary resistance:  Drug  exposure  for at least  6 months  with best response 
of CR or PR or SD for ≥6 months. If prior anti -PD-(L)1 was stopped prior to PD, 
PD must have occurred at least 12 weeks after the last dose of anti -PD-(L)1. 
• Prior  treatment  with an anti-cytotoxic  T lymphocyte- associated  antigen  4 (CTLA -4) 
antibody is allowed but not required.  
• Prior  treatment  with BRAF/MEK  inhibitor  therapy  (if BRAF  mutated)  is allowed  but not 
required.  
• No more  than 5 prior lines of therapy.  
 
6.1.4 Cohort  3 (PD-1 R/R NSCLC)  
 
• PD-1 refractory disease as defined as progression on treatment with anti -PD-(L)1 
inhibitor administered either as monotherapy or in combination with other checkpoint 
inhibitors  or other  therapies.  PD-1 treatment  progression is defined by meeting all of the 
following criteria:  
• Receipt  of at least  2 doses  of an approved or investigational  anti-PD-(L)1 
inhibitor.  
• Demonstrated  PD after anti-PD-(L)1 inhibitor  as defined by RECIST  v1.1.  
o Note: This determination is made by the investigator. Once PD is 
confirmed,  the initial date of PD documentation will be considered the 
date of disease progression.  
o Note: The initial evidence of PD is to be confirmed by a second 
assessment no less than 4 weeks from the date of the first 
documented  PD, in the absence of rapid  clinical progression  (as 
defined by the criteria in the sub -point below).  
o Subjects who progressed on/within 3 months of adjuvant therapy with 
anti-PD-(L)1 inhibitor  will be allowed;  an adjuvant  therapy  will count  as 
1 prior line of therapy if received within the prior 6 months.  
o Progressive  disease should be documented at least  12 weeks  from the 
last dose of anti -PD-(L)1 inhibitor.  
• Primary  resistance:  Drug  exposure  for at least  6 weeks with  best response 
of PD,  or SD for <6 months  (including PD at any  time after stopping anti-PD- 
(L)1 for any reason  unrelated to toxicity  if best response while  receiving anti- 
PDx therapy was PD or SD <6 months).  
• Secondary resistance: Drug exposure for at least 6 months with best 
response  of CR or PR or SD for ≥6 months.  If prior anti-PD-(L)1 was stopped 
prior to PD, PD must have occurred at least 12 weeks after the last dose of 
anti-PD-(L)1. 
• Prior  treatment  with an anti-cytotoxic  T lymphocyte- associated  antigen  4 (CTLA -4) 
antibody is allowed but not required.  
• Prior  treatment  with BRAF/MEK  inhibitor  therapy  (if BRAF  mutated)  must  have  received 
and progressed or have demonstrable intolerance to approved targeted therapy.  
32  
• Patients  with NSCLC with known oncogenic  driver  (including but not limited  to EGFR, 
ALK, ROS, MET alterations) must have received and progressed past driver -specific 
therapy.  
• No more  than 5 prior lines of therapy.  
 
6.1.5 Other  Criteria  
 
• The participant  (or legally  acceptable representative if applicable)  provides  written 
informed consent for the trial.  
• Have measurable disease based on RECIST 1.1. Lesions situated in a previously 
irradiated  area are considered measurable  if progression has been  demonstrated in such 
lesions.  
• Have  provided  newly  obtained core or excisional  biopsy  of a tumor  lesion  not previously 
irradiated to undergo tumor biopsy (core, punch, incisional or excisional).  
o Biopsy  must  meet  minimal sampling criteria  as defined in Schedule of Events 
(Section 2.0) . 
• Have  an Eastern  Cooperative Oncology  Group  (ECOG)  performance  status  of 0 to 1. 
Evaluation of ECOG is  to be performed within  28 days  prior to the date of enrollment.  
• Adequate organ function as defined  in Table 6.1.5 -1 below  performed on screening labs 
obtained within 4 weeks of Cycle 1 day 1  
 
Table  6.1.5– 1 Adequate  Organ  Function  Laboratory  Values  
33  
 
System Laboratory  Value  
Hematological  
Absolute neutrophil  count  (ANC)  ≥1500/µL 
Platelets  ≥100 000/µL  
Hemoglobin  ≥9.0 g/dL or ≥5.6 mmol/La 
Renal 
Creatinine OR 
Measured or calculatedb creatinine clearance 
(GFR  can also be used  in place  of creatinine or 
CrCl)  ≤1.5 ×  ULN OR 
≥30 mL/min  for participant  with creatinine levels  
>1.5 × institutional  ULN 
Hepatic  
Total  bilirubin  ≤1.5 ×ULN OR direct  bilirubin  ≤ULN for participants  
with total bilirubin  levels  >1.5 × ULN 
AST (SGOT) and ALT  (SGPT)  ≤2.5 × ULN (≤5 × ULN for participants  with liver 
metastases)  
Coagulation  
International  normalized  ratio (INR)  OR prothrombin 
time (PT)  
Activated  partial  thromboplastin time (aPTT)  ≤1.5 × ULN unless participant is receiving 
anticoagulant  therapy  as long as PT or aPTT  is 
within therapeutic range of intended use of 
anticoagulants  
ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate 
aminotransferase  (serum glutamic  oxaloacetic  transaminase);  GFR=glomerular  filtration  rate; ULN=upper  limit 
of normal.  
a Criteria must  be met without  erythropoietin dependency  and without  packed red blood cell (pRBC) 
transfusion within last 2 weeks.  
b Creatinine clearance  (CrCl)  should  be calculated per institutional  standard.  
Note: This table includes eligibility -defining laboratory value requirements for treatment; laboratory value 
requirements  should be adapted according to local regulations  and guidelines  for the administration  of specific 
chemotherapies.  
 
• Proteinuria exceeding  1gram  in a 24 hour period.  
• Female subject of childbearing potential should have a negative urine or serum 
pregnancy  within  72 hours  prior to receiving the first dose  of study  medication. If  the urine 
test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.  
• Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the 
study  through 120 days  after the last dose  of study  medication  (Section 5.7.2).  Subjects 
of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.  
• Male  subjects  should  agree to use an adequate  method of contraception starting with the 
first dose of study therapy through 120 days after the last dose of study therapy.  
• Note:  Abstinence  is acceptable if this is the usual  lifestyle  and preferred  contraception for 
the subject.  
 
6.2 Exclusion  Criteria  
 
• Is currently  participating  in or has participated in a study  of an investigational  agent  or using 
an investigational device within 4 weeks of the first dose of treatment.  
34  
• History of allergy and/or hypersensitivity and/or other clinically significant adverse drug 
reaction to heparin or other anti -coagulant agents, or to any monoclonal antibody.  
• Use of heparin (including low -molecular weight heparin and/or fondaparinux) within 2 
weeks prior to enrollment.  
o Patients  who are currently  receiving  low-molecular  weight  heparin (or fondaparinux 
or other heparin product) for therapeutic anticoagulation may be enrolled if they 
have tested negative for anti -heparin antibodies at Screening.  
• Has a diagnosis of immunodeficiency, immunosuppression and/or is receiving systemic 
steroid therapy  or any other  form of immunosuppressive therapy  within 7  days prior  to the 
first dose of trial treatment.  
• Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 
2 weeks  prior to study  Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline)  from 
AEs due to a previously administered agent.  
o Note:  Subjects with ≤ Grade  2 neuropathy  are an exception  to this criterion  
and may qualify for the study.  
o Note:  If subject  received major  surgery,  they must  have recovered  adequately 
from the toxicity and/or complications from the intervention prior to starting 
therapy.  
o Note: Subjects with autoimmune disorders of Grade 4 while on prior 
immunotherapy will be excluded. Subjects who developed autoimmune 
disorders of Grade ≤ 3 may enroll if the disorder has resolved to Grade ≤1 and  
the subject  has been  off systemic steroids at doses >10 mg/d for at least 2 
weeks.  
• Active  (i.e., symptomatic  or growing)  central  nervous  system  (CNS)  metastases.  
o Note: Subjects with treated and stable CNS metastases are permitted to enroll. 
Stability  for prior treated  CNS  disease should  be assessed  on a contrast -enhanced 
imaging study  obtained no sooner  than 14 days  from data of definitive  radiotherapy 
and/or surgery for CNS disease.  
o Note:  Subjects  with leptomeningeal  carcinomatosis  are excluded.  
• Has a known additional malignancy that is progressing or requires active treatment. 
Exceptions include basal  cell carcinoma of  the skin, squamous  cell carcinoma of  the skin, 
or in situ cervical cancer that has undergone (or is being planned to undergo) potentially 
curative therapy.  
• Has a systemic disease that requires systemic pharmacologic doses of corticosteroids 
greater than 10 mg daily prednisone (or equivalent).  
o Note: Subjects who are currently receiving steroids at a dose of ≤10 mg daily do 
not need to discontinue steroids prior to enrollment.  
o Note:  Subjects  that require topical,  ophthalmologic  and inhalational  steroids  are not 
excluded from the study.  
o Note: Subjects with hypothyroidism stable on hormone replacement or Sjogren’s 
syndrome are not excluded from the study.  
o Note: Subjects who require active immunosuppression (greater than steroid dose 
discussed above) for any reason are excluded from the study.  
• Has evidence of interstitial  lung disease or active,  non-infectious  pneumonitis.  
• Has an active  infection requiring systemic therapy.  
• Has a history  or current  evidence of any condition, therapy,  or laboratory  abnormality  that 
might confound the results of the trial, interfere with the subject’s participation for the full 
duration of the trial, or is  not in the best interest of  the subject  to participate, in  the opinion 
of the treating investigator.  
• Has known  psychiatric  or substance abuse  disorders  that would  interfere with cooperation 
with the requirements of the trial.  
35  
• Is pregnant  or breastfeeding or expecting to conceive or father  children within  the projected 
duration of the trial, starting with the pre -screening or screening visit through 26 weeks 
after the last dose of trial treatment.  
• Has a known history  of Human Immunodeficiency  Virus  (HIV)  (HIV 1/2 antibodies).  
o Note: Subjects with HIV that is well controlled (undetectable viral load and CD4 
count >200 cells/mm3) on anti -retroviral therapy are permitted to enroll.  
• Has known active hepatitis B (e.g., HBsAg reactive) or hepatitis C (e.g., HCV RNA 
[qualitative] is detected.  
o Note:  Subjects  with treated hepatitis  B and/or  C with no evidence of active  infection 
may be enrolled.  
• Has a history of significant cardiac disease including but not limited to symptomatic 
congestive heart failure (New York Heart Association Class III/IV), uncontrolled 
hypertension (≥150/90mmHg) despite appropriate anti -hypertensive medication (patients 
with stab ly controlled hypertension are eligible), unstable angina pectoris or myocardial 
infarction (≤ 6 months prior to screening), uncontrolled cardiac arrhythmia, clinically 
significant cardiac valvopathy requiring treatment.  
• Receipt  of live vaccine(s)  within  30 days  prior to the first dose  of trial treatment.  
• Other  uncontrolled intercurrent  illness,  including but not limited  to, ongoing/active infection, 
active interstitial lung disease, serious chronic gastrointestinal conditions associated with 
diarrhea, or psychiatric illness/social situations that would limit compliance with study 
requirement, substantially increase risk of incurring AEs and /or compromise the ability of 
the patient to give written informed consent.  
36  
7. TRIAL  TREATMENTS  
 
7.1 Treatment  Details  
 
Nivolumab  monotherapy  (2mg/kg  every  3 weeks;  240 mg every  2 weeks;  480 mg every  4 weeks)  is approved 
for the treatment of advanced melanoma regardless of BRAF mutation status. Pharmacokinetic analyses 
have established flat exposure- response  relationships  between  these  various  doses  and schedules;112,113 and 
in this study 480 mg q4 will be used.  
 
Pixatimod  monotherapy  has been demonstrated to be safe and well tolerated in patients  with refractory  solid 
tumors.8 In a phase Ib study, combination of pixatimod with nivolumab demonstrated promising results in 
uninflamed  tumors  including  pancreatic  cancer  and microsatellite -stable  colorectal  carcinoma.9 Based on this 
study,  the recommended  phase  II dose of pixatimod is 25 mg IV weekly.  In this study,  pixatimod  will be dosed 
at 25 mg IV weekly.  
 
Low-dose Cy is safe, and non- myelosuppressive with an immunomodulatory effect that is dependent upon 
the dose and duration of the drug -free interval.114-116 In this context, the ideal immunological dose and 
schedule of low-dose Cy which  shows  sustained natural  killer (NK) T cell function and induction of TA- specific 
memory  CD8+  T cells is  50 mg twice daily, 1 -week -on, 1 -week -off.114-116 This dose has been explored in two 
studies (PEMBROSARC, and [STUDY_ID_REMOVED]) in combination with PD -1 inhibitor pembrolizumab in patients 
with advanced osteosarcoma and soft tissue sarcomas.95,96 
 
In Cohort  1:  
• Nivolumab  480 mg Q4W  
• Pixatimod  25mg  Q1W  
• Cyclophosphamide (50 mg twice  daily,  1-week -on, 1-week -off). 
 
In Cohorts 2 and 3: 
• Nivolumab  480 mg Q4W  
• Pixatimod  25 mg Q1W.  
 
7.2 Nivolumab  Dose  Selection,  Modification,  Timing,  and Duration  
 
7.2.1 Nivolumab dose  selection 
 
Rationale for nivolumab  dose selection is provided  in Section  3.8.3  - Rationale for Dose  Selection: 
Nivolumab.  
 
7.2.2 Nivolumab dose modification 
 
No nivolumab dose modification is allowed.  
 
Nivolumab  will be withheld for drug-related Grade  4 hematologic  toxicities,  non-hematological  toxicity  ≥ 
Grade  3 including laboratory  abnormalities,  and severe  or life-threatening AEs as per Table  7.2.2 -1 below.  
 
Table  7.2.2- 1: Dose Modification  Guidelines  for Drug -related  Adverse  Events  (AEs)  
 
 
Toxicity  Hold 
Treatment For Grade   
Timing  for Restarting  Treatment   
Treatment  Discontinuation  
Diarrhea/Colitis  2-3 Toxicity resolves  to Grade 0-1 Toxicity does not resolve within 12 weeks of last 
dose  or inability  to reduce  corticosteroid  to 10 mg or 
37  
 
 
Toxicity  Hold 
Treatment For Grade   
Timing  for Restarting  Treatment   
Treatment  Discontinuation  
   less of prednisone  or equivalent  per day within  12 
weeks  
4 Permanently  discontinue  Permanently  discontinue  
 
AST, ALT, or 
Increased  Bilirubin  2 Toxicity resolves  to Grade 0-1 Toxicity  does  not resolve  within  12 weeks  of last 
dose 
3-4 Permanently  discontinue 
(see exception below)a Permanently  discontinue  
Type  1 diabetes 
mellitus (if new 
onset) or  
Hyperglycemia   
T1DM  or 
3-4 Hold nivolumab and pixatimod for new 
onset  Type  1 diabetes  mellitus  or Grade 
3-4 hyperglycemia associated with  
evidence  of beta cell failure   
Resume nivolumab when  patients  are clinically  and 
metabolically stable  
Hypophysitis   
2-4 Toxicity  resolves  to Grade  0-1. Therapy 
with nivolumab and pixatimod can be 
continued while  endocrine  replacement 
therapy is instituted  Toxicity does not resolve within 12 weeks of last 
dose  or inability  to reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per day within 12 
weeks  
 
 
Hyperthyroidism   
3  
Toxicity resolves  to Grade 0-1 Toxicity does not resolve within 12 weeks of last 
dose  or inability  to reduce  corticosteroid to 10 mg or 
less of prednisone or equivalent  per day within  12 
weeks  
4 Permanently  discontinue  Permanently  discontinue  
 
Hypothyroidism   Therapy  with nivolumab  and pixatimod 
can be continued while thyroid  
replacement  therapy  is instituted  Therapy  with nivolumab can be continued while 
thyroid replacement therapy is instituted  
 
Infusion  Reaction  2b Toxicity  resolves  to Grade  0-1 Permanently  discontinue  if toxicity  develops  despite 
adequate premedication  
3-4 Permanently  discontinue  Permanently  discontinue  
 
 
 
Pneumonitis   
 
2  
 
Toxicity resolves  to Grade 0-1 Toxicity does not resolve within 12 weeks of last 
dose  or inability  to reduce  corticosteroid to 10 mg or 
less of prednisone or equivalent per day within 12 
weeks  
Permanently  discontinue for recurrent  Grade  2 
pneumonitis  
3-4 Permanently  discontinue  Permanently  discontinue  
 
Renal  Failure or 
Nephritis   
2  
Toxicity resolves  to Grade 0-1 Toxicity does not resolve within 12 weeks of last 
dose  or inability  to reduce  corticosteroid to 10 mg or 
less of prednisone or equivalent per day within 12 
weeks  
3-4 Permanently  discontinue  Permanently  discontinue  
 
 
All Other Drug- 
Related  Toxicityc  
 
3 or Severe   
 
Toxicity resolves  to Grade 0-1 Toxicity does not resolve within 12 weeks of last 
dose or inability  to reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per day within 12 
weeks.  Exceptions  may be sought  for neuropathy  or 
other  AE following discussion  with Principle 
Investigator.  
4 Permanently  discontinue  Permanently  discontinue  
Note:  Permanently  discontinue  for any severe  or Grade  3 drug -related  AE that recurs  or any life-threatening  event.  
a For patients  with liver metastasis who begin treatment  with Grade 2 AST or ALT,  if AST or ALT increases  by greater  than or equal  to 
50% relative to baseline and lasts for at least 1 week then patients should be discontinued.  
b If symptoms resolve within one hour of stopping drug infusion, the infusion may be restarted at 50% of the original infusion rate 
(e.g., from 100 mL/h  to 50 mL/h).  Otherwise dosing  will be held until symptoms  resolve  and the subject  should be premedicated  for 
the next scheduled dose and the infusion rate reduced by 50% for next scheduled dose. Infusion rate may be subsequently 
increased at investiagtor discretion.  
c Patients  with intolerable  or persistent  Grade 2 drug-related AE may hold study  medication  at physician  discretion.  Permanently 
discontinue study drug for persistent Grade 2 adverse reactions for which treatment with study drug has been held, that do not 
recover to Grade 0 -1 within 12 weeks of the last dose.  
38  
In case toxicity does not resolve to Grade 0 -1 within 12 weeks after last infusion, trial treatment should be 
discontinued after consultation with the Sponsor -Investigator. With Sponsor -Investigator’s agreement, 
subjects with a laboratory AE still at Grade  2 after 12 weeks may continue treatment in the trial only if 
asymptomatic and controlled. For information on the management of AEs, see Section 7.7.1 . 
 
Subjects who experience a recurrence of the same severe or life- threatening event at the same grade or 
greater with re -challenge of nivolumab should be discontinued from trial treatment.  
 
7.2.3 Nivolumab timing  of administration 
 
Trial treatment should be administered after all procedures/assessments have been completed as detailed 
on the Schedule of Activities in Section 2.0 . Trial treatment may be administered up  to ± 2 days  before or 
after the scheduled Day 1 due to administrative reasons.  
 
All trial treatments  will be administered on an outpatient  basis.  
 
Nivolumab will be administered as a 30- minute IV infusion (treatment intervals may be increased due to 
toxicity  as described).  Sites  should make every  effort  to target  infusion timing  to be as close  to 30 minutes  as 
possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 
minutes is permitted (i.e., infusion time is 30 minutes: - 5 min/+10 min).  
 
7.2.4 Nivolumab duration of administration  
 
In all 3 cohorts,  nivolumab will be administered at 480 mg every  4 weeks.  Nivolumab  480 mg Q4 will be 
administered till progression and/or unacceptable toxicity.  
 
 
7.3 Pixatimod  (PG545)  Dose  Selection,  Modification,  Timing  and Duration  
 
7.3.1 Pixatimod (PG545)  dose selection  
 
Rationale for pixatimod  dose  selection is provided in Section  3.8.4  - Rationale for Dose Selection: 
Pixatimod (PG545).  
 
7.3.2 Pixatimod (PG545)  dose modification  
 
No pixatimod dose  modification is allowed.  
 
Pixatimod  will be withheld  for drug-related Grade 4 hematologic  toxicities,  non-hematological  toxicity  ≥ Grade 
3 including laboratory abnormalities (but excluding Grade 3 lipid elevations), and severe or life- threatening 
AEs. 
 
Subjects who experience a recurrence of the same severe or life- threatening event at the same grade or 
greater with re- challenge of pixatimod will have this discontinued. If pixatimod is permanently discontinued 
for, subjects may continue to receive nivolumab.  
 
7.3.3 Pixatimod (PG545)  prophylaxis 
 
In the initial 5 patients  treated in this study,  patients  were  premedicated with acetaminophen 1000mg prior to 
pixatimod infusion  to prophylax  against  pixatimod -induced cytokine release.  However,  given the low incidence 
of cytokine -release observed, observed negative impact on vaccination response, and possible deleterious 
effects upon immune therapy observed in retrospective analyses117,118, this was discontinued with protocol 
v6. 
39  
7.3.4 Pixatimod (PG545)  timing  of administration  
 
Trial treatment should be administered after all procedures/assessments have been completed as detailed 
on the trial Schedule of Activities  in Section 2.0. Trial treatment  may be administered up to ± 2 days  before 
or after the scheduled Day 1 due to administrative reasons.  
 
All trial treatments  will be administered on an outpatient  basis.  
 
Pixatimod  will be administered as a 60-minute IV infusion (treatment  intervals  may be increased due to toxicity 
as described).  Sites  should make  every  effort  to target  infusion timing  to be as close  to 60 minutes  as possible. 
However, given the variability of infusion  pumps  from site  to site, a  window of  -5 minutes  and +10 minutes is 
permitted (i.e., infusion time is 30 minutes: - 5 min/+10 min).  
 
Pixatimod  will be administered after nivolumab.  
 
7.3.5 Pixatimod (PG545)  duration of administration 
 
In all 3 cohorts,  pixatimod will be administered at 25 mg Q1W.  Pixatimod  25 mg Q1W  will be administered till 
progression and/or unacceptable toxicity.  
 
7.4 Cy Dose Selection,  Modification,  Timing  and Duration 
 
7.4.1 Cyclophosphamide  dose selection  
 
Rationale for pixatimod  dose  selection is provided  in Section  3.8.2.  - Rationale for Adding Low-dose Cy 
in MSSm CRC.  
 
7.4.2 Cyclophosphamide  dose modification  
 
Cyclophosphamide will be withheld  for drug- related Grade  4 hematologic  toxicities,  non-hematological  toxicity  
≥ Grade 3 including laboratory  abnormalities,  and severe  or life-threatening  AEs. 
 
Further, in Cohort  1, continuous  toxicity  monitoring  will be done as delineated in Section  9.4. In this context, 
cyclophosphamide dose modification may be permitted for recurrent drug- related G4 hematologic  
 
Subjects who experience a recurrence of the same severe or life- threatening event at the same grade or 
greater with re -challenge of cyclophosphamide will have this discontinued. If cyclophosphamide is 
permanently discontinued for, subjects may continue to receive nivolumab and pixatimod.  
 
7.4.3 Cy timing  of administration 
 
Trial treatment should be administered after all procedures/assessments have been completed as detailed 
on the trial Schedule of Activities  in Section 2.0. Trial treatment  may be administered up to ± 2 days  before 
or after the scheduled Day 1 due to administrative reasons.  
 
All trial treatments  will be administered on an outpatient  basis.  
 
In Cohort  1 only,  cyclophosphamide will be administered orally  at 50 mg twice  daily on D1-D7, and D15-D21 
of a 28- day cycle. Pill compliance will be assessed using a pill diary.  
40  
7.4.4 Cy duration  of administration 
 
In Cohort 1 only, cyclophosphamide will be administered orally  at 50 mg twice  daily on D1-D7, and D15- 
D21 of a 28- day cycle. Pill compliance will be assessed using a pill diary. cyclophosphamide will be 
administered till progression and/or unacceptable toxicity.  
 
7.5 Treatment  Allocation  
 
Following  Enrollment  and completion of Screening,  patients  will enter  the Treatment  phase.  
 
7.6 Concomitant  Medications 
 
Medications or vaccinations specifically prohibited in the exclusion criteria and outlined in Section 7.8.2 are 
not allowed during the ongoing trial. If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be 
required.  The treating Investigator  should discuss any questions  regarding this with the Principal  Investigator. 
The final decision on any supportive therapy or vaccination re sts with the investigator and/or the subject's 
treating Investigator. However, the decision to continue the subject on trial therapy or vaccination schedule 
requires the mutual agreement of the treating Investigator, the Principal Investigator, and the sub ject. 
 
7.6.1 Acceptable Concomitant  Medications  
 
All treatments that the investigator considers necessary for a subject’s welfare may be administered at the 
discretion of the investigator in keeping with the community standards of medical care. All concomitant 
medication will be recorded in the research record including all prescription, over -the-counter (OTC), herbal 
supplements, and IV medications and fluids. If changes occur during the trial period, documentation of drug 
dosage, frequency, route, and date may also be included in the research record.  
 
All concomitant  medications  received within  28 days  before the first dose of trial  treatment and 30 days  after 
the last dose of trial treatment  should be recorded.  Concomitant  medications  administered  after 30 days  after 
the last dose of trial treatment should be recorded for SAEs and ECIs as defined in Section 9.2.  
 
7.6.2 Prohibited Concomitant  Medications  
 
Subjects  are prohibited  from receiving  the following  therapies  during the Screening and Treatment  Phase 
(including retreatment  for post-complete  response  relapse)  of this trial: 
• Anti-cancer  systemic chemotherapy  or biological  therapy ; 
• Immunotherapy  not specified in this protocol ; 
• Chemotherapy  not specified in this protocol ; 
• Investigational  agents  other  than pixatimod;  
• Radiation therapy . 
 
Live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial. Examples  of live vaccines include,  but are not limited  to, the following:  measles,  mumps,  rubella,  chicken  pox, 
yellow fever,  rabies,  BCG,  and typhoid  (oral) vaccine.  Seasonal  influenza  vaccines  for injection  are generally 
killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu- Mist®) are live 
attenuated vaccines and are not allowed.  
 
Glucocorticoids for any purpose other than to modulate symptoms from an event of clinical interest of 
suspected immunologic etiology. The use of physiologic doses of corticosteroids may be approved after 
consultation with the Principal Investigator.  
41  
 
Subjects  who,  in the assessment  by the investigator,  require the use of any of the aforementioned treatments 
for clinical management should be removed from the trial. Subjects may receive other medications that the 
investigator deems to be medically necessary. However, if a patient who is otherwise deriving benefit as 
assessed by the treating investigator may be permitted to receive radiation therapy to a non -target lesion for 
the purposes of symptom control.  
 
The Exclusion Criteria  (Section 6.2) describes  other  medications  which  are prohibited in this trial. 
There are no prohibited therapies during the Post -Treatment Follow -up Phase (Section 8.5.5) . 
Agents  known  to have  TLR9 antagonist  activity  are prohibited  throughout  the study.  Known antagonists 
include chloroquine, hydroxychloroquine, and quinacrine.  
 
Medications  intended  solely  for supportive care (i.e., antiemetics,  analgesics,  megestrol  acetate for anorexia) 
are allowed.  
 
7.7 Rescue Medications and Supportive Care  
 
7.7.1 Supportive Care  Guidelines 
 
Subjects should receive appropriate supportive care measures as deemed necessary by the treating 
investigator. Suggested supportive care measures for the management of AEs with potential immunologic 
etiology are outlined below. Where appropriate, these gui delines include the use of oral or intravenous 
treatment  with corticosteroids  as well as additional  anti-inflammatory  agents  if symptoms do not improve  with 
administration of corticosteroids.  Note that several courses of steroid tapering may be necessary a s 
symptoms  may worsen when the steroid dose is decreased. For each disorder, attempts should be made to 
rule out other  causes  such  as metastatic  disease or bacterial  or viral infection,  which  might  require additional 
supportive care. The treatment guidelines are intended to be applied when the investigator determines the 
events to be related to nivolumab.  
 
Note:  If after the evaluation the event  is determined not to be related,  the investigator  does  not need to follow 
the treatment guidance (as outlined below). Refer to Sections 7.2 -7.4 for dose modification guidelines for 
nivolumab, pixatimod and cyclophosphamide.  
 
It may be necessary  to perform  conditional  procedures  such  as bronchoscopy,  endoscopy,  or skin 
photography as part of evaluation of the event.  
 
• Pneumonitis 
 
o For Grade 2 events , treat with systemic corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks.  
o For Grade 3 -4 events , immediately treat with intravenous steroids.  Administer additional anti - 
inflammatory measures, as needed.  
o Add prophylactic antibiotics for opportunistic infections in the case of prolonged steroid 
administration.  
• Diarrhea/Colitis  
 
o Subjects  should be carefully  monitored  for signs  and symptoms  of enterocolitis  (such  as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such as 
peritoneal signs and ileus).  
42  
o All subjects who experience diarrhea/colitis should be advised to drink liberal quantities of clear 
fluids.  If sufficient oral fluid intake is not feasible, fluid and electrolytes should be substituted via 
IV infusion.  For Grade 2 or higher  diarrhea,  consider  GI consultation and endoscopy  to confirm  or 
rule out colitis.  
o For Grade  2 diarrhea/colitis,  administer  oral corticosteroids.  
o For Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by high dose oral 
steroids.  
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.  
• Type  1 diabetes mellitus  (if new onset,  including diabetic  ketoacidosis [DKA])  or ≥ Grade  3 
Hyperglycemia,  if associated with ketosis  (ketonuria)  or metabolic acidosis  (DKA)  
o For T1DM  or Grade  3-4 Hyperglycemia  
 Insulin replacement therapy is recommended for Type I diabetes mellitus and for Grade 3- 4 
hyperglycemia associated with metabolic acidosis or ketonuria.  
 Evaluate patients  with serum  glucose and a metabolic  panel,  urine  ketones,  glycosylated 
hemoglobin, and C -peptide.  
• Hypophysitis  
 
o For Grade 2 events,  treat with corticosteroids.  When  symptoms  improve  to Grade  1 or less, steroid 
taper should be started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.  
o For Grade 3-4 events,  treat with an initial  dose of IV corticosteroids  followed  by oral corticosteroids. 
When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.  Replacement  of appropriate  hormones  may be required as the steroid dose 
is tapered.  
• Hyperthyroidism  or Hypothyroidism  
 
o Thyroid disorders can occur at any time during treatment.  Monitor patients for changes in thyroid 
function (at the start of treatment,  periodically  during treatment, and as indicated based on clinical 
evaluation) and for clinical signs and symptoms of thyroid disorders.  
 
o Grade  2 hyperthyroidism  events  (and Grade  2-4 hypothyroidism):  
 In hyperthyroidism, non -selective beta- blockers (e.g. propranolol) are suggested as initial 
therapy.  
 In hypothyroidism,  thyroid hormone  replacement  therapy,  with levothyroxine or liothyroinine,  is 
indicated per standard of care.  
o Grade  3-4 hyperthyroidism  
 Treat  with an initial dose of IV corticosteroid followed  by oral corticosteroids.  When  symptoms 
improve to Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.  Replacement  of appropriate  hormones  may be required  as the steroid  dose is tapered.  
• Hepatic 
 
o For Grade 2 events, monitor liver function tests more frequently until returned to baseline values 
(consider weekly).  
 Treat  with IV or oral corticosteroids  
43  
o For Grade 3-4 events,  treat with intravenous  corticosteroids  for 24 to 48 hours.  
o When symptoms  improve to Grade 1 or less, a steroid taper  should be started  and continued over 
no less than 4 weeks.  
• Nephritis 
 
o For Grade 2 events,  treat with corticosteroids.  
o For Grade  3-4 events,  treat with systemic corticosteroids.  
o When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.  
• Management  of infusion reactions  
 
o Signs  and symptoms  usually  develop during or shortly  after drug infusion and generally  resolve 
completely within 24 hours of completion of infusion. 
Table  7.7.1 -1 below  shows  treatment  guidelines  for subjects  who experience an infusion reaction 
associated with administration of nivolumab.  
 
Table  7.7.1- 1: Infusion Reaction  Management  Guidelines  
NCI CTCAE  Grade  Treatment  Premedication  at Subsequent 
Dosing  
Grade 1 
Mild reaction:  infusion  interruption 
not indicated,  intervention  not 
indicated  Increase  monitoring  of vital signs as medically 
indicated until the subject  is deemed  medically 
stable in the opinion of the investigator.  None  
Grade 2 
Requires  infusion interruption  but 
responds promptly to 
symptomatic treatment (e.g., antihistamines, NSAIDS, 
narcotics, IV fluids); prophylactic 
medications indicated for ≤24 h Stop Infusion and monitor symptoms. 
Additional  appropriate  medical therapy  may 
include but is not limited to:  
IV fluids Antihistamines NSAIDS  
Acetaminophen 
Narcotics  
Increase  monitoring of vital signs as medically 
indicated until the subject  is deemed  medically 
stable in the opinion of the investigator.  
If symptoms resolve within one hour of stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion rate (e.g., from 100 mL/h to 50 mL/h).  Otherwise 
dosing will be held until symptoms resolve  and 
the subject should be premedicated for the next scheduled dose.  
Subjects  who develop  Grade  2 toxicity  despite 
adequate premedication should be permanently discontinued from further trial 
treatment administration.  Subject  may be premedicated  1.5 h 
(± 30 min) prior to infusion of nivolumab with:  
 
Diphenhydramine 50 mg po (or equivalent  dose  of antihistamine).  
 
Acetaminophen 500– 1000 mg po 
(or equivalent  dose  of antipyretic).  
Grades  3 or 4 
Grade 3:  
Prolonged (i.e., not rapidly responsive to symptomatic medication and/or brief 
interruption of infusion); 
recurrence of symptoms following 
initial improvement; hospitalization indicated for other 
clinical sequelae (e.g., renal  
impairment,  pulmonary  infiltrates) 
Grade 4:  Stop  Infusion.  
Additional  appropriate  medical therapy  may 
include but is not limited to:  
IV fluids 
Antihistamines NSAIDS  
Acetaminophen Narcotics Oxygen Pressors  
Corticosteroids 
Epinephrine  No subsequent  dosing  
44  
 
Life-threatening; pressor or 
ventilatory  support  indicated  Increase  monitoring  of vital signs as medically 
indicated until the subject  is deemed  medically 
stable in the opinion of the investigator.  
Hospitalization may be indicated.  
Subject  is permanently  discontinued from 
further trial treatment administration.   
Appropriate  resuscitation  equipment  should  be available  in the room  and a physician  readily  available  during  the period  of 
drug administration.  
 
7.8 Subject  Withdrawal/Discontinuation  Criteria  
 
Subjects  are free to withdraw from the study  at any time and without  penalty  or loss of future  medical  care,  or 
any other  benefits  to which  they are otherwise  entitled.  Subjects  may discontinue study  medication for any of 
the following conditions:  
• Dose -limiting  or other  unacceptable toxicity  considered to be related to either  study  medication;  
o Patients who develop unacceptable toxicity deemed related to pixatimod but not nivolumab 
may continue nivolumab  after pixatimod  discontinuation for duration  as defined in Section  
7.3.2 if the patients have ongoing benefit in the assessment of treating investigator after 
consultation with Sponsor -Investigator.  
o Patients who develop unacceptable toxicity deemed related to cyclophosphamide but not 
pixatimod or nivolumab may continue pixatimod and nivolumab after cyclophosphamide 
discontinuation for duration as defined in Section 7.4.2 . 
o Patients who develop unacceptable toxicity deemed related to nivolumab but not pixatimod 
must  discontinue both pixatimod and nivolumab  (and  if appropriate,  cyclophosphamide).  
• PD by RECIST (Version 1.1) if accompanied by medically significant clinical deterioration, in the 
judgment of the Investigator. (Continuation of treatment through suspected pseudo- progression is 
permitted.);  
• If, in the opinion of the Investigator,  it is medically  necessary;  
• Subject  withdraws  consent  for the study  (note that subjects  who withdraw consent  for additional  study 
treatment and procedures will continue to be followed for long- term 
• survival  unless  they explicitly  withdraw  consent  for any follow- up); 
• Subject  develops  an intercurrent  illness  or AE that precludes  further  participation,  or requires  a 
prohibited concomitant treatment;  
• Subject  becomes  pregnant  or begins  breastfeeding;  
• Subject  is lost to follow- up. 
 
Patients discontinuing study medication earlier than planned or withdrawing from the study should undergo 
the subsequent  End of Treatment  (EOT) clinical and laboratory  assessments  as soon as possible  after study 
medication is stopped  and the requisite  safety  follow- up period of 30 days  should also be followed.  The reason 
for withdrawal will be recorded in the electronic case report form (eCRF) and the subject’s source medical 
record. All subjects will continue to be followed every three months after the last nivolumab/pixatimod treatment  for long- term survival  follow- up until death,  loss to follow- up, or withdrawal  of consent  for follow- up. 
 
7.9 Subject  Replacement  Strategy 
 
Patients  who receive at least 1 dose  each of nivolumab and pixatimod (cohorts  2 and 3); and at least 1  dose 
each of nivolumab, pixatimod and low -dose cyclophosphamide (cohort 1) are evaluable for safety.  
 
All patients  who met the eligibility  criteria;  received at least  1 dose each  of nivolumab and pixatimod  (cohorts 
2 and 3); and at least 1 dose each of nivolumab, pixatimod and low -dose  cyclophosphamide (cohort 1); and 
underwent restaging imaging are evaluable for response.  
45  
Patients who did not undergo restaging scans for reasons other than disease progression (treatment 
discontinuation,  trial withdrawal etc.) will be deemed non-evaluable.  Non-evaluable subjects  may be replaced.  
 
If in the opinion of the treating investigator and Principal Investigator, the subject’s disease is rapidly 
progressing,  restaging scans  may be expedited.  These patients  are evaluable for objective response rate and 
other efficacy endpoints.  
 
7.10 Clinical  Criteria  for Early  Trial  Termination  
 
Early  trial termination  will be the result  of the criteria  specified below:  
• Quality  or quantity  of data recording  is inaccurate or incomplete.  
• Poor  adherence to protocol  and regulatory  requirements.  
• Incidence or severity of adverse drug reaction in this or other studies indicates a potential health 
hazard to subjects.  
• Plans  to modify  or discontinue the development  of the study  drugs.  In the event  of an Aculeus 
Therapeutics  decision to no longer supply  study drug(s), ample notification will be provided so that  
appropriate  adjustments  to subject treatment can be made.  
46  
8. STUDY  ASSESSMENTS AND PROCEDURES  
 
8.1 Trial  Procedures 
 
The trial Schedule of Activities in Section 2.0 summarizes the trial procedures to be performed at each visit. 
Individual trial procedures are described in detail below. It may be necessary to perform these procedures at 
unscheduled time points if deemed clinically necessary by the investigator.  
 
Furthermore, additional evaluations/testing may be deemed necessary by the Sponsor -Investigator and/or 
Zuecro for reasons related to subject safety. In some cases, such evaluation/testing may be potentially 
sensitive  in nature  (e.g.,  HIV, Hepatitis  C, etc.),  and thus local regulations  may require that additional  informed 
consent be obtained from the subject. In these cases, such evaluations/testing will be performed in accordance with those regulations.  
 
8.2 Treatment  Period  
 
Following Screening, during the Treatment Period, patients will receive treatment delineated below. Each 
cycle  is 28 days  long.  In each  cycle,  patients  will receive  pixatimod,  nivolumab ± cyclophosphamide  (in Cohort 
1). 
 
Cohort  1 (MSS  mCRC):  
• IV nivolumab  480 mg Q4W  
• IV pixatimod  25 mg Q1W  
• PO cyclophosphamide at 50 mg twice  daily on D1-D7, and D15-D21 of a 28-day cycle  
 
Cohort  2 (PD-1 R/R melanoma):  
• IV nivolumab  480 mg Q4W  
• IV pixatimod  25 mg Q1W  
 
Cohort  3 (PD-1 R/R NSCLC):  
• IV nivolumab  480 mg Q4W  
• IV pixatimod  25 mg Q1W  
 
8.3 Administrative Procedures 
 
Informed consent  must  be documented by the subject’s  dated signature or by the subject’s  legally  acceptable 
representative’s dated signature on a consent form along with the dated signature of the person conducting 
the consent discussion prior to enrollment.  
 
During  initial enrollment  visit, study  investigator  (or designee)  must  discuss  the following  with patients:  
• Inclusion and exclusion criteria  
 
• Medical history  – pertinently any condition diagnosed within the prior 10  years that are considered  to 
be clinically significant by the Investigator.  
 
• Prior and concomitant medications. All medications related to reportable SAEs and ECIs should be 
recorded as defined in Section 8.6.  
• Disease  details  and treatments.  
47  
8.4 Clinical  Procedures  and Assessments  
 
8.4.1 Adverse  Events  (AE) monitoring 
 
The investigator  or qualified designee will assess each subject  to evaluate for potential  new or worsening AEs 
as specified in the trial Schedule of Activities (Section 2.0 ) and more frequently if clinically indicated. 
Adverse experiences will be graded and recorded throughout the study and during the follow -up period 
according to NCI CTCAE Version 5.0 (see Section 8.6). Toxicities will be characterized in terms regarding 
seriousness,   causality,   toxicity   grading,   and  action   taken  with  regards   to  trial  treatment.  
 
All AEs of unknown etiology associated with nivolumab exposure should be evaluated to determine if it is 
possibly an event of clinical interest (ECI) of a potentially immunologic etiology (irAE). See Section 7.7.1 
regarding the identification, evaluation and management of AEs of a potential immunological etiology.  
 
Related and clinically significant AEs occurring within 30 days after the last dose of study drug should be 
recorded. Patients who are discontinued from the study due to an unacceptable drug -related AE will be 
followed until the resolution of the AE to Grade 0- 1 or stabilization or until initiation of a new  therapy  for their 
cancer, whichever occurs first. Related SAEs that occur within 90 days of the end of treatment or before 
initiation of a new antineoplastic treatment should also be followed and recorded.  
 
Please refer to Section  8.6 for detailed information  regarding the assessment  and recording of AEs. 
 
8.4.2 Full physical  exam  
 
The Investigator or qualified designee will perform a complete physical exam during Screening and as 
otherwise indicated in Schedule of Activities (Section 2.0). Clinically significant abnormal findings should 
be recorded as medical history.  
 
8.4.3 Vital  signs 
 
The Investigator or qualified designee will obtain vital signs during Screening and as otherwise indicated in 
trial Schedule of Activities (Section 2.0). Vital signs should include temperature, pulse, respiratory rate, 
weight and blood pressure. Height will be measured at Screening only.  
 
8.4.4 Eastern Cooperative Oncology Group  (ECOG)  performance  scale 
 
The Investigator or qualified designee will assess ECOG status at Screening, prior to the administration of 
each dose of trial treatment and discontinuation of trial treatment as specified in the trial Schedule of 
Activities (Section 2.0 ). 
 
8.5 Visit  Requirements 
 
8.5.1 Requirements 
 
Visit requirements are outlined in trial Schedule of Activities (Section 2.0 ). Specific procedure- related 
details are provided above in Section 8.1 - Trial Procedures.  
 
 
8.5.2 Screening  
 
Screening starts  with the subject’s  provision  of a written  informed consent  form (ICF)  and should be 
completed within 28 days of initiation of study drug(s).  
48  
8.5.3 Thirty- day safety  follow -up 
 
The mandatory  30-day Safety  Follow -Up Visit should be conducted approximately  30 days  after the last dose 
of trial treatment or before the initiation of a new anti -cancer treatment, whichever comes first. All AEs that 
occur  prior to the Safety  Follow -Up Visit should be recorded.  Subjects  with an AE of Grade  > 1 will be followed 
until the resolution of the AE to Grade 0- 1 or until the beginning of a new anti -neoplastic therapy, whichever 
occurs first. SAEs that occur within 90 days of the end of treatment or before initiation of a new anti -cancer 
treatment should also be  followed and recorded.  
 
 
8.5.4 End of Treatment  (EOT)  
 
Subjects who discontinue trial treatment for disease progression will complete an EOT visit. EOT visit 
requirements include physical exam, medical history, AE assessment and collection of correlative samples 
as indicated in the trial Schedule of Activities ( Section 2.0 ). 
 
8.5.5 Post -treatment  Surveillance Phase 
 
Subjects  who discontinue trial treatment  for a reason other than disease progression (including patients  who 
do not progress but discontinue for intolerance/toxicity) will move into the Post -treatment Surveillance 
Phase. These patients  will continue to be assessed clinically and radiographically to monitor  disease status. 
Post -Treatment Surveillance Phase will start 12 weeks after the last on- treatment time point for patients 
who have no disease progression.  
 
These patients are evaluated per the standard follow -up schedule with imaging [contrast -enhanced CT 
chest/abdomen/pelvis and (if applicable) vs. PET at the discretion of the treating physician] at the following 
intervals. Every 3 months (±2 weeks) if patient is < 2 years from study entry, every 6 months (±4 weeks) if 
patient  is 2-5 years  from study  entry,  and every  12 months  (±4 weeks)  if patient  is > 5 years  from study  entry 
for up to 15 years.  
 
Patients who develop recurrent cancer will be followed for information on survival and for information on 
salvage patterns. The schedule of clinical follow up for these patients will be at the discretion of the treating 
Investigator and according to establ ished guidelines for the relevant disease. AE assessment on the study 
will continue for all patients until 90 days after the last study drug administration.  
 
Every effort should be made to collect information regarding disease status until the start of new anti - 
neoplastic  therapy,  disease progression,  death,  end of the study  as detailed in Survival  Follow  Up (Section 
8.5.6 ). Information regarding post-study  anti-neoplastic  treatment  will be collected if new treatment  is initiated.  
 
Note – Patient accrual was terminated early owing to the discontinuation of pixatimod supply. Follow -up 
assessments will no longer be completed upon IRB approval of protocol version 02/23/2024 . 
 
8.5.6 Survival  follow  up 
 
If a subject has confirmed disease progression or starts a new anti -cancer therapy, the subject moves into 
the survival follow -up phase and should be contacted to assess for survival status until death, withdrawal of 
consent, or the end of the study, whichever occurs first. This will be done every 3 months.  
 
Note – Patient accrual was terminated early owing to the discontinuation of pixatimod supply. Follow -up 
assessments will no longer be completed upon IRB approval of protocol version 02/23/2024 . 
 
8.6 Laboratory  Assessments 
 
Details  regarding specific  laboratory  assessments to be performed in this trial are provided below.  
49  
8.6.1 Screening  laboratory  assessments  
 
Screening laboratory tests should be performed within 28 days of registration. Requirements are stated 
below  in Table  8.6.1 -1. Results  must  be reviewed by the Investigator  or qualified  designee and found to be 
acceptable prior to each dose of trial treatment.  
 
There is 28-day window  to obtain Screening  (XK-S) laboratory  assessments  from signing consent.  
 
Table  8.6.1- 1: Screening  laboratory  assessments (XK-S) 
Blood  Urine  Other  
• CBC: WBC (total and 
differential including 
absolute  neutrophil  count), 
hemoglobin and 
hematocrit; platelet count  
• Renal  function:  blood  urea 
nitrogen, bicarbonate, 
calcium, chloride, 
creatinine, glucose, 
phosphorus, potassium, 
magnesium and sodium  
• Liver function: albumin, total protein, alkaline 
phosphatase (ALP), 
alanine aminotransferase 
(ALT), aspartate 
aminotransferase (AST), total bilirubin  (direct  only if 
total is elevated above 
ULN)  
• Lactate  dehydrogenase 
(LDH)  
• Coagulation parameters: 
PT and aPTT  
• Thyroid function studies: 
TSH,  free T3 and free T4 
• 
$Infectious  serologies:  HIV, 
hepatitis B  surface antigen 
(HBsAg) and hepatitis B  
surface  antibody  (HBsAb) 
and HCV RNA  • pH 
• Specific  gravity  
• Glucose  
• Protein 
• Blood 
• Nitrites  
• WBCs  
• Microscopic battery  (RBCs, 
WBCs, epithelial cells, 
casts) - only if significant 
positive findings on 
urinalysis  • *Serum  or urine  pregnancy 
test (β -human chorionic 
gonadotropin)  
• &Anti-heparin antibodies 
(patients  on heparin,  low- 
molecular  weight  heparin, 
fondaparinux or other similar agents)  
*Perform  on women  of childbearing  potential  and at Screening  only.  If urine  pregnancy  results  cannot  be 
confirmed as negative,  serum  β-human chorionic  gonadotropin will be required.  
$HIV, hepatitis  B and C studies  will be obtained at Screening  only 
&Anti-heparin antibodies  will be obtained  at Screening  only in patients  who are currently  or have  recently  (within  6 
months) been on heparin, low -molecular weight heparin, fondaparinux or other similar agents.  
 
 
8.6.2 On-treatment  laboratory assessments 
 
Pre-C1D1 and  on-treatment  laboratory  tests  should be  performed  at the appropriate  intervals  as indicated in 
the trial Schedule of Activities (Section  2.0). Requirements  are stated  below  in Table 8.6.2 -1. Results  must 
be reviewed by the Investigator or qualified designee and found to be acceptable prior to each dose of trial 
treatment.  
 
There is a 2-day window  to obtain on-treatment  (XK-B and XK-T) laboratory  assessments.  
50  
Table  8.6.2- 1: On-treatment laboratory  assessments (XK-B and XK-T) 
Blood  Urine  Other  
• CBC: WBC (total and 
differential including 
absolute  neutrophil  count), 
hemoglobin and 
hematocrit; platelet count  
• Renal  function:  blood  urea 
nitrogen, bicarbonate, 
calcium, chloride, 
creatinine, glucose, 
phosphorus, potassium, 
magnesium and sodium  
• Liver function: albumin, 
total protein, alkaline 
phosphatase (ALP), 
alanine aminotransferase 
(ALT), aspartate 
aminotransferase (AST), 
total bilirubin  (direct  only if 
total is elevated above 
ULN)  
• Lactate  dehydrogenase 
(LDH)  
• Coagulation parameters: 
PT and aPTT  
• *Thyroid function  studies: 
TSH,  free T3 and free T4 • pH 
• Specific  gravity  
• Glucose  
• Protein 
• Blood 
• Nitrites  
• WBCs  
• Microscopic battery  (RBCs, 
WBCs, epithelial cells, 
casts) - only if significant 
positive findings on urinalysis  • *Fasting lipids 
(triglycerides,  LDL,  HDL, 
total cholesterol)  
*Only  on D1 of each  cycle  (XK-B) only 
 
8.7 Efficacy  Assessments  
 
8.7.1 Tumor  imaging and disease assessment  
 
Tumor imaging is strongly preferred to be acquired by  contrast -enhanced computed tomography  (CT). Brain 
imaging will be obtained only at Screening in melanoma and NSCLC patients and need not be repeated 
unless prior CNS disease was identified, and previously treated CNS lesions were captured as non- target 
lesions.  For CRC patients,  brain imaging at screening is not required.  For brain imaging a contrast  enhanced 
MRI is ideal.  If an MRI of the brain cannot  be done  (or is contraindicated)  a contrast  enhanced CT of the brain 
is acceptable.  
 
Confirmation  that the participant’s  imaging shows  at least  1 lesion  that is appropriate for selection as a target 
lesion per RECIST 1.1 is highly recommended prior to participation.  
 
Participant eligibility will be determined using Investigator assessment based on RECIST 1.1. In addition, 
images (including via other modalities) that are obtained at an unscheduled time point to determine disease 
progression, as well as imaging obtained for other reasons, but which demonstrate radiologic progression, 
should also be used to determine progression.  
 
When the Investigator identifies radiographic progression per RECIST 1.1, efforts should be made to verify 
radiologic  PD. Treatment  should continue  until PD has been  verified.  Regardless  of whether  PD is verified,  if 
the Investigator considers the participant has progressed, but elects to implement iRECIST, the Investigator 
will assess for confirmation of progression by iRECIST at subsequent time points.  
51  
8.7.2 Initial tumor  imaging  
 
Initial tumor  imaging at Screening must  be performed  within  28 days  prior to the Cycle  1 Day 1 date.  The site 
study team must review screening images to confirm the participant has measurable disease per RECIST 
1.1. 
 
8.7.3 Tumor  imaging  during  the study 
 
The first on- study imaging assessment should be  performed at 8 weeks (56 days ± 7 days) from the date of 
start of treatment.  Subsequent  tumor  imaging should be performed every  8 weeks  (56 days  ± 7 days)  or more 
frequently if clinically indicated. In patients who complete therapy and enter Post -Treatment Surveillance, 
imaging will be performed as outlined in Section  8.5.5 . Imaging timing  should follow calendar  days  and should 
not be adjusted for delays  in cycle  starts.  Imaging should continue to be performed until disease progression 
is identified by the Investigator.  
 
All objective response should be ideally confirmed by a repeat imaging assessment where possible. Tumor 
imaging to confirm PR or CR should be performed at least 4 weeks after the first indication of a response is 
observed.  Participants  will then return  to regular  scheduled imaging every  8 weeks  (56 days  ± 7 days),  starting 
with the next scheduled imaging time point. Participants who receive additional imaging for confirmation do 
not need to undergo the next scheduled tumor imaging if it is less than 4 weeks  later; tumor imaging may 
resume at the subsequent scheduled imaging time point.  
 
Per iRECIST ( Section 8.7.6 ), disease progression should be confirmed 4 to 8 weeks after first radiologic 
evidence of  PD in clinically stable  participants.  Participants  who have  unconfirmed  disease  progression may 
continue on treatment at  the discretion of the investigator until progression is  confirmed by the site provided, 
they have met the conditions  detailed in Section 8.7.6 . Participants  who receive  confirmatory  imaging do not 
need to undergo  the next scheduled tumor  imaging if it is less than 4 weeks  later;  tumor  imaging may resume 
at the subsequent  scheduled imaging time point,  if clinically  stable.  Participants  who have confirmed  disease 
progression by iRECIST ( Section 8.7.6), as assessed by the site, will discontinue study treatment.  
 
 
8.7.4 End of treatment  and follow -up tumor  imaging  
 
In participants  who discontinue study  treatment,  tumor imaging should be performed at the time of treatment 
discontinuation (±4- week window). If previous imaging was obtained within 4 weeks prior to the date of 
discontinuation, then imaging at treatment discontinuation is not mandatory. In participants who discontinue 
study treatment due to documented disease progression and the investigator elects not to implement 
iRECIST, this is the final required tumor imaging.  
 
For participants who discontinue study treatment without documented disease progression, every effort 
should be made to continue monitoring their disease status by tumor imaging using the same imaging 
schedule used while  on treatment  (as outlined in Section  8.5.5. ) to monitor disease status  until the start of a 
new anti -cancer treatment, disease progression, pregnancy, death, withdrawal of consent, or the end of the 
study, whichever occurs first.  
 
8.7.5 RECIST  v1.1 disease assessment  
 
Response and progression will be evaluated in this study using the international criteria proposed by the 
Response Evaluation  Criteria  in Solid  Tumors  (RECIST  v.1.1)  Committee.119 It is known  that patients  receiving 
immunotherapy have atypical response patterns that in some cases may lead to incorrect determination of the response status. In the case of a measurable lesion increase or detection of a previously occult tumor 
lesion, RECIST 1.1 would fail to recognize the potential pseudo -progression and long- term effectiveness of  
52  
immunotherapy. Since significant tumor growth and/or newly detectable tumor lesions will generally be 
classified  as progressive disease (PD) based on RECIST  1.1, this could result  in an erroneous  termination of 
the treatment and unjustified patient exclusion from clinical studies.  
 
Although RECIST 1.1 references a maximum of 5 target lesions in total and 2 per organ, the Sponsor - 
Investigator allows a maximum of 10 target lesions in total and 5 per organ, if clinically relevant to enable a 
broader sampling of tumor burden.  
 
 
8.7.6 iRECIST  disease  assessment  
 
To address this limitation of RECIST 1.1 in cases of pseudoprogression under immunotherapy, Wolchok et 
al. developed modified ‘immune -related  Response Criteria’ (irRC)  based on the WHO  criteria  for the first time 
in 2009.120 Subsequently,  bi-dimensional  irRC were adapted  to the uni-dimensional  immune- related  RECIST 
(irRECIST) criteria.121,122 In both irRC and irRECIST, new measurable tumor lesions are to be added to the 
sum of the target lesions, while only a significant increase (irRC ≥25%; irRECIST ≥20%) results in 
determination of tumor progression (iPD = ‘immune -related progressive disease’).  One point of criticism with 
respect  to these criteria,  particularly  irRC,  was that non-measurable tumor  lesions  (i.e. non-target  lesions)  did 
not contribute to tumor progression. Moreover, in case of stable or minimal tumor decrease following 
pseudoprogression, iPD was confirmed according to irRC and irRECIST.  
 
To reduce inconsistency between different studies depending on which response assessment protocol was 
utilized,  the official RECIST  Working Group published the new iRECIST  guideline in 2017 to assess response 
to immunotherapy in clinical trials. In iRECIST, the basic principles of defining tumor lesions as measurable 
or non- measurable and assessing tumor responses are unchanged from RECIST 1.1. However, an 
additional confirmatory imaging study must be done to confirm or withdraw an ‘unconfirmed’ tumor 
progression after any initial increase in size.  
 
Given the novel nature of pixatimod and the uncertain nature of tumor kinetics in patients receiving 
nivolumab/pixatimod ± Cy, although RECIST will be primarily used to assess response, a key secondary 
endpoint is response by iRECIST as delineated in Figure 8.7.6 -1 and Table 8.7.6 -2 below.123 iRECIST will 
be used by the Investigator to assess tumor progression, and make treatment decisions. This is further elaborated upon in Appendix 4.  
53  
 
Figure 8.7.6 -1: iRECIST  Response Evaluation 
 

54  
 
 
Table  8.7.6 -2: Imaging and Treatment  after  First  Radiologic Evidence  of Progressive Disease 
 
 Clinically  Stable  Clinically  Unstable  
Imaging  Treatment  Imaging  Treatment  
First radiologic  evidence  of Repeat  imaging at  4 to May continue  study  treatment  at Repeat  imaging at  4 to Discontinue  treatment  
PD by RECIST  1.1 8 weeks  to confirm PD the Investigator’s  discretion  8 weeks  to confirm  PD per  
  while  awaiting  confirmatory  Investigator’s  discretion   
  tumor  imaging  by site by only  
  iRECIST    
Repeat  tumor  imaging  No additional  imaging  Discontinue  treatment  No additional  imaging  Not applicable  
confirms  PD (iCPD)  by required  (exception  is possible  upon  required.   
iRECIST  per Investigator   consultation  with Sponsor -   
assessment   Investigator)    
Repeat  tumor  imaging  Repeat  imaging at  4 to Continue  study  treatment  at the Repeat  imaging at  4 to Discontinue  treatment  
shows  iUPD  by iRECIST  8 weeks  to confirm PD. Principal  Investigator’s  8 weeks  to confirm  PD per  
per Investigator  May occur  at next discretion  Investigator’s  discretion   
assessment  regularly  scheduled   only  
 imaging  visit    
Repeat  tumor  imaging  Continue  regularly  Continue  study  treatment  at the Continue  regularly  May restart  study  treatment  if 
shows  iSD, iPR, or iCR by scheduled  imaging  Principal  Investigator’s  scheduled  imaging  condition  has improved  and/or  
iRECIST  per Investigator  assessments  discretion  assessments.  clinically  stable  per Investigator’s  
assessment.     discretion.  Next tumor  imaging  
    should  occur  according  to the 
    regular  imaging  schedule.  
iCPD = iRECIST  confirmed progressive  disease;  iCR = iRECIST  complete response;  iRECIST  = modified  Response Evaluation  Criteria  in Solid  Tumors  1.1 for 
immune- based therapeutics; iSD = iRECIST stable disease;  iUPD = iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1 = 
Response Evaluation Criteria in Solid Tumors 1.1.  
55  
 
8.8 Adverse  Events  (AEs)  
 
8.8.1 Definitions  
 
8.8.1.1 Definition of AEs  
An AE is an untoward or medical occurrence associated with the use of study drug (active or 
placebo drug, biologic, or device) in clinical investigation subjects, which does not necessarily have a causal relationship with the study drug. An AE can therefore be any unfavorable and 
unintended symptom, sign, disease or condition, or test abnormality  whether or not considered 
related to study drug. AEs that do not meet  the definition for serious AEs  (SAEs) are  considered 
non-SAEs.  
 
AEs include:  
• Changes  described by the subject  or signs  observed by the Investigator  or medical  staff.  
• Test abnormalities  (i.e., laboratory  tests,  ECGs)  that result  in an alteration in medical  care 
(diagnostic or therapeutic).  
 
Disease  Progression  is not considered  an AE in this study.  
 
Abnormalities  present  at baseline are considered AEs only if they reoccur  after resolution or they 
worsen during the study.  
 
8.8.1.2  SAE and serious  unexpected adverse reactions (SUSAR) 
An SAE is any AE that fulfills one of the criteria outlined in Table 8.8.1.2 -1. 
Table 8.8.1.2-1 : Criteria for Determination of Serious Adverse Events (SAEs)  
Death  An AE that results  in death.  
*In this study,  deaths  that are unequivocally  due to Disease Progression 
are not to be reported as SAEs.  
Life-threatening  AE An AE that places  the subject,  in the view of the Investigator,  at immediate 
risk of death from the AE as it occurred (i.e., does not include an AE that 
had it occurred in a more severe form, might have caused death).  
Required or prolonged 
inpatient  hospitalization  An AE that results in an initial inpatient hospitalization or prolongs an 
existing  hospitalization  of the subject.  If a subject  is hospitalized  as part of 
the clinical use of the study drug,  a period  of normal  hospitalization  will be 
outlined in the protocol or by the judgment of the Investigator.  
Hospitalizations  longer  than this period will be prolonged hospitalizations.  
Persistent  or significant 
disability/incapacity  An AE that results  in a substantial  disruption  of a subject’s  ability  to conduct 
normal life functions.  
Congenital 
anomaly/birth  defect  A congenital  anomaly/birth  defect  that occurs  in the offspring  of a subject 
exposed to the study drug.  
Important  medical  event  An AE that may not result in death, be life-threatening, or require 
hospitalization may be considered an SAE when,  based upon  appropriate 
medical judgment, the event may jeopardize the subject and may require medical  or surgical  intervention  to prevent  1 of the outcomes  listed  above.  
 
56  
Examples of such “important medical events” include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result 
in inpatient hospitalization, or the development of drug dependency or drug abuse.  
 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as with important medical events described above.  
 
Events that meet SAE criteria must be recorded and reported regardless of expectedness or assessed association with study drug.  
 
Note:  
• Planned hospital admissions or surgical procedures for elective procedures or for an 
illness or disease that existed before the signing of the ICF or before the subject was 
enrolled in the study will not be captured as SAEs.  
• If planned admissions or procedures occur at a time other than what was planned (i.e., 
due to an exacerbation in the preexisting illness or disease), they should be reported as 
SAEs.  
 
8.8.1.3  Unexpected AEs 
 
An unexpected AE is any AE that is not consistent  in specificity  or severity with the current  IB for 
either pixatimod or nivolumab.  
 
 
8.8.2 Evaluation  of AEs and SAEs  
 
The Investigator or designee is responsible for making an assessment as to the severity/grade 
(as defined in Section 8.8.2.1, below), causality/relationship (as defined in Section 8.8.2.2 , 
below), and outcome of AEs and SAEs (as defined in Section 8.8.2.3, below). In addition, the 
Investigator or designee must report any actions taken as a result of an AE or SAE.  
 
8.8.1.4  AE severity/grade  
 
For each recorded AE or SAE, the  Investigator or  designee must  make an assessment of  Grade 
using the Common Terminology Criteria for Adverse Events  (CTCAE) version 5. Grade refers  to 
the severity of the AE. Note that severity is not the same as “seriousness”. Seriousness (not 
severity) serves as a guide for defining regulatory reporting obligations.  
 
8.8.1.5  Causality and relationship to study  drug(s)  
 
For each AE or SAE, the Investigator will determine whether there is a reasonable possibility demonstrated  by evidence that suggests  a causal relationship between  the study  drug regimens 
– nivolumab and pixatimod ( Cohorts 2 and 3) and nivolumab, pixatimod and low -dose 
cyclophosphamide (Cohort  1) - and the AE according to the categories  provided  in Table  8.8.2.2 - 
1. Attribution of adverse events specifically to either pixatimod or nivolumab is challenging, 
therefore, the  relationship to study drug should be based on attribution to the combination of the 
two drugs, not a single drug.  
57  
The cumulative experience with low -dose cyclophosphamide suggests that AE/SAE related to 
this agent and/or its administration are rare. However, investigators will make every effort to 
evaluate for AE/SAE that may be related to cyclophosphamide.  
 
An AE with causal relationship not initially determined will require follow -up to assign causality 
which must be made by the Investigator prior to completion of the study. The Investigator may 
change his/her  opinion of causality  in light of follow- up information;  if this occurs,  the Investigator 
must amend the AE or SAE information accordingly.  
 
Table  8.8.2.2 -1: Classifications  for Adverse  Event  (AE) Causality/Relationship  
Classification  Definition  
Unrelated  There  is no suspicion  of a causal  relationship  between  exposure  to 
the study drug regimen and the AE; another cause of the AE has  
been  identified,  no temporal  association  with study  drug has been 
identified, or the study drug cannot be implicated.  
Possibly  related  There is some evidence supporting the possibility of a causal 
relationship between study drug regimen exposure and the AE; an 
alternative explanation (i.e., concomitant drug or concomitant 
disease)  is inconclusive,  the temporal  association  with study  drug is 
reasonable, and the causal relationship cannot be excluded.  
Probably  related  An adverse  event  that has a timely  relationship  to the administration 
of the investigational drug regimen and follows a known pattern of 
response, but for which a potential alternative cause may be  
present.  
Definitely  related  There  is strong  evidence  that there  is a causal  relationship  between 
study drug regimen and the AE; the AE cannot be reasonably explained by an alternative explanation (i.e., concomitant drug or  
concomitant  disease)  and the temporal  association with study  drug 
is suggestive of a causal relationship.  
 
8.8.1.6  Classification  of AE outcome 
 
Adverse event outcome describes the status of the AE at the last observation. The Investigator 
will document the outcome of each  AE or SAE using the  categories provided in Table  8.8.2.3 -1. 
 
Table  8.8.2.3 -1: Classifications  for Adverse  Event  (AE) Outcome  
Classification  Definition  
Fatal  Termination  of life as a result  of an AE. 
Not recovered/not  resolved  Subject  has not recuperated,  or the AE has not improved.  
Recovering/resolving  Subject  is recuperating  or the AE is improving.  
Recovered/resolved  Subject  has recuperated,  the AE resolved,  or returned  to baseline 
status / stabilized.  
Recovered/resolved  with 
sequelae  Adverse  event  has resolved,  but the subject  has been  left with 
symptoms or pathology.  
Unknown  Not known,  not observed,  not recorded,  or refused.  
 
 
8.8.1.7  Action taken regarding AE 
 
The Investigator will provide the action taken regarding study drug in response to the AE. 
Classifications for each of the  potential actions  taken are provided in Table  8.8.2.4 -1. More  than 
one option may apply  to a single  AE/SAE.  For example,  study  drug may be delayed,  and the dose  
58  
reduced in response to an AE. Action related to nivolumab, pixatimod and/or low -dose 
cyclophosphamide will be assessed and recorded separately in the EDC.  
 
Table  8.8.2.4 -1: Classifications  for Actions  Taken  Regarding  an Adverse  Event  (AE) 
Classification  Definition  
Dose  not changed  No change  in administration  of study  drug 
Dose  reduced1 Reduction  in the amount  of study  drug administered  
Study  drug interrupted  Temporary  interruption  (termination)  in administration  of the study 
drug 
Study  drug withdrawn  Administration  of the study  drug terminated  (no further  dosing)  
Not applicable  Determination  of a value  is not relevant  in the current  context  
Unknown  Not known,  not observed,  not recorded,  or refused  
1Refer  to Section  7.2.2.  (nivolumab) , Section  7.2.3.  (pixatimod)  and Section  7.2.4.  (Cy) 
regarding dose reductions of nivolumab, pixatimod or Cy due to dose- limiting toxicities, 
respectively.  
 
 
8.8.3 Timeframe  for AE/SAE  Collection 
 
The Investigator  is required to record all AEs occurring during the clinical study  (21 CFR 312.64[b] 
and ICH E6 [R1])  starting  from the date of first dose of study  treatment  until 30 days  after the last 
dose of nivolumab and pixatimod (± cyclophosphamide) on the AE page of the eCRF. SAEs  that 
occur within 90 days of the end of treatment or before initiation of a new anti -cancer treatment 
should also be followed  and recorded.  SAEs  as defined in Section 8.8.1.2.  must  also be reported 
to the Sponsor -Investigator  or representative  within  24 hours  of knowledge of their occurrence,  in 
accordance with Section 8.8.5.  
 
8.8.3.1  TRAE  and treatment -related SAE (TRSAE)  
 
TRAEs and treatment -related SAEs (TRSAEs) are defined as AEs or SAEs that started or 
worsened in severity on or after the date the study drugs were first administered.  
 
TRAE/TRSAE information will be collected  from the time of the subject’s  first receipt  of nivolumab 
and pixatimod (± cyclophosphamide)  until 30 days  after the last dose of nivolumab and pixatimod 
(± cyclophosphamide).  
 
 
8.8.3.2  SAEs  
 
SAE information will be collected from the point the subject starts study treatment until 90 days 
after the last dose of nivolumab and pixatimod (± cyclophosphamide).  If, at any time after the 
subject  has completed participation in the study,  the Investigator  or study  staff becomes  aware  of 
an SAE that they believe is possibly related or related to nivolumab and pixatimod (± 
cyclophosphamide,  see Section 8.8.1.2 ), then the event  and any known details  must  be reported 
promptly  to the Sponsor -Investigator. The  reporting  instructions  described  in Section  8.8.5  must 
be followed.  
59  
8.8.4 Recording  AEs/SAEs  
 
All AEs and SAEs  experienced by a subject  will be recorded  on the appropriate research record. 
Information including a concise description of the event; date and time of event onset and 
resolution; determination of seriousness, severity, corrective treatment, outcome, relationship to 
study drug; and action taken regarding the study drug will  be recorded.  
 
Vital signs,  laboratory  results, and other  safety  assessments  as obtained  as detailed in Sections 
8.4, 8.5, and 8.6 will be recorded as AEs if they are determined to be clinically  significant  findings 
in the opinion of the Investigator.  When possible,  a diagnosis  should be recorded as an AE, rather 
than symptoms  or isolated  laboratory  abnormalities  related  to that diagnosis.  A medical  or surgical 
procedure is not an AE; rather the condition leading to the procedure should be recorded as the 
AE. If the condition is not known, the procedure must be recorded as an AE instead. Similarly, 
death is not an AE, but is rather the outcome of the AE(s) that resulted in death. If the AE(s) 
leading to death are not known, then death must be reported as an AE.  
 
All SAEs  experienced by the subject will be entered into the CTMA  and reported to the Sponsor - 
Investigator or designee, in accordance with Section 8.8.5 . 
 
 
8.8.5 Reporting SAEs  and Serious Unexpected  AEs (SUAE)  
 
8.8.5.1  SAE and SUAE  reporting 
 
All events  meeting the definition  of a serious  adverse event,  which  occur  after the date of first 
dose of study treatment and within 30 days after the last dose of study treatment, should be 
reported according to the CRS SAE checklist and SAE form. The initial SAE form should be 
sent to the following within 24 hours of the Principal Investigator becoming aware:  
• Sponsor -Investigator  
Email:  davard@upmc.edu ; 
• crssafetysubmissions@upmc.edu 
• The Aculeus Therapeutics  Drug Safety contact information is available for SAE reporting 
on a 24 -hour basis  and is reviewed during  normal  business  hours.  The contact  information  
is as follows: Email: mdevlin@aculeustx.com   
• Local  Institutional  Review Board when reporting  requirements  are met 
 
In addition to completing appropriate patient demographic and suspect medication 
information,  the report should include  as applicable the following  information that is available 
at the time of report within the CRS departmental SAE form:  
o CTCAE  term(s)  and grade(s)  
o Current  status  of study  drug 
o Intervention(s)  to address  the AE (testing  and result,  treatment  and response)  
o Hospitalization  and/or  discharge dates 
o Event  relationship to study  drug combination  
 
8.8.5.2  Events of clinical  interest  (ECI)  
60  
Selected non-serious  and serious  adverse events  are also known as Events of Clinical  Interest 
(ECI)  and must  be reported within  24 hours  to the Sponsor -Investigator  and within  2 working  days 
to Aculeus Therapeutics  Drug Safety Contact (see Section 8.8.5.1. ). 
 
For the time period beginning when the consent  form is signed until treatment initiation,  any ECI, 
or follow up to an ECI, that occurs  to any subject  must  be reported  within  24 hours  to the Sponsor - 
Investigator and within 2 working days to Aculeus Therapeutics  Drug Safety Contact if it causes 
the subject to be excluded from the trial, or is the result of a protocol -specified intervention, 
including but not limited to washout or discontinuation of usual therapy, diet, placebo treatment or 
a procedure.  
 
For the time period beginning at treatment initiation through 90 days following cessation of 
treatment, or 30 days following cessation of treatment if the subject initiates new anticancer 
therapy,  whichever  is earlier,  any ECI, or follow up to an ECI, whether  or not related to Checkmate 
product, must be reported within 24 hours to the Sponsor -Investigator and within 24 hours to 
Aculeus Therapeutics  Drug Safety Contact.  
 
ECI for this trial include:  
• An overdose  of Aculeus Therapeutics  product  
 
8.8.5.3  Pregnancies  
 
Female subjects  or the partners  of male  subjects  who discover  they are pregnant  within  a year of 
their last nivolumab and pixatimod (± cyclophosphamide) dose will be instructed to notify the 
Investigator immediately.  
 
If the Investigator  learns  of a report  of pregnancy  at any time after signing the ICF, the Investigator 
must  report  the pregnancy  to Aculeus Therapeutics  Pharmaceuticals  Drug  Safety  within  24 hours  
(following  the same reporting process outlined in Section 8.8.5.1 ). 
 
The Investigator will inform the subject that the Sponsor -Investigator or its designee is required to 
gather information regarding the course and outcome of a pregnancy that has occurred after exposure to a study drug. The progress of the pregnancy must be followed until the outcome of 
the pregnancy is known (i.e., delivery, elective termination, or spontaneous abortion). If the 
pregnancy results in the birth of a child, additional follow -up information may be requested.  
 
The Investigator will be asked to obtain follow -up information no later than 2 months after the 
gestational period to  obtain maternal/fetal/neonatal outcome and  any other relevant information. 
Follow -up information may be requested at additional time points. All study -related contacts 
involving a known pregnancy should include pregnancy status assessment until pregnancy outcome is known.  
 
Please note that pregnancy in and of itself is not an AE or an SAE. Pregnancy should not be 
entered into the eCRF  as an AE unless  the Investigator  suspects  an interaction between the study 
drug and the contraceptive method.  Additionally,  all information received will be assessed for any 
AEs and SAEs and processed per study guidelines. If the subject is discontinued because of 
pregnancy,  pregnancy  will be documented  as the reason  for study  discontinuation.  Spontaneous 
abortions and stillbirths will be reported as SAEs.  
61  
8.8.6 IND safety  report  
 
The Sponsor -Investigator  must  notify  FDA and all participating  investigators  (i.e., all investigators 
to whom the Sponsor -Investigator is providing drug under its INDs or under any investigator's 
IND) in an IND safety report of potential serious risks, from clinical trials or any other source, as 
soon as possible, but in no case later than 15  calendar days after the Sponsor -Investigator 
determines that the information qualifies for reporting under Sections 8.8.6.1. to  8.8.6.3. below. 
In each  IND safety  report,  the Sponsor -Investigator  must  identify  all IND safety  reports  previously 
submitted to FDA concerning a similar suspected adverse reaction, and must analyze the 
significance of the suspected adverse reaction in light of previous, similar reports or any other 
relevant information.  
 
8.8.6.1  Serious and unexpected adverse reactions  
 
The Sponsor -Investigator must report any suspected adverse reaction that is both serious and 
unexpected. The Sponsor -Investigator must report an adverse event as a suspected adverse 
reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event, such as:  
• A single occurrence of an event that is uncommon and known to be strongly associated 
with drug exposure (e.g., angioedema, hepatic injury, Stevens -Johnson Syndrome);  
 
• One or more  occurrences  of an event  that is not commonly  associated  with drug exposure, 
but is otherwise uncommon in the population exposed to the drug (e.g., tendon rupture);  
 
• An aggregate analysis of specific events observed in a clinical trial (such as known 
consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indic ates 
those events occur more frequently in the drug treatment group than in a concurrent or 
historical control group.  
 
8.8.6.2  Findings from  other  studies 
 
The Sponsor -Investigator  must  report  any findings  from epidemiological  studies,  pooled analysis 
of multiple  studies,  or clinical studies  (other  than those  reported under  Section 8.8.6.1.),  whether 
or not conducted under an IND, and whether or not conducted by the Sponsor -Investigator, that 
suggest a significant risk in humans exposed to the drug. Ordinarily, such a finding would result in a safety -related change in the protocol, informed con sent, investigator brochure (excluding 
routine updates of these documents), or other aspects of the overall conduct of the clinical investigation.  
 
8.8.6.3  Findings from  animal  and/or  in vitro  studies  
 
The Sponsor -Investigator must report any findings from animal or in vitro testing, whether or not 
conducted by the Sponsor -Investigator, that suggest a significant risk in humans exposed to the 
drug, such as reports of mutagenicity, teratogenicity, or carcinogenicity, or reports of significant 
organ toxicity  at or near the expected human exposure.  Ordinarily,  any such  findings  would  result 
in a safety -related change in the protocol, informed consent, investigator brochure (excluding 
routine updates of these documents), or other aspects of the overall conduct of the clinical 
investigation.  
62  
8.8.6.4  Increase rate of occurrence of serious suspected adverse reactions  
 
The Sponsor -Investigator must report any clinically important increase in the rate of a serious  
suspected adverse reaction over that listed in the protocol or investigator brochure.  
 
8.8.6.5  Submission  of IND safety  reports  
 
The Sponsor -Investigator must submit each IND safety report in a narrative format or on FDA 
Form 3500A or in an electronic format that FDA can process, review, and archive. FDA will 
periodically issue guidance on how to provide the electronic submission (e.g., method of 
transmission,  media,  file formats,  preparation and organization of files).  The Sponsor -Investigator 
may submit foreign suspected adverse reactions on a Council for International Organizations of Medical Sciences (CIOMS) I Form instead of a F DA Form 3500A. Reports of overall findings or 
pooled analyses from published and unpublished in vitro, animal, epidemiological, or clinical 
studies must be submitted in a narrative format. Each notification to FDA must bear prominent 
identification of its contents, i.e., "IND Safety Report," and must be transmitted to the review 
division  in the Center  for Drug  Evaluation and Research or in the Center  for Biologics  Evaluation 
and Research that has responsibility  for review  of the IND. Upon request  from FDA,  the Sponsor - 
Investigator must submit to FDA any additional data or information that the agency deems 
necessary, as soon as possible, but in no case later than 15 calendar days after receiving the 
request.  
 
8.8.6.5.1  Unexpected fatal or life -threatening suspected adverse reaction 
reports 
 
The Sponsor -Investigator must also notify FDA of any unexpected fatal or life- threatening 
suspected adverse reaction as soon as possible but in no case later than 7 calendar days after 
the sponsor's initial receipt of the information.  
 
8.8.6.5.2  Reporting format  or frequency  
 
FDA may require the Sponsor  to submit  IND safety  reports  in a format  or at a frequency  different 
than that required under Sponsor -Investigator paragraph. The Sponsor may also propose and 
adopt  a different  reporting format  or frequency  if the change  is agreed  to in advance by the director 
of the FDA review division that has responsibility for review of the IND.  
 
8.8.6.5.3  Investigations of marketed drugs 
 
A Sponsor  of a clinical study  of a drug marketed  or approved  in the United  States  that is conducted 
under an IND is required to submit IND safety reports for suspected adverse reactions that are 
observed in the clinical study, at domestic or foreign study sites. The Sponsor must also submit 
safety information from the clinical study as prescribed by the post marketing safety reporting 
requirements.  
 
8.8.6.5.4  Reporting study endpoints 
 
Study endpoints (e.g., mortality or major morbidity) must be reported to FDA by the Sponsor - 
Investigator  as described in the protocol  and ordinarily  would  not be reported under  Section 9.6. 
However, if a serious and unexpected adverse event occurs for which there is evidence suggesting a causal  relationship between the drug and the event  (e.g.,  death from  anaphylaxis), 
the event must be reported under Serious and unexpected suspected adverse reaction as a serious and unexpected suspected adverse reaction even if it is a component of the study 
endpoint (e.g., all -cause mortality).  
63  
8.8.7 Follow -Up 
 
• The sponsor  must  promptly  investigate all safety  information it receives.  
• Relevant follow -up information to an IND safety  report must be submitted as soon as  the 
information is available and must  be identified as such,  i.e., "Follow -up IND Safety  Report."  
• If the results of a sponsor's investigation show that an adverse event not initially 
determined to be reportable under section IND safety reports of this section is so 
reportable, the sponsor must report such suspected adverse reaction in an IND safety 
report as soon as possible, but in no case later than 15 calendar days after the 
determination is made.  
 
8.8.8 Disclaimer  
 
A safety report or other information submitted by a sponsor under this part (and any release by FDA of that report  or information)  does  not necessarily  reflect  a conclusion by the sponsor  or FDA 
that the report or information constitutes an admission that the drug caused or contributed to an 
adverse event.  A sponsor  need not admit,  and may deny,  that the report  or information submitted 
by the sponsor  constitutes  an admission  that the drug caused  or contributed to an adverse  event.  
 
The principal investigator must promptly review all information relevant to the safety of the drug obtained or otherwise received from foreign or domestic sources, including information derived 
from any clinical or epidemiological investigations, animal or  in vitro studies, reports in the 
scientific literature, and unpublished scientific papers, as well as reports from foreign regulatory 
authorities and reports of foreign commercial marketing experience for drugs that are not 
marketed in the United States.  The study sponsor must notify all participating investigators of 
potential serious risks, from clinical trials or any other source, as soon as possible.  
 
 
8.8.9 Reporting AEs to the responsible Institutional  Review  Board (IRB)  
 
In accordance with applicable policies of the University of Pittsburgh Institutional Review Board 
(IRB),  the Sponsor -Investigator  will report,  to the IRB, any observed  or volunteered  adverse  event 
that is determined to be 1) associated with the investigational drug or study treatment(s); 2) serious; and 3) unexpected. Adverse event reports will be submitted to the IRB in accordance 
with the respective IRB procedures.  
 
Applicable adverse events  will be reported  to the IRB as  soon as possible and, in no event, later 
than 10 calendar days following the sponsor -investigator’s receipt of the respective information. 
Adverse events which are 1) associated with the investigational drug or study treatment(s); 2) 
fatal or life- threatening; and 3) unexpected will be reported to the IRB within 24 hours of the 
Sponsor -Investigator’s receipt of the respective information.  
 
Follow -up information to a reported adverse event will be submitted to the IRB as soon as the 
relevant  information  is available.  If the results  of the Sponsor -Investigator’s  follow- up investigation 
show  that an adverse event  that was initially  determined to not require reporting to the IRB does, 
in fact, meet  the requirements  for reporting;  the Sponsor -Investigator  will report  the adverse  event 
to the IRB as soon  as possible,  but in no event  later than 10 calendar  days,  after the determination 
was made.  
64  
8.8.10 Follow -up of AEs and SAEs  
 
All AEs and SAEs documented at a previous visit that are designated as either 
recovering/resolving or not recovered/resolved,  will be reviewed by the Investigator  at subsequent 
visits.  
 
All AEs will be followed until resolution of AE, completion of the subject’s participation, or study termination, whichever occurs first.  
 
Serious  AEs and AEs resulting in discontinuation will be followed  until one of the following  occurs:  
• The event  resolves.  
• The event  stabilizes.  
• The event  returns  to a baseline value,  if a baseline value is available.  
• The event can be attributed to agents  other than the study  drug or to factors unrelated  to 
study conduct.  
• The Investigator  agrees  that follow- up is no longer  necessary.  
 
Follow -up reports  from the  Investigator  must be  provided as  indicated using  the SAE report form 
within  24 hours of the Investigator’s  first knowledge of the new information.  Additional information 
(i.e., hospital  records,  laboratory,  or other  diagnostic  test results) should be provided if requested 
and/or indicated.  
 
Rules for AE/SAE follow up apply to all subjects, including those who withdraw consent prior to study completion (to the extent allowed). The Investigator will ensure that follow up includes 
further  investigations  to elucidate the nature  and/or  causality  of the AE/SAE.  These  investigations 
must be consistent with appropriate medical management and subject consent.  
 
Investigators are not obligated to actively seek AEs or SAEs in former study subjects that occur 
pursuant  to the follow- up period.  However,  if the Investigator  or designee learns  of any AE or SAE 
at any time after a subject has been discharged from the study and the event is considered as reasonably related to the study drug, the Sponsor -Investigator will notify Aculeus Therapeutics . 
 
 
8.9 Tumor  Tissue Collection  and Correlative Studies 
 
The total amount of blood/tissue to be drawn/collected over the course of the trial (from pre- trial 
to post -trial visits), including approximate blood/tissue volumes drawn/collected by visit and by 
sample type per subject can be found in the Laboratory Manual and is reproduced below.  
 
Planned correlative analyses will include flow cytometric analyses of tumor samples, TIL and 
peripheral blood  mononuclear  cells (PBMC),  IHC analyses  of pre-/post - treatment  tumor  samples, 
tumor  whole  exome/RNA  sequencing.  Single -cell RNA  sequencing will be performed  on a subset 
of treated  patients.  Studies  will be performed  under  the direction  of the Principal Investigator  along 
with co -Investigator Dr. Hassane Zarour in Dr. Zarour’s lab.  
 
Tumor  tissue  
Patients must undergo protocol mandated research biopsies during Screening and on Cycle 2 
Day 1. Biopsies  may be on any suitable previously  non-radiated  representative lesion.  Biopsy  site 
must be sized suitably to permit investigator to obtain minimum quantity of tissue as specified in  
65  
the Schedule  of Activities (Section  2.0), which  is 6 core biopsies  of minimum  16gauge (or 
greater). Tumor tissue will be processed as described in the Laboratory Manual . 
 
Primary  tumor  (if available)  
FFPE tissue block(s) or 10 unstained slides (air dried) from patients’ originally resected primary 
tumor (melanoma, NSCLC or CRC) will be requested as well.  
 
Blood biospecimens  
Blood biospecimens  will be collected at baseline,  and per the schedule outlined in the trial 
Schedule of Activities  (Section  2.0). 
 
At EACH time point  please submit  the following:  
• Six (6) 10mL  sodium  heparin tubes  (Fisher  Scientific  catalog number  02-685-114A)  
• Two (2) 5mL SST tubes  (Fisher  Scientific  catalog number  02-683-145) 
• One (1) 10mL  Streck  cf DNA  tube 
• One (1) 4mL K2 EDTA tube ( SCREENING ONLY ) (Fisher Scientific catalog number 02 - 
689-4) 
 
Each  tube must  be clearly  labeled to include:  
• Protocol  number:  HCC 20-266 
• Patient  number:  UOP -XXX 
• Patient  initials:  
• Originating institution/investigator  name:  
• Date  and time drawn:  
• Collection  time point:  
 
Stool  specimens  
Stool  biospecimens  will be collected  at baseline,  and per the schedule outlined in the trial 
Schedule of Activities  (Section  2.0). 
 
Dietary  questionnaire 
DHQ -3 questionnaire may be administered electronically  or on paper.  Electronic  administration is 
preferred. Data will be entered into DHQ -3 online per instructions as outlined in Appendix 1. 
 
 
8.9 Pharmacokinetics  Sampling 
 
8.9.1 Pixatimod (PG545)  Pharmacokinetics 
 
Pixatimod  pharmacokinetic  sampling will be collected from 10 subjects  in Cohort  1, and a total of 
10 subjects from Cohorts 2 and 3. Samples will be collected at the following time- points relative 
to the pixatimod infusion (Cycle 1 Day 1):  
 
Pre-dosing 
Post-dosing:  
• 30 minutes  post-infusion (± 5 minutes)  
• 2 hours  post-infusion  (± 15 minutes)  
• 4 hours  post-infusion  (± 15 minutes)  
• 6 hours  post-infusion  (± 30 minutes)  
66  
• 24 hours  post-infusion (± 60 minutes)  
• 72 hours  post-infusion (± 24 hours)  
• 168 hours  post-infusion  (± 24 hours)  (i.e. prior to dosing on Cycle  1 Day 8). 
 
Post-dose samples cannot be taken from the same vein as used for dosing. At each of the 
sampling periods, samples will be collected into 2.7 mL sodium citrate tubes. At each of the 
collection  time points  each subject  will have 1 x 2.7 mL collection,  with the exception of the Cycle 
1 Day 1 pre-dose sample where 2 x 2.7 mL collections  will be required.  Pharmacokinetic  analysis 
will be performed  using an LC-MS/MS  method  validated  for pixatimod  in human  plasma.  Samples 
will be clearly labelled, frozen, and forwarded to the contracted laboratory for analysis. The 
laboratory will measure pixatimod concentrations on each sample. The exact date and time of infusion state  and finish,  and the exact  time of each sample,  will be recorded on a supplementary 
page of the CRF.  
 
The individual pixatimod pharmacokinetic profile and parameters of the AUC (area under the curve), Cmax (maximum concentration), Tmax (time to maximum concentration), and t1/2, clearance (Cl) and volume of distribution (Vd) will be estimated provided the ‘fit’ of the time versus 
concentration curves permit such analysis. Summary statistics will be used to describe pharmacokinetic results.  
 
8.9.2 Cyclophosphamide  Pharmacokinetics 
 
Cyclophosphamide pharmacokinetic  sampling  will be collected from 10 subjects  in Cohort  1 only. 
Samples will be collected at the following time -points relative to the pixatimod infusion (Cycle 1 
Day 1):  
 
Pre-dosing 
Post-dosing:  
• 10 minutes  (± 5 minute)  
• 30 minutes  post-dose  (± 5 minutes)  
• 1 hour post-dose (± 10 minutes)  
• 2 hours  post-dose  (± 15 minutes)  
• 4 hours  post-dose  (± 15 minutes)  
• 6 hours  post-dose  (± 30 minutes)  
• 24 hours  post-dose (± 1 hour)  
 
At each of the sampling periods, samples will be collected into 2.0 mL sodium heparin tubes. At 
each of the collection  time points  each subject  will have  1 x 2.0 mL collection, with  the exception 
of the Cycle 1 Day 1 pre- dose sample where 2 x 2.0 mL collections will be required. 
Pharmacokinetic analysis will be performed using an LC -MS/MS method validated for 
cyclophosphamide in human plasma. Samples will be clearly labelled, frozen, and forwarded to 
the contracted laboratory for analysis. The laboratory will measure cyclophosphamide 
concentrations on each sample. The exact date and time of infusion state and finish, and the 
exact time of each sample, will be recorded on a supplementary page of the CRF.  
 
The individual  cyclophosphamide pharmacokinetic  profile  and parameters  of the AUC (area  under 
the curve), C max (maximum concentration), T max (time to maximum concentration), and t 1/2, 
clearance (Cl) and volume of distribution (Vd) will be estimated provided the ‘fit’ of the time versus  
67  
concentration curves  permit  such  analysis.  Summary  statistics  will be used to describe 
pharmacokinetic results.  
 
9. STATISTICAL  CONSIDERATIONS  
 
9.1 Study Design 
 
This is a phase II study  of nivolumab in combination with pixatimod in 3 separate  cohorts:  
• Cohort  1: nivolumab,  pixatimod and low-dose  cyclophosphamide in MSS mCRC  
• Cohort  2: nivolumab and pixatimod in PD-1 relapsed/refractory  melanoma  
• Cohort  3: nivolumab and pixatimod in PD-1 relapsed/refractory  NSCLC.  
 
The goal of this study is to assess response of PD -1 R/R melanoma/NSCLC to nivolumab and 
pixatimod; and MSS mCRC to nivolumab, pixatimod and low -dose cyclophosphamide. Simon’s 
two-stage design will be used for each cohort separately.  
 
9.2 Safety Monitoring 
 
Anti-PD-1 therapy  including nivolumab  has been  tested in PD-1 R/R melanoma,  NSCLC  and PD- 
1 naive MSS mCRC in multiple studies.  
 
The safety  profile  observed thus far suggests  that the combination  of nivolumab  and pixatimod  is 
unlikely  to pose a high risk of toxicity  in the setting of PD-1 R/R melanoma and PD-1 R/R NSCLC. 
Hence, in this study, we will monitor dose limiting toxicities (DLTs, defined below at the end of this 
section) for 4 weeks for the 1st 3 patients accrued in Cohorts 2 and 3. If we see at least 1 DLT  
out of the 3 patients,  we will hold the accrual  in this cohort,  and the study  committee  and the 
Principal Investigator (Sponsor -Investigator) will decide whether to modify or discontinue the 
study.  
 
The combination of nivolumab and pixatimod has been studied in MSS mCRC in a small phase 
IB study wherein no untoward safety signals were observed. PD -1 inhibitor pembrolizumab and 
low-dose cyclophosphamide (50 mg twice  daily,  1-week -on, 1-week -off) has been  explored  in two 
studies  in patients  with advanced osteosarcoma and soft tissue  sarcomas  with a low incidence of 
grade 3/4 adverse  events.95,96 Based on the above,  it is unlikely  that the combination of nivolumab, 
pixatimod and low -dose cyclophosphamide has overlapping toxicities, nor is there a plausible 
basis for pharmacodynamic or pharmacokinetic interactions leading to a DLT. As such, it is not felt that this combination  requires  a formal  phase I study.  However,  the combination of nivolumab, 
pixatimod and low -dose cyclophosphamide has hitherto not been studied in advanced cancer 
patients in general and MSS mCRC patients in particular. To mitigate toxicity, in Cohort 1 , we will 
utilize a safety run- in and monitor toxicities continuously using the following method and decision 
rule. 
 
In the safety  run-in (Cohort  1 only), 6 patients  will be enrolled at a rate of no more  than 1 patient 
per month.  Toxicities  will be monitored as delineated below.  At the end of the safety  run-in period 
(defined as 1 month following the enrollment of the 6th patient in Cohort 1 ), the formal DLT rate 
will be calculated.  If the DLT rate is ≤25%,  the study  will continue to proceed.  Should the DLT rate 
exceed 25% (i.e. at least 2 DLTs in the first 6 enrolled patients), the study will be stopped.  
 
To further  mitigate  toxicity,  we will use a Bayesian monitoring scheme  to continuously  monitor  the 
DLT rate of the study combination at 25%. A non -informative prior of Beta(1, 1) for the DLT rate 
will be used. We will hold the accrual  if the posterior probability  Pr (DLT  rate>25%)  ≥ 0.7  and the 
study committee  and the PI will decide whether to  modify  or discontinue  the study. The  stopping 
boundary for toxicity is given in the following table.  
68  
 
Number  of DLTs≥  in Number  of Patients  = 
4 7-9 
5 10-12 
6 13-15 
7 16-18 
8 19-22 
9 23-25 
10 26-27 
 
 
We simulate the operating characteristics under various assumed true toxicity rate (see the 
following table):  
Scenario  Prob.Of.Tox  Prob.Early.Stop  
1 0.05 0.001  
2 0.15 0.05 
3 0.25 0.30 
4 0.35 0.67 
5 0.45 0.92 
 
A DLT is defined as any adverse event(s) (AEs) considered related to nivolumab and pixatimod 
that occurs during the first 28 days of therapy in  Cohorts 2 and 3; and  related to nivolumab and 
pixatimod and cyclophosphamide that occurs during the safety  run-in period (defined as 1 month 
following the enrollment of the 6th patient) in Cohort 1 . During DLT monitoring period, no further 
accrual will be permitted. Any patient who has started the study treatment will be evaluable for 
safety.  
 
The following  events  will be considered DLTs  if deemed related to study  therapy:  
• Hematologic  
 
o Grade  4 neutropenia  
 
o Febrile neutropenia,  defined as absolute  neutrophil  count  (ANC)  ≤1000/mm3 with 
a temperature of ≥ 38.3 degrees °C  
 
o Grade ≥3 neutropenic  infection  
o Grade  ≥3 thrombocytopenia with bleeding  
o Grade  4 thrombocytopenia 
• Non-hematologic  
 
o Grade  >3 fatigue lasting  ≥1 week  
o Grade ≥3 nausea,  vomiting  or diarrhea  despite maximal  medical  intervention 
o Grade ≥3 toxicities  (non-laboratory)  
69  
o Grade >3 electrolyte abnormality that last >72 hours, unless the patient has 
clinical symptoms, in which  case all grade >3 electrolyte  abnormalities  regardless 
of duration should count as a DLT.  
o Grade ≥4 hepatic toxicity [excluding isolated grade ≥3 gamma - 
glutamyltransferase  (GGT)  abnormalities]  according to Hy's law.124 
• Any death (grade 5 event) not clearly due to the underlying disease and/or extraneous  
cause(s).  
 
• Other  (non-AST/non -ALT)  non-hematologic  Grade  ≥3 laboratory  value if the abnormality  
leads  to overnight  hospitalization.  
 
An AE  believed to be caused by tumor  flare or pseudoprogression is not considered a DLT. Any 
such cases that would otherwise meet DLT criteria must be discussed immediately with the 
Principal Investigator. If the Principal Investigator agrees that tumor flare is a likely explanation 
for the AE, treatment with nivolumab/pixatimod may continue so long as the subject is closely 
monitored by the Principal Investigator or study staff while on study. 
 
 
9.3 Efficacy  Decision Rule 
 
We hypothesize that the nivolumab/pixatimod combination in PD -1 relapsed/refractory (R/R) 
cutaneous melanoma and NSCLC patients will be associated with anti -tumor effects. We also 
hypothesize that the nivolumab/pixatimod/cyclophosphamide combination in MSS  mCRC 
patients will be associated with anti- tumor effects.  
 
We further  hypothesize that nivolumab/pixatimod/cyclophosphamide  combination in MSS mCRC 
patients and nivolumab/pixatimod combination in PD -1 R/R melanoma or NSCLC will be 
associated with increased CD8+ T cells intra-tumorally and PD -1+Ki67+ CD8+ T cells peripherally 
in responders on treatment compared to baseline; and that response will be associated with 
evidence of antigen- specific immunity responses intra -tumorally and peripherally.  
 
In the 1st stage of Cohort  1 (MSS mCRC),  we will enroll  13 patients.  If ≥1 response(s)  are seen,  
14 additional patients will be enrolled in the 2nd stage. The 
nivolumab/pixatimod/cyclophosphamide combination will be considered worthy of further 
evaluation if ≥4 responses (ORR 15%) are seen across both stages in this cohort. This study 
design,  using Simon’s  2-stage Minimax  design,  provides  80% power  with 5% type I error  to detect 
a response rate of 20% against a null hypothesis of 5%.  
 
For Cohorts 2 ( PD-1 R/R melanoma) and 3 (PD-1 R/R NSCLC), we will use the same design, 
but separately, as follows. In the 1st stage, will enroll 9 patients. If ≥1 response(s) are seen, 8 
additional patients  will be  enrolled in the 2nd stage. The combination will be  considered worthy  of 
further evaluation if ≥3 responses (ORR 18%) are seen across both stages. This study design, using Simon’s optimal 2 -stage design, provides 81% power with 5% type I error to detect a 
response rate of 25% against a null hypothesis of 5%. 
 
9.4 Efficacy  Analysis 
 
Definition  of response -evaluable patient  
Each patient will be assigned one of the following categories: 1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6)  
70  
early death  from toxicity, 7) early death  because of other cause, or 9) unknown (not assessable, 
insufficient data). All patients who met the eligibility criteria ; received at least 1 dose each of 
nivolumab and pixatimod ( cohorts 2 and 3); and at least 1 dose each of nivolumab, pixatimod 
and low -dose Cy ( cohort 1); and underwent restaging imaging are evaluable for response.  
 
Definition  of survival endpoints  
PFS is defined as the time from initiation of treatment till cancer relapse or death. All suspected 
relapses should be biopsied to confirm relapse. In the event where this is difficult and/or 
dangerous, imaging may be used as a surrogate.  
 
OS is defined as the time from initiation of treatment till death. Where possible, investigators 
should endeavor  to confirm  if death is related to disease or other  concomitant  illness.  In the event 
where this is impossible  to confirm  conclusively, it will be assumed that death is related to disease 
progression.  
 
Kaplan- Meier  estimates  of PFS and OS will be provided.  The corresponding median  survival time 
(with  95% confidence  intervals)  will be determined,  along with survival estimates  at selected  time 
points (e.g. 6 months, 1 years, and 2 years).  
 
9.5 Safety Analysis  
 
Definition  of safety -evaluable patient  
Any patient who has received at least 1 dose each of nivolumab and pixatimod ( cohorts 2 and 
3); and at least 1 dose each of nivolumab, pixatimod and cyclophosphamide ( cohort 1) is 
evaluable for safety.  
 
As per NCI CTCAE  Version 5.0, the term toxicity  is defined as adverse events  that are  classified 
as either  possibly,  probably,  or definitely  related to study  treatment.  The maximum  grade  for each 
type of toxicity will be recorded for each patient, and frequency tables will be reviewed to 
determine toxicity patterns.  
 
As these agents singly and in combination have previously been studied in the diseases in 
question and the relevant biologically active doses determined, no “dose- escalation” will be 
performed in this study. However, to accurately capture toxicities for the use of this agent in this 
space, we will be monitoring toxicities closely. The detailed data and safety monitoring plan is in 
Section 9.7 . 
 
9.6 Biomarker  Analysis  
 
To search for potential prognostic biomarkers (and toxicity marker) for the regimen, logistic 
regression will be used to assess the association between each marker and objective 
radiographic response.  
 
The Cox proportional hazards model will be used to assess the association of each marker and 
survival endpoints (i.e. PFS and OS).  
71  
9.7 Data  Safety  and Monitoring Plan 
 
All enrolled patients  will be reviewed weekly  to discuss  AEs,  in particular  during DLT period.  
 
Principle Investigator/Sub- investigators, regulatory, CRS management, clinical research 
coordinators, clinical research associates, data managers, and clinic staff meet monthly in 
disease center Data Safety Monitoring Boards (DSMB) to review and discuss st udy data to 
include, but not limited to, the following:  
 
• SAEs  
 
• Subject  safety  issues  
 
• Recruitment  issues  
 
• Accrual  
 
• Protocol  deviations  
 
• Unanticipated problems  
 
• Breaches  of confidentiality  
 
Minutes  from the disease  center DSMB  meetings  are sent to those  who are unable to 
participate during the scheduled meeting time.  
 
All toxicities  encountered  during the study  will be evaluated on an ongoing  basis  according to the 
NCI Common Toxicity  Criteria  version 5.0. All study  treatment  associated adverse events  that are 
serious, at least possibly related and unexpected will be reported to the IRB. Any modifications 
necessary  to ensure subject  safety  and decisions  to continue or close  the trial to accrual  are also 
discussed during these meetings. If any literature becomes available which changes the risk/benefit ratio or suggests that conducting the trial is no longer ethical, the IRB will be notified 
in the form of an Unanticipated Problem submission and the study may be terminated.  
 
All study  data reviewed and discussed  during these  meetings  will be kept confidential.  Any breach 
in subject confidentiality will be reported to the IRB in the form of an Unanticipated Problem 
submission. The summaries of these meetings are forwarded to the UPCI DSMC which also 
meets monthly following a designated format.  
 
For all research protocols, there will be a commitment to comply with the IRB’s policies for 
reporting unanticipated problems involving risk to subjects or others (including adverse events). 
DSMC progress reports, to include a summary of all serious advers e events and modifications, 
and approval will be submitted to the IRB at the time of renewal.  
 
Protocols  with subjects  in long- term (survival)  follow -up or protocols  in data analysis  only,  will be 
reviewed twice a year rather than monthly by the disease center DSMB.  
 
Both the UPMC Hillman Cancer Center DSMC as well as the individual disease center DSMB 
have the authority to suspend accrual or further investigate treatment on any trial based on 
information discussed at these meetings.  
72  
All records  related to this research study  will be stored in a  double locked environment. Only  the 
researchers affiliated with the research study and their staff will have access to the research 
records.  
 
10. LABELING,  PACKAGING,  STORAGE,  AND RETURN OF CLINICAL  SUPPLIES  
 
10.1 Investigational  Product:  Pixatimod (PG545)  
 
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of 
investigational  product  in accordance with the protocol  and any applicable laws and regulations.  
 
Clinical supplies  provided by Aculeus Therapeutics  are summarized  in Table  10.1-1. 
 
Table  10.1- 1: Product  Description  
Product  Name  Dosage  Form  
Pixatimod  (PG545)  Pixatimod  is a white  to off-white  powder  with no odor.  It is manufactured  using 
maltotetraose derived from hydrolysis of starch. The compound also features 
a cholestanol moiety conjugated to the synthetic, sulfated tetrasaccharide 
component. This lipophilic moiety is considered a critical structural feature of 
the molecule which leads to novel immunomodulatory activity and enhanced 
pharmacodynamic and pharmacokinetic properties compared to similarly 
designed compounds (known as heparan sulfate mimetics) lacking the 
aglycone. Pixatimod is presented in an anomerically pure form.  
 
Pixatimod  drug product  is presented as a frozen aqueous  solution  for infusion 
containing 60 mg or 100 mg pixatimod  per vial (25 mg/mL).  Prior to 
administration the appropriate dose of pixatimod is diluted in 250 mL 0.9% 
saline infusion solution and infused over one hour.  
 
 
10.1.1 Packaging and Labeling Information:  Pixatimod  (PG545)  
 
The pixatimod drug product  vials will be labeled with the following  information:  
• Hillman  Cancer  Center  (HCC)  protocol  number  
• The batch number  of the drug  
• The drug name,  concentration,  and nominal  volume per vial 
• The recommended  storage  conditions  of the secondary  container  
• Cautionary  statement  to keep away  from children  
• The route  of administration 
• Cautionary  statement  indicating  that the drug is for investigational  use only 
• The name  and address  of Aculeus Therapeutics  (Aculeus Therapeutics Pty Ltd; Bio 21 
Incubator, 30 Flemington Rd, Parkville VIC 3052, Australia) . 
 
The pixatimod kit carton will be labeled with the following  information:  
• Hillman  Cancer  Center  (HCC)  protocol  number  
• Number  of vials per kit 
• The batch number  of the drug  
• The drug name,  concentration,  and nominal  volume per vial 
• The recommended storage conditions  of the drug 
• Cautionary  statement  to keep away  from children  
• The route  of administration 
• Cautionary  statement  indicating  that the drug is for investigational  use only;  
• The name  and address  of Aculeus Therapeutics  (Aculeus Therapeutics Pty Ltd; Bio 21 
Incubator, 30 Flemington Rd, Parkville VIC 3052, Australia)  
73  
10.1.2 Handling,  Storage and Accountability:  Pixatimod (PG545)  
 
All pixatimod drug product  vials will be transported, received,  stored,  and handled in accordance 
with the container or drug product kit/vial label, the instructions supplied to the site and its 
designated pharmacy  personnel,  the site’s  standard operating  procedures  (SOPs),  and applicable 
regulations.  
 
Appropriate storage and transportation conditions will be maintained for the pixatimod drug 
product  vials from the point  of manufacture up to delivery  of pixatimod.  All shipments  of pixatimod 
drug product vials will include a temperature monitoring device that records required storage conditions for the vials, at regular intervals for the entire time the shipment is in transit.  
 
Upon receipt  by the site, the designated  site personnel  will examine the shipment  and temperature 
monitoring devices to verify the pixatimod drug product vials were received in acceptable 
condition. If not received in acceptable condition, the site must notify Aculeus Therapeutics  and 
the site should quarantine the drug until a decision has been made by Aculeus Therapeutics . 
Once inspected, vials should be stored at the specified temperature ( -20°C) in a locked area 
accessible only to designated site personnel until dispensing. Once dispensed, pixatimod drug 
product vials will be stored in a limited access area under appropr iate environmental conditions.  
 
The designated site personnel  will be responsible for maintaining accurate records  of the quantity 
and dates of all study drug supplies received, dispensed, and returned, in accordance with applicable regulations and the site’s SOPs. The quantity of study drug lost, destroyed, etc. must 
also be accounted for and documented.  
 
All original vials, whether empty or containing pixatimod will be kept at the site and destroyed according to the site’s  drug destruction standard  operating procedures. Used pixatimod vials will 
not be dispensed again (even to the same subject) nor will they be relabeled or reassigned for use by other subjects. Contents of the pixatimod drug product vials will not be combined. At the 
termination of the study,  a final drug  accountability  review and reconciliation must be completed, 
and any discrepancies must  be investigated and their resolution documented.  
 
All pixatimod drug product vials will be destroyed onsite as per institutional standard operating 
procedures, after site close out has been completed.  
10.1.3 Dispensing:  Pixatimod (PG545)  
 
The pixatimod drug product vials will be dispensed and pixatimod drug product will be administered according to applicable site SOPs. Details regarding the preparation and 
administration of the study  drug will be outlined in a study -specific  pharmacy  manual.  Only eligible 
subjects participating in the study will receive pixatimod. Only authorized and qualified site staff may supply or administer pixatimod.  
 
 
10.2 Commercial  Product:  Nivolumab 
 
Pharmaceutical and therapeutic background of nivolumab is detailed in Section 3.2. Preclinical 
and clinical trial data pertaining to nivolumab is summarized  in Nivolumab  IB. For the purposes 
of this trial, commercial supply of nivolumab will be used. Nivolumab dose, schedule and 
administration is detailed in Section 3.8.3 . 
74  
10.3 Commercial  Product:  Cyclophosphamide  
 
Pharmaceutical and therapeutic background of cyclophosphamide is detailed in Section 3.4. 
Preclinical and clinical trial data pertaining to cyclophosphamide is summarized in Section 3.4. 
For the purposes of this trial, commercial supply of cyclophosphamide will be used. 
Cyclophosphamide dose, schedule and administration is detailed in Section 3.8.6.  
75  
11. REFERENCES  
 
1 Ascierto,  P. A. et al. Survival  Outcomes  in Patients  With  Previously  Untreated  BRAF  Wild - 
Type Advanced Melanoma Treated With Nivolumab Therapy: Three -Year Follow -up of a 
Randomized Phase 3 Trial. JAMA Oncol 5 , 187 -194, doi:10.1001/jamaoncol.2018.4514  
(2019).  
2 Reck,  M. et al. Pembrolizumab  versus  Chemotherapy  for PD-L1-Positive  Non -Small -Cell 
Lung Cancer. N Engl J Med 375, 1823- 1833, doi:10.1056/NEJMoa1606774 (2016).  
3 Reck, M. et al. Updated Analysis of KEYNOTE -024: Pembrolizumab Versus Platinum-  
Based Chemotherapy for Advanced Non -Small- Cell Lung Cancer With PD- L1 Tumor 
Proportion  Score  of 50%  or Greater.  J Clin Oncol  37, 537-546,  doi:10.1200/JCO.18.00149 
(2019).  
4 Robert,  C. et al. Nivolumab  in previously  untreated melanoma without  BRAF mutation.  
N Engl  J Med  372,  320-330,  doi:10.1056/NEJMoa1412082  (2015).  
5 Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE - 
006): post -hoc 5 -year results from an open -label, multicentre, randomised, controlled, 
phase  3 study.  Lancet  Oncol  20, 1239 -1251,  doi:10.1016/S1470- 2045(19)30388- 2 (2019).  
6 Robert,  C. et al. Pembrolizumab  versus  Ipilimumab  in Advanced Melanoma.  N Engl  J 
Med 372, 2521 -2532, doi:10.1056/NEJMoa1503093 (2015).  
7 Lanzi,  C. & Cassinelli,  G. Heparan  Sulfate  Mimetics  in Cancer  Therapy:  The Challenge  to 
Define Structural Determinants and the Relevance of Targets for Optimal Activity. 
Molecules 23, doi:10.3390/molecules23112915 (2018).  
8 Dredge, K. et al. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod)  in subjects  with  advanced solid  tumours.  Br J Cancer  118, 1035 -1041, 
doi:10.1038/s41416 -018- 0006- 0 (2018).  
9 Kuo, J. C. et al. Preliminary results from a phase 1b study of pixatimod (PG545) in 
combination  with nivolumab  in patients  with  advanced  solid  tumors  with  an expansion 
cohort in patients with metastatic pancreatic cancer. Ann Oncol 2018 (2018).  
10 Ahlmann,  M. & Hempel,  G. The effect  of cyclophosphamide  on the immune  system: 
implications for clinical cancer therapy. Cancer Chemother Pharmacol 78, 661- 671, 
doi:10.1007/s00280 -016- 3152- 1 (2016).  
11 Leong,  W. I. et al. Low-dose  metronomic  cyclophosphamide  complements  the actions  of 
an intratumoral C -class CpG TLR9 agonist to potentiate innate immunity and drive 
potent T cell -mediated anti -tumor responses. Oncotarget 10, 7220- 7237, 
doi:10.18632/oncotarget.27322 (2019).  
12 Brennan,  T. V. et al. Heparan  sulfate  mimetic  PG545 -mediated  antilymphoma effects 
require TLR9 -dependent NK cell activation. J Clin Invest 126, 207 -219, 
doi:10.1172/JCI76566 (2016).  
13 Dong,  H., Zhu,  G., Tamada,  K. & Chen,  L. B7-H1, a third member of the B7 family,  co- 
stimulates T -cell proliferation and interleukin -10 secretion. Nat Med 5, 1365 -1369, 
doi:10.1038/70932 (1999).  
76  
14 Freeman,  G. J. et al. Engagement  of the PD-1 immunoinhibitory  receptor  by a novel  B7 
family member leads to negative regulation of lymphocyte activation. J Exp Med 192, 
1027 -1034 (2000).  
15 Latchman,  Y. et al. PD-L2 is a second  ligand  for PD-1 and inhibits  T cell activation.  Nat 
Immunol 2, 261 -268, doi:10.1038/85330 (2001).  
16 Tseng,  S. Y. et al. B7-DC, a new  dendritic  cell molecule  with potent  costimulatory 
properties for T cells. J Exp Med 193, 839 -846 (2001).  
17 Liang,  S. C. et al. Regulation  of PD-1, PD-L1, and PD-L2 expression  during  normal and 
autoimmune responses. Eur J Immunol 33, 2706- 2716, doi:10.1002/eji.200324228 
(2003).  
18 Loke,  P. & Allison,  J. P. PD-L1 and PD -L2 are differentially  regulated  by Th1 and Th2 cells.  
Proc  Natl  Acad Sci U S A 100, 5336- 5341,  doi:10.1073/pnas.0931259100  (2003).  
19 Jin, H. T. et al. Cooperation  of Tim-3 and PD-1 in CD8 T-cell exhaustion during  chronic 
viral infection. Proc Natl Acad Sci U S A 107 , 14733 -14738, 
doi:10.1073/pnas.1009731107 (2010).  
20 Fourcade, J. et al. PD -1 is a regulator of NY -ESO-1-specific CD8+ T cell expansion in 
melanoma  patients.  J Immunol  182, 5240 -5249,  doi:10.4049/jimmunol.0803245 (2009).  
21 Fourcade,  J. et al. Upregulation  of Tim-3 and PD-1 expression  is associated  with tumor 
antigen -specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207, 2175 - 
2186, doi:10.1084/jem.20100637 (2010).  
22 Borghaei,  H. et al. Nivolumab  versus  Docetaxel  in Advanced  Nonsquamous  Non -Small-  
Cell Lung Cancer. N Engl J Med 373, 1627- 1639, doi:10.1056/NEJMoa1507643 (2015).  
23 Brahmer,  J. et al. Nivolumab  versus  Docetaxel  in Advanced  Squamous -Cell Non -Small - 
Cell Lung Cancer. N Engl J Med 373, 123 -135, doi:10.1056/NEJMoa1504627 (2015).  
24 Motzer,  R. J. et al. Nivolumab  versus  Everolimus  in Advanced Renal -Cell Carcinoma.  N 
Engl J Med 373 , 1803- 1813, doi:10.1056/NEJMoa1510665 (2015).  
25 Powles, T. et al. MPDL3280A (anti -PD-L1) treatment leads to clinical activity in 
metastatic  bladder cancer.  Nature  515, 558-562,  doi:10.1038/nature13904 (2014).  
26 Hodi,  F. S. et al. Nivolumab  plus ipilimumab  or nivolumab  alone  versus  ipilimumab  alone 
in advanced melanoma (CheckMate 067): 4 -year outcomes of a multicentre, 
randomised, phase 3 trial. Lancet Oncol 19, 1480- 1492, doi:10.1016/S1470 - 
2045(18)30700- 9 (2018).  
27 Larkin,  J. et al. Combined  Nivolumab  and Ipilimumab  or Monotherapy  in Untreated 
Melanoma. N Engl J Med 373, 23 -34, doi:10.1056/NEJMoa1504030 (2015).  
28 Larkin,  J. et al. Five-Year  Survival with  Combined Nivolumab  and Ipilimumab  in Advanced 
Melanoma. N Engl J Med 381, 1535- 1546, doi:10.1056/NEJMoa1910836 (2019).  
29 Wolchok, J. D. et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced  Melanoma.  N Engl  J Med  377, 1345- 1356,  doi:10.1056/NEJMoa1709684 
(2017).  
30 Hellmann,  M. D. et al. Nivolumab  plus Ipilimumab  in Advanced Non -Small -Cell Lung 
Cancer. N Engl J Med 381, 2020- 2031, doi:10.1056/NEJMoa1910231 (2019).  
31 Le, D. T. et al. PD-1 Blockade in  Tumors  with  Mismatch -Repair  Deficiency.  N Engl J Med  
372,  2509- 2520,  doi:10.1056/NEJMoa1500596 (2015).  
77  
32 Overman, M. J. et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA 
Mismatch  Repair -Deficient/Microsatellite  Instability -High  Metastatic  Colorectal  Cancer.  J 
Clin Oncol 36, 773 -779, doi:10.1200/JCO.2017.76.9901 (2018).  
33 Toh,  J. W. T. et al. The Potential Value  of Immunotherapy  in Colorectal  Cancers:  Review 
of the Evidence for Programmed Death -1 Inhibitor Therapy. Clin Colorectal Cancer 15, 
285- 291, doi:10.1016/j.clcc.2016.07.007 (2016).  
34 Tumeh,  P. C. et al. PD-1 blockade  induces  responses  by inhibiting  adaptive  immune 
resistance. Nature 515, 568 -571, doi:10.1038/nature13954 (2014).  
35 Wong,  P. F. et al. Multiplex  Quantitative  Analysis  of Tumor -Infiltrating  Lymphocytes  and 
Immunotherapy Outcome in Metastatic Melanoma. Clin Cancer Res 25, 2442- 2449, 
doi:10.1158/1078 -0432.CCR -18-2652 (2019).  
36 Ayers,  M. et al. IFN-gamma- related  mRNA  profile  predicts  clinical response  to PD-1 
blockade. J Clin Invest 127, 2930- 2940, doi:10.1172/JCI91190 (2017).  
37 Cristescu,  R. et al. Pan-tumor  genomic  biomarkers  for PD-1 checkpoint  blockade -based 
immunotherapy.  Science  (New  York,  N.Y.)  362,  eaar3593,  doi:10.1126/science.aar3593 
(2018).  
38 Rizvi, H. et al. Molecular Determinants of Response to Anti -Programmed Cell Death 
(PD)- 1 and Anti -Programmed Death -Ligand 1 (PD -L1) Blockade in Patients With Non-  
Small- Cell Lung  Cancer  Profiled  With  Targeted  Next -Generation  Sequencing.  J Clin Oncol 
36, 633 -641, doi:10.1200/JCO.2017.75.3384 (2018).  
39 Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy 
across  multiple  cancer  types.  Nat Genet  51, 202-206,  doi:10.1038/s41588- 018- 0312- 8 
(2019).  
40 Herbst, R. S. et al. Predictive correlates of response to the anti -PD-L1 antibody 
MPDL3280A  in cancer  patients.  Nature  515, 563-567,  doi:10.1038/nature14011 (2014).  
41 Taube,  J. M. et al.  Association  of PD-1, PD-1 ligands,  and other  features  of the tumor 
immune microenvironment with response to anti -PD-1 therapy. Clin Cancer Res 20, 
5064 -5074, doi:10.1158/1078 -0432.CCR -13-3271 (2014).  
42 Salmon,  H. et al. Expansion  and Activation  of CD103(+)  Dendritic  Cell Progenitors  at the 
Tumor Site Enhances Tumor Responses to Therapeutic PD- L1 and BRAF Inhibition. 
Immunity 44, 924 -938, doi:10.1016/j.immuni.2016.03.012 (2016).  
43 Krieg,  A. M. Toll-like receptor  9 (TLR9) agonists  in the treatment  of cancer.  Oncogene  27, 
161- 167, doi:10.1038/sj.onc.1210911 (2008).  
44 Demoulin, S., Herfs, M., Delvenne, P. & Hubert, P. Tumor microenvironment converts 
plasmacytoid  dendritic  cells  into immunosuppressive/tolerogenic  cells:  insight into the 
molecular mechanisms. J Leukoc Biol 93, 343 -352, doi:10.1189/jlb.0812397 (2013).  
45 Lombardi, M. S., Gillieron, C., Dietrich, D. & Gabay, C. SIK inhibition in human myeloid cells  modulates  TLR and IL-1R signaling  and induces  an anti-inflammatory  phenotype.  J 
Leukoc Biol 99, 711 -721, doi:10.1189/jlb.2A0715- 307R (2016).  
46 Disis,  M. L. Immune  regulation  of cancer.  J Clin Oncol  28, 4531 -4538, 
doi:10.1200/JCO.2009.27.2146 (2010).  
78  
47 Boon,  T., Coulie,  P. G., Van den  Eynde,  B. J. & van der Bruggen,  P. Human T  cell 
responses against melanoma. Annu Rev Immunol 24, 175 -208, 
doi:10.1146/annurev.immunol.24.021605.090733 (2006).  
48 Boon,  T. & Old, L. J. Cancer  Tumor  antigens.  Curr  Opin Immunol  9, 681-683 (1997).  
49 Boon,  T. & van der Bruggen,  P. Human  tumor  antigens  recognized  by T lymphocytes.  J 
Exp Med 183 , 725 -729, doi:10.1084/jem.183.3.725 (1996).  
50 Ercolini, A. M. et al. Recruitment of latent pools of high- avidity CD8(+) T cells to the 
antitumor  immune  response.  J Exp Med  201,  1591 -1602,  doi:10.1084/jem.20042167 
(2005).  
51 Galon, J. et al. Type, density, and location of immune cells within human colorectal 
tumors  predict  clinical outcome.  Science  313, 1960 -1964,  doi:10.1126/science.1129139 
(2006).  
52 Galon,  J. et al. Cancer  classification  using  the Immunoscore:  a worldwide  task force.  J 
Transl Med 10, 205, doi:10.1186/1479 -5876- 10-205 (2012).  
53 Hiraoka,  N. Tumor -infiltrating  lymphocytes  and hepatocellular  carcinoma:  molecular 
biology. Int J Clin Oncol 15, 544 -551, doi:10.1007/s10147 -010-0130 -1 (2010).  
54 Parry, R. V. et al. CTLA -4 and PD -1 receptors inhibit T -cell activation by distinct 
mechanisms.  Mol Cell Biol 25, 9543- 9553,  doi:10.1128/MCB.25.21.9543 -9553.2005 
(2005).  
55 Hodi,  F. S. et al.  Immunologic  and clinical effects  of antibody  blockade  of cytotoxic T 
lymphocyte -associated  antigen 4 in previously  vaccinated  cancer  patients.  Proc  Natl 
Acad Sci U S A 105 , 3005 -3010, doi:10.1073/pnas.0712237105 (2008).  
56 Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD -1 pathway in tolerance and 
autoimmunity.  Immunol  Rev 236, 219-242,  doi:10.1111/j.1600- 065X.2010.00923.x  
(2010).  
57 Francisco,  L. M. et al. PD-L1 regulates  the development,  maintenance,  and function of 
induced regulatory T cells. J Exp Med 206 , 3015- 3029, doi:10.1084/jem.20090847 
(2009).  
58 Ferro,  V. et al. Discovery  of PG545:  a highly  potent  and simultaneous  inhibitor of 
angiogenesis, tumor growth, and metastasis. J Med Chem 55, 3804 -3813, 
doi:10.1021/jm201708h (2012).  
59 Dredge, K. et al. The PG500 series: novel heparan sulfate mimetics as potent 
angiogenesis and heparanase  inhibitors  for cancer  therapy.  Invest  New  Drugs  28, 276- 
283, doi:10.1007/s10637 -009-9245- 5 (2010).  
60 Hammond, E., Handley, P., Dredge, K. & Bytheway, I. Mechanisms of heparanase inhibition  by the heparan  sulfate  mimetic  PG545 and three  structural  analogues.  FEBS 
Open Bio 3 , 346- 351, doi:10.1016/j.fob.2013.07.007 (2013).  
61 Vlodavsky, I. et al. Heparanase: From basic research to therapeutic applications in cancer  and inflammation.  Drug Resist  Updat  29, 54-75, doi:10.1016/j.drup.2016.10.001 
(2016).  
62 Barash,  U. et al. Involvement  of Heparanase  in the Pathogenesis  of Mesothelioma:  Basic 
Aspects and Clinical Applications. J Natl Cancer Inst 110 , 1102- 1114, 
doi:10.1093/jnci/djy032 (2018).  
79  
63 Boyango, I. et al. Heparanase cooperates with Ras to drive breast and skin tumorigenesis.  
Cancer  Res 74, 4504 -4514,  doi:10.1158/0008 -5472.CAN -13-2962 (2014).  
64 Katz,  A. et al. Patient  derived  xenografts  (PDX)  predict  an effective  heparanase -based 
therapy  for lung  cancer.  Oncotarget  9, 19294 -19306,  doi:10.18632/oncotarget.25022 
(2018).  
65 Ostapoff,  K. T. et al. PG545,  an angiogenesis and heparanase  inhibitor,  reduces  primary 
tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther 12, 
1190 -1201, doi:10.1158/1535 -7163.MCT- 12-1123 (2013).  
66 Lin, Y., Xu, J. & Lan, H. Tumor- associated macrophages in tumor metastasis: biological 
roles  and clinical  therapeutic  applications.  J Hematol  Oncol  12, 76, doi:10.1186/s13045-  
019- 0760- 3 (2019).  
67 Dredge, K. et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent 
anti-tumour  and anti-metastatic  efficacy in preclinical models.  Br J Cancer  104, 635-642, 
doi:10.1038/bjc.2011.11 (2011).  
68 Hammond, E., Brandt, R. & Dredge, K. PG545, a heparan sulfate mimetic, reduces 
heparanase  expression  in vivo,  blocks  spontaneous  metastases  and enhances  overall 
survival in the 4T1 breast carcinoma model. PLoS One 7, e52175, 
doi:10.1371/journal.pone.0052175 (2012).  
69 Kundu, S. et al. Heparanase Promotes Glioma Progression and Is Inversely Correlated 
with  Patient  Survival.  Mol Cancer  Res 14, 1243- 1253,  doi:10.1158/1541- 7786.MCR -16- 
0223 (2016).  
70 Mondal, S. et al. HSulf -1 deficiency dictates a metabolic reprograming of glycolysis and 
TCA cycle  in ovarian  cancer.  Oncotarget  6, 33705- 33719,  doi:10.18632/oncotarget.5605 
(2015).  
71 Shteingauz, A. et al. Heparanase Enhances Tumor Growth and Chemoresistance by 
Promoting  Autophagy.  Cancer  Res 75, 3946 -3957,  doi:10.1158/0008- 5472.CAN -15-0037 
(2015).  
72 Singh,  P. et al. The Heparanase  Inhibitor  PG545 Attenuates  Colon  Cancer  Initiation  and 
Growth, Associating with Increased p21 Expression. Neoplasia 19, 175 -184, 
doi:10.1016/j.neo.2016.12.001 (2017).  
73 Spyrou,  A. et al. Inhibition of Heparanase  in Pediatric  Brain  Tumor  Cells  Attenuates  their 
Proliferation, Invasive Capacity, and In Vivo Tumor Growth. Mol Cancer Ther 16, 1705-  
1716, doi:10.1158/1535- 7163.MCT -16-0900 (2017).  
74 Weissmann,  M. et al. Heparanase -neutralizing  antibodies  attenuate  lymphoma tumor 
growth and metastasis. Proc Natl Acad Sci U S A 113 , 704 -709, 
doi:10.1073/pnas.1519453113 (2016).  
75 Jung,  D. B. et al. The heparan  sulfate  mimetic  PG545 interferes  with Wnt/beta -catenin 
signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget 6, 4992 -5004,  
doi:10.18632/oncotarget.3214  (2015).  
76 Winterhoff,  B. et al. PG545 enhances  anti-cancer  activity  of chemotherapy  in ovarian 
models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur J Cancer 51, 879 -892, doi:10.1016/j.ejca.2015.02.007 (2015).  
80  
77 Matar,  P., Rozados,  V. R., Gervasoni,  S. I. & Scharovsky,  G. O. Th2/Th1 switch induced by 
a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer 
Immunol Immunother 50, 588 -596, doi:10.1007/s00262- 001-0237- 3 (2002).  
78 Viaud,  S. et al. Cyclophosphamide  induces  differentiation  of Th17 cells  in cancer 
patients. Cancer Res 71, 661- 665, doi:10.1158/0008- 5472.CAN -10-1259 (2011).  
79 Onizuka,  S. et al. Tumor  rejection  by in vivo administration  of anti-CD25  (interleukin -2 
receptor alpha) monoclonal antibody. Cancer Res 59, 3128 -3133 (1999).  
80 Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing 
CD25+CD4+  T cells:  a common  basis  between  tumor  immunity  and autoimmunity.  J 
Immunol 163, 5211 -5218 (1999).  
81 Proietti,  E. et al. Importance  of cyclophosphamide -induced  bystander  effect  on T cells 
for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101 , 429 -441, doi:10.1172/JCI1348 (1998).  
82 Schiavoni,  G. et al. Cyclophosphamide  induces  type  I interferon  and augments  the 
number of CD44(hi) T lymphocytes in mice: implications for strategies of 
chemoimmunotherapy of cancer. Blood 95, 2024- 2030 (2000).  
83 Bracci, L. et al. Cyclophosphamide enhances the antitumor efficacy of adoptively 
transferred  immune  cells  through the induction of cytokine  expression,  B-cell and T-cell 
homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13, 644 -653, 
doi:10.1158/1078 -0432.CCR -06-1209 (2007).  
84 Nakahara,  T. et al. Cyclophosphamide  enhances  immunity  by modulating  the balance  of 
dendritic cell subsets in lymphoid organs. Blood 115, 4384 -4392, doi:10.1182/blood - 
2009 -11-251231 (2010).  
85 Salem, M. L. et al. Cyclophosphamide induces dynamic alterations in the host 
microenvironments  resulting  in a Flt3 ligand -dependent  expansion  of dendritic  cells.  J 
Immunol 184, 1737 -1747, doi:10.4049/jimmunol.0902309 (2010).  
86 Salem,  M. L. et al. Recovery from cyclophosphamide -induced  lymphopenia  results  in 
expansion of immature dendritic cells which can mediate enhanced prime -boost 
vaccination antitumor responses in vivo when stimulated with the TLR3 agonist 
poly(I:C). J Immunol 182, 2030- 2040, doi:10.4049/jimmunol.0801829 (2009).  
87 Salem,  M. L., El -Naggar,  S. A. & Cole,  D. J. Cyclophosphamide  induces  bone marrow  to 
yield  higher  numbers  of precursor  dendritic  cells  in vitro  capable  of functional  antigen 
presentation to T cells in vivo. Cell Immunol 261, 134 -143, 
doi:10.1016/j.cellimm.2009.11.011 (2010).  
88 Salem, M. L. et al. Defining the ability of cyclophosphamide preconditioning to enhance 
the antigen -specific  CD8+  T-cell response  to peptide  vaccination:  creation  of a beneficial 
host microenvironment involving  type I IFNs and myeloid cells. J  Immunother 30, 40 -53, 
doi:10.1097/01.cji.0000211311.28739.e3 (2007).  
89 Schiavoni, G. et al. Cyclophosphamide synergizes with type I interferons through 
systemic  dendritic  cell reactivation  and induction of immunogenic  tumor  apoptosis. 
Cancer Res 71, 768 -778, doi:10.1158/0008 -5472.CAN -10-2788 (2011).  
81  
90 Curiel,  T. J. et al. Specific  recruitment  of regulatory  T cells  in ovarian  carcinoma fosters 
immune privilege and predicts reduced survival. Nat Med 10, 942 -949, 
doi:10.1038/nm1093 (2004).  
91 Saito,  T. et al. Two  FOXP3(+)CD4(+) T cell subpopulations  distinctly  control  the prognosis 
of colorectal cancers. Nat Med 22, 679 -684, doi:10.1038/nm.4086 (2016).  
92 Togashi, Y. & Nishikawa, H. Regulatory T Cells: Molecular and Cellular Basis for 
Immunoregulation.  Curr  Top Microbiol  Immunol  410, 3-27, doi:10.1007/82_2017_58 
(2017).  
93 Huang,  X. M. et al. Antitumor  immunity  of low-dose  cyclophosphamide:  changes  in T 
cells and cytokines TGF- beta and IL -10 in mice with colon -cancer liver metastasis. 
Gastroenterol Rep (Oxf) 8, 56-65, doi:10.1093/gastro/goz060 (2020).  
94 Simsek,  C., Esin,  E. & Yalcin,  S. Metronomic  Chemotherapy:  A Systematic  Review  of the 
Literature and Clinical Experience. J Oncol 2019, 5483791, doi:10.1155/2019/5483791 
(2019).  
95 Le Cesne,  A. et al. Programmed  cell death  1 (PD-1) targeting  in patients  with  advanced 
osteosarcomas: results from the PEMBROSARC study. Eur J Cancer 119 , 151 -157, 
doi:10.1016/j.ejca.2019.07.018 (2019).  
96 Toulmonde,  M. et al. Use of PD-1 Targeting,  Macrophage  Infiltration,  and IDO Pathway 
Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncol 4 , 93-97, 
doi:10.1001/jamaoncol.2017.1617 (2018).  
97 Hammond,  E. et al. Immunomodulatory  activities  of pixatimod:  emerging  nonclinical 
and clinical data, and its potential utility in combination with PD- 1 inhibitors. J 
Immunother Cancer 6 , 54, doi:10.1186/s40425 -018-0363 -5 (2018).  
98 Capone,  M. et al. Baseline  neutrophil -to-lymphocyte  ratio  (NLR) and derived  NLR could 
predict overall survival  in patients with advanced melanoma  treated with nivolumab. J 
Immunother Cancer 6 , 74, doi:10.1186/s40425 -018-0383 -1 (2018).  
99 Dell'Aquila, E. et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in 
metastatic  colorectal cancer:  a retrospective  analysis  of the TRIBE  study  by GONO. Ann 
Oncol 29, 924 -930, doi:10.1093/annonc/mdy004 (2018).  
100 Sjoquist, K. M. et al. Personalizing Survival Predictions in Advanced Colorectal Cancer: 
The ARCAD  Nomogram Project.  J Natl  Cancer  Inst 110, 638-648,  doi:10.1093/jnci/djx253 
(2018).  
101 Wen,  S. et al.  Peripheral monocyte  counts  predict  the clinical outcome  for patients  with 
colorectal cancer: a systematic review and meta- analysis. Eur J Gastroenterol Hepatol 
31, 1313 -1321, doi:10.1097/MEG.0000000000001553 (2019).  
102 Hu, B. et al. Systemic  immune -inflammation  index  predicts  prognosis of patients  after 
curative resection for hepatocellular carcinoma. Clin Cancer Res 20, 6212 -6222, 
doi:10.1158/1078 -0432.CCR -14-0442 (2014).  
103 Passardi,  A. et al. Inflammatory  indexes  as predictors  of prognosis and bevacizumab 
efficacy in patients with metastatic colorectal cancer. Oncotarget 7, 33210 -33219, 
doi:10.18632/oncotarget.8901 (2016).  
82  
104 Fuca, G. et al. The Pan -Immune -Inflammation Value is a new prognostic biomarker in 
metastatic  colorectal cancer:  results  from  a pooled -analysis  of the Valentino  and TRIBE 
first-line trials. Br J Cancer 123, 403 -409, doi:10.1038/s41416 -020-0894 -7 (2020).  
105 Fuca, G. et al. The Pan -Immune -Inflammation Value in Patients with Metastatic 
Melanoma Receiving  First -Line Therapy.  Target  Oncol  16, 529-536,  doi:10.1007/s11523-  
021- 00819- 0 (2021).  
106 Dimeloe, S. et al. Human regulatory T cells lack the cyclophosphamide -extruding 
transporter ABCB1  and are more  susceptible  to cyclophosphamide -induced apoptosis. 
Eur J Immunol 44, 3614- 3620, doi:10.1002/eji.201444879 (2014).  
107 Zhao, J. et al. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low -dose 
cyclophosphamide  is explained  by reduced  intracellular  ATP levels.  Cancer  Res 70, 4850-  
4858, doi:10.1158/0008- 5472.CAN -10-0283 (2010).  
108 Page,  A. J., Cosgrove,  D. C., Herman,  J. M. & Pawlik,  T. M. Advances  in understanding  of 
colorectal liver metastasis and implications for the clinic. Expert Rev Gastroenterol 
Hepatol 9, 245 -259, doi:10.1586/17474124.2014.940897 (2015).  
109 Azad, N. S. et al. Nivolumab Is Effective in Mismatch Repair -Deficient Noncolorectal 
Cancers:  Results  From Arm  Z1D-A Subprotocol  of the NCI-MATCH (EAY131)  Study.  J Clin 
Oncol 38, 214 -222, doi:10.1200/JCO.19.00818 (2020).  
110 Morse,  M. A. et al. Safety  of Nivolumab  plus Low-Dose  Ipilimumab  in Previously  Treated 
Microsatellite Instability -High/Mismatch Repair -Deficient Metastatic Colorectal Cancer. 
Oncologist 24, 1453- 1461, doi:10.1634/theoncologist.2019- 0129 (2019).  
111 Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-  
deficient  or microsatellite  instability -high  colorectal  cancer  (CheckMate  142):  an open - 
label, multicentre, phase 2 study. Lancet Oncol 18 , 1182- 1191, doi:10.1016/S1470-  
2045(17)30422- 9 (2017).  
112 Freshwater,  T. et al. Evaluation  of dosing  strategy  for pembrolizumab  for oncology 
indications. J Immunother Cancer 5 , 43, doi:10.1186/s40425 -017-0242 -5 (2017).  
113 Long,  G. V. et al. Assessment  of nivolumab  exposure  and clinical safety  of 480 mg every 
4 weeks flat- dosing schedule in patients with cancer. Ann Oncol 29, 2208- 2213, 
doi:10.1093/annonc/mdy408 (2018).  
114 Chen, C. S., Doloff, J. C. & Waxman, D. J. Intermittent metronomic drug schedule is essential  for activating  antitumor  innate  immunity  and tumor  xenograft  regression. 
Neoplasia 16, 84 -96, doi:10.1593/neo.131910 (2014).  
115 Madondo,  M. T., Quinn,  M. & Plebanski,  M. Low dose  cyclophosphamide:  Mechanisms 
of T cell modulation. Cancer Treat Rev 42, 3 -9, doi:10.1016/j.ctrv.2015.11.005 (2016).  
116 Wu, J. & Waxman,  D. J. Metronomic  cyclophosphamide  schedule -dependence  of innate 
immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett 353, 272 -280, doi:10.1016/j.canlet.2014.07.033 (2014).  
117 Bessede,  A. et al. Impact  of acetaminophen on the efficacy of immunotherapy  in cancer 
patients. Ann Oncol , doi:10.1016/j.annonc.2022.05.010 (2022).  
118 Ooi, E. E. et al. Use of analgesics/antipyretics in the management of symptoms associated  with  COVID -19 vaccination.  NPJ Vaccines  7, 31, doi:10.1038/s41541- 022- 
00453- 5 (2022).  
83  
119 Eisenhauer,  E. A. et al. New response  evaluation  criteria in solid  tumours:  revised  RECIST 
guideline (version  1.1). Eur J Cancer 45, 228 -247,  doi:10.1016/j.ejca.2008.10.026  (2009).  
120 Wolchok,  J. D. et al. Guidelines  for the evaluation  of immune  therapy  activity  in solid 
tumors: immune -related response criteria. Clin Cancer Res 15, 7412- 7420, 
doi:10.1158/1078 -0432.CCR -09-1624 (2009).  
121 Nishino,  M. Immune -related  response  evaluations  during  immune -checkpoint  inhibitor 
therapy: establishing a "common language" for the new arena of cancer treatment. J 
Immunother Cancer 4 , 30, doi:10.1186/s40425 -016-0134 -0 (2016).  
122 Nishino,  M., Gargano,  M., Suda,  M., Ramaiya,  N. H. & Hodi,  F. S. Optimizing  immune - 
related tumor response assessment: does reducing the number of lesions impact 
response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2, 17, doi:10.1186/2051- 1426- 2-17 (2014).  
123 Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing 
immunotherapeutics.  Lancet  Oncol  18, e143 -e152,  doi:10.1016/S1470 -2045(17)30074 -8 
(2017).  
124 Reuben,  A. Hy's law. Hepatology  39, 574-578,  doi:10.1002/hep.20081  (2004).  
125 Oken,  M. M. et al. Toxicity and response  criteria  of the Eastern  Cooperative  Oncology 
Group. Am J Clin Oncol 5 , 649 -655 (1982).  
84  
12. APPENDICES  
 
12.1 Appendix  1: ECOG  Performance Status125 
 
Grade  Description  
0 Normal activity. Fully active, able to carry on all pre -disease performance without 
restriction.  
1 Symptoms,  but ambulatory.  Restricted  in physically  strenuous  activity,  but 
ambulatory  and able to carry  out work  of a light or sedentary  nature  (e.g., light 
housework, office work).  
2 In bed <50%  of the time.  Ambulatory  and capable  of all self-care,  but unable  to carry 
out any work activities. Up and about more than 50% of waking hours.  
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or chair 
more than 50% of waking hours.  
4 100%  bedridden.  Completely  disabled.  Cannot  carry  on any self-care.  Totally 
confined to bed or chair.  
5 Dead.  
*As published  in Oken  MM et al, Am J Clin Oncol  1982.125 
85  
12.2 Appendix 2: Common Terminology Criteria for Adverse Events V5.0 
(CTCAE)  
 
The descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for adverse event reporting. ( http://ctep.cancer.gov/reporting/ctc.html
) 
86  
12.3 Appendix  3: Contraceptive Guidance and Pregnancy Testing 
Woman of Childbearing Potential (WOCBP)  
• A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below)  
• Women in the following  categories  are not considered WOCBP:  
• Premenarchal  
• Premenopausal  female  with 1 of the following:  
o Documented  hysterectomy  
o Documented  bilateral  salpingectomy  
o Documented  bilateral  oophorectomy  
o Note:  Documentation can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history 
interview.  
• Postmenopausal  female  
o A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  
o A high follicle stimulating hormone (FSH) level in the postmenopausal range 
may be used  to confirm  a postmenopausal  state  in women  not using  hormonal 
contraception or hormonal replacement therapy (HRT). However, in the 
absence of 12 months of amenorrhea, confirmation with two FSH 
measurements in the postmenopausal range is required.  
o Females  on HRT and whose  menopausal  status  is in doubt  will be required to 
use one of the non- hormonal highly effective contraception methods if they 
wish to continue  their HRT during the study.  Otherwise,  they must  discontinue 
HRT to allow confirmation of postmenopausal  status before study enrollment.  
Contraception Requirements 
Male Participants:  
Male  participants  with female  partners  of childbearing potential  are eligible  to participate  if they 
agree to one of the following  during the protocol  defined time frame  in Section 6.1. 
 
● Be abstinent from penile- vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent.  
● Use a male  condom  plus partner  use of a contraceptive method with a failure  rate of <1% per 
year as described in Table A3- 1 when having penile- vaginal intercourse with a woman of 
childbearing potential who is not currently pregnant.  
○ Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile- vaginal intercourse or use a male condom during each episode of penile 
penetration.  
 
Female  Participants:  
87  
Female participants  of childbearing potential  are eligible  to participate if they agree to use a highly 
effective method of contraception consistently and correctly as described in Table A3- 1 during 
the protocol -defined time frame in Section 6.1.  
 
Table  A3-1 Highly  Effective Contraception Methods  
Highly  Effective  Contraceptive  Methods  That  Are User  Dependent  a 
Failure  rate of <1% per year when  used  consistently  and correctly.  
● Combined  (estrogen - and progestogen - containing)  hormonal  contraception  b, c 
○ Oral 
○ Intravaginal  
○ Transdermal  
○ Injectable  
● Progestogen -only hormonal  contraception  b, c 
○ Oral 
○ Injectable  
Highly  Effective  Methods  That Have  Low User  Dependency  
Failure rate of <1% per year when used consistently  and correctly.  
● Progestogen - only contraceptive  implant  b, c 
● Intrauterine hormone-releasing  system (IUS) b 
● Intrauterine device  (IUD)  
● Bilateral  tubal  occlusion  
● Vasectomized  partner  
A vasectomized partner  is a highly effective contraception method provided that the partner is the sole male sexual 
partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method 
of contraception should be used.  
● Sexual  abstinence  
Sexual  abstinence is considered a highly  effective  method only if defined as refraining from heterosexual  intercourse 
during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.)  
Notes:  
Use should be consistent  with local regulations  regarding the use of contraceptive methods  for participants  of clinical 
studies.  
 
a) Typical  use failure  rates  are lower  than perfect -use failure rates  (i.e. when used consistently  and correctly).  
b) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable hormonal 
contraceptives are limited to those which inhibit ovulation.  
 
 
Pregnancy Testing 
WOCBP  should only be included after a negative highly  sensitive  urine or serum  pregnancy  test. 
Pregnancy testing will be performed whenever an expected menstrual cycle is missed or when 
pregnancy is otherwise suspected.  
12.4 Appendix  4: Description of the iRECIST  Process for Assessment  of Disease 
Progression  
 
Assessment  at Screening and Prior to RECIST  1.1 Progression 
Until radiographic progression based on RECIST 1.1, there is no distinct iRECIST 
assessment.  
 
Assessment  and Decision  at RECIST  1.1 Progression 
88  
In participants  who show  evidence  of radiological  PD by RECIST  1.1 the Investigator  will 
decide whether to continue a participant on study treatment until repeat imaging is 
obtained using iRECIST for participant management (see Section  8.7.6, Figure 8.7.6 -1 
and Table  8.7.6 -2). This decision by the Investigator  should be based  on the participant’s 
overall clinical condition.  
Clinical stability  is defined  as the following:  
• Absence of symptoms and signs indicating clinically significant progression of disease 
• No decline in ECOG  performance  status  
• No requirements for intensified management, including increased analgesia, or other palliative care  
Any participant deemed clinically unstable should be discontinued from study treatment 
at site -assessed first radiologic evidence of  PD and is not required  to have repeat tumor 
imaging  for confirmation of PD by iRECIST.  
 
If the Investigator decides to continue treatment, the participant may continue to receive 
study treatment and the tumor assessment should be repeated 4 to 8 weeks later to confirm
    PD    by    iRECIST,     per    Investigator     assessment.  
 
Tumor flare may manifest as any factor causing radiographic progression per RECIST 1.1, including:  
• Increase in the sum of diameters  of target  lesion(s)  identified  at baseline to ≥ 20% 
and ≥  5 mm from nadir  
o Please note: the iRECIST publication uses the terminology “sum of 
measurements”,  but “sum  of diameters”  will be used  in this protocol,  consistent 
with the original RECIST 1.1 terminology.  
• Unequivocal  progression of non-target  lesion(s)  identified at baseline  
• Development  of new lesion(s)  
iRECIST defines new response categories, including iUPD (unconfirmed progressive disease) and iCPD (confirmed progressive disease).  For purposes of iRECIST 
assessment,  the first visit showing  progression according to RECIST  1.1 will be assigned 
a visit (overall) response of iUPD, regardless of which factors caused the progression.  
 
At this visit, target and non- target lesions identified at baseline by RECIST 1.1 will be 
assessed as usual.  
 
New lesions will be classified as measurable or non- measurable, using the same size 
thresholds  and rules  as for baseline  lesion  assessment  in RECIST  1.1. From measurable 
new lesions,  up to 5 lesions  total (up to 2 per organ),  may be selected  as New Lesions  – 
Target.  The sum of diameters of these lesions will be calculated and kept distinct from 
the sum of diameters  for target  lesions  at baseline.  All other  new lesions  will be followed 
qualitatively as New Lesions –  Non-target.  
89  
Assessment  at the Confirmatory  Imaging  
 
On the confirmatory imaging, the participant will be classified as progression confirmed 
(with an overall response of iCPD), or as showing persistent unconfirmed progression (with an overall response of iUPD), or as showing disease stability or response (iSD/iPR/iCR).  
 
Confirmation of Progression 
 
Progression is considered confirmed,  and the overall  response will be iCPD,  if ANY of the 
following occurs:  
 
• Any of the factors  that were the  basis  for the initial iUPD show  worsening 
o For target  lesions,  worsening  is a further  increase in the sum of diameters  of 
≥ 5 mm, compared to any prior iUPD time point 
o For non- target lesions, worsening is any significant growth in lesions overall, 
compared to a prior iUPD time point; this does not have to meet the 
“unequivocal” standard of RECIST 1.1  
o For new lesions,  worsening  is any of these:  
 An increase  in the new lesion  sum of diameters  by ≥ 5 mm from a prior iUPD 
time point  
 Visible  growth  of new non-target  lesions  
 The appearance  of additional  new lesions  
• Any new factor  appears  that would  have  triggered  PD by RECIST  1.1 
Persistent  iUPD 
 
Progression is considered not confirmed,  and the overall  response remains  iUPD,  if: 
 
• None of the progression- confirming  factors  identified  above  occurs  AND 
• The target  lesion  sum of diameters  (initial  target lesions)  remains  above the initial 
PD threshold (by RECIST 1.1)  
 
Additional imaging for confirmation should be scheduled 4 to 8 weeks from the scan on 
which iUPD is seen.  This may correspond to the next visit in the original visit schedule. 
The assessment of the subsequent confirmation scan proceeds in an identical manner, with possible outcomes of iCPD, iUPD, and iSD/iPR/iCR.  
 
Resolution  of iUPD  
 
Progression is considered not confirmed,  and the overall  response becomes  iSD/iPR/iCR, 
if: 
90  
• None of the progression- confirming  factors  identified  above  occurs,  AND 
• The target  lesion sum of diameters  (initial target  lesions)  is not above the initial PD 
threshold.  
 
The response is classified  as iSD or iPR (depending on the sum of diameters  of the target 
lesions), or iCR if all lesions resolve.  
 
In this case, the initial iUPD is considered to be pseudo- progression, and the level of 
suspicion  for progression is “reset”.  This means  that the next visit that shows  radiographic 
progression, whenever it occurs, is again classified as iUPD by iRECIST, and the 
confirmation process is repeated before a response of iCPD can be assigned.  
 
Management  Following  the Confirmatory  Imaging 
 
If repeat  imaging  does  not confirm  PD per iRECIST,  as assessed  by the Investigator,  and 
the participant continues to be clinically stable, study treatment may continue and follow the regular imaging schedule.  If PD is confirmed, participants will be discontinued from 
study treatment.  
 
NOTE: If  a participant  has confirmed radiographic  progression (iCPD)  as defined  above, 
but the participant is achieving a clinically meaningful benefit, an exception to continue study treatment may be considered.  In this case, if study treatment is continued, tumor 
imaging should  continue to  be performed following the intervals as  outlined  in Section  6. 
 
Detection  of Progression at Visits  After  Pseudo- progression Resolves  
 
After resolution of pseudo- progression (ie, achievement of iSD/iPR/iCR), iUPD is 
indicated by any of the following events:  
 
• Target  lesions  
o Sum of diameters  reaches  the PD threshold (≥ 20% and ≥ 5 mm increase  from 
nadir) either for the first time, or after resolution of previous pseudo-  
progression.  The nadir is always the smallest sum of diameters seen during 
the entire trial, either before or after an instance of pseudo- progression.  
• Non-target  lesions  
o If non-target  lesions  have  never  shown  unequivocal  progression,  their doing so 
for the first time results in iUPD.  
o If non -target lesions had shown previous unequivocal progression, and this 
progression has  not resolved, iUPD results from any significant further growth 
of non- target lesions, taken as a whole.  
• New lesions  
o New lesions  appear  for the first time 
o Additional  new lesions  appear  
91  
o Previously  identified  new target  lesions  show  an increase  of ≥ 5 mm in the new 
lesion sum of diameters, from the nadir value of that sum  
o Previously  identified  non-target  lesions  show  any significant  growth 
If any of the events  above  occur,  the overall  response for that visit is iUPD,  and the iUPD 
evaluation process (see Assessment at the Confirmatory Imaging above) is repeated. 
Progression must be confirmed before iCPD can occur.  
 
The decision process is identical to the iUPD confirmation process for the initial PD, except in one respect. If new lesions occurred at a prior instance of iUPD, and at the confirmatory scan the burden of new lesions has increased from its smallest value (for new target  lesions,  their sum of diameters  is ≥5 mm increased from its nadir),  then iUPD 
cannot  resolve  to iSD or iPR. It will remain iUPD until either  a decrease in the new lesion 
burden allows resolution to iSD or iPR, or until a confirmatory factor causes iCPD.  
 
Additional  details  about  iRECIST  are provided  in the iRECIST  publication.123 
92  
12.5 Appendix  5: Dietary  History  Questionnaire (DHQ -3) Administration  
 
Dietary history  questionnaire  will be administered  either  on paper  or electronically  and data entered 
and stored securely electronically. Instrument will be administered by PI or designee.  
 
Detailed  information for study  staff:  
1. Please  obtain  patient’s  username  and password from study  PI. 
2. Please  provide instructions  (see below)  to patients.  
3. Patients  are to be instructed to provide detailed dietary  information  either  during visit (preferred)  or 
at home.  
4. Please  instruct  the patients  to report  intake  as averaged over the preceding 4 weeks.  
 
Detailed  information for patients:  
• Thank  you for participating  in this study.  We are interested in evaluating  your dietary  history.  To do 
this we are using a validated questionnaire termed the “Diet History Questionnaire (DHQ -3)”. 
• This questionnaire takes approximately 30 minutes to complete. You can do this either while 
receiving your therapy or at home.  
• After completing the questionnaire, you will receive a Respondent Nutrition Report. This report 
shows  estimated daily nutrient  and food group intakes  based on questionnaire responses.  Recommended 
values are only available for some nutrients and food groups.  
• Please  feel free to discuss this with your study  doctor.  
 
Dietary study  login  URL:  
Your  username  (case sensitive):    
Your  study  password  (case sensitive):    